ASSET PURCHASE AGREEMENT BY AND BETWEEN MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. AND ADVANSOURCE BIOMATERIALS CORPORATION
Exhibit 2.1
Β
Execution Version
Β
Β
Β
Redactions with respect to certain portions hereof are denoted with β***β
Β
Β
Β
ASSET PURCHASE AGREEMENT
Β
BY AND BETWEEN
Β
MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC.
Β
AND
Β
ADVANSOURCE BIOMATERIALS CORPORATION
Β
Dated as of November 25, 2019
Β
Β
Β
Β
Β
Β
Β
Β
Β
Β
TABLE OF CONTENTS
Β
Β
i
Β
Β
Β
ii
Β
Β
Β
iii
Β
Β
Exhibits
Β
Exhibit A | Support and Voting Agreement |
Exhibit B | Form of Employment Agreement |
Exhibit C | Xxxx of Sale |
Exhibit D | Assignment and Assumption Agreement |
Exhibit E | Intellectual Property Assignment Agreement |
Exhibit F | Patent Assignment Agreement |
Exhibit G | Trademark Assignment Agreement |
Exhibit H | Assignment and Assumption of Lease |
Β
iv
Β
Β
ASSET PURCHASE AGREEMENT
Β
This Asset Purchase Agreement (this βAgreementβ), dated as of November 25, 2019, is entered into by and between AdvanSource Biomaterials Corporation, a Delaware corporation (βSellerβ) and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βBuyerβ).
Β
Recitals
Β
WHEREAS, Seller is engaged in the business of developing advanced polymer materials that provide critical characteristics in the design and development of medical devices (the βBusinessβ);
Β
WHEREAS, Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, substantially all of the assets of the Business, subject to the terms and conditions set forth herein;
Β
WHEREAS, the members of the Board of Directors of Seller (the βSeller Boardβ) voting on the matter have unanimously (a) declared this Agreement advisable, (b) determined that this Agreement is in the best interests of Seller and Sellerβs stockholders, (c) approved this Agreement, (d) directed that this Agreement be submitted for approval by Sellerβs stockholders at a special meeting thereof, and (e) resolved to recommend that Sellerβs stockholders approve this Agreement; in each case, in accordance with the Delaware General Corporate Law, as amended (the βDGCLβ);
Β
WHEREAS, as an inducement to the willingness of Buyer to enter into this Agreement and cause the transactions contemplated hereunder to be consummated, concurrently with the execution and delivery of this Agreement the stockholders of Seller listed on Schedule A and Buyer are executing a Support and Voting Agreement in the form set out in ExhibitΒ A and each such stockholder is granting an irrevocable proxy to a mutually agreed-upon proxy holder, pursuant to which each such shareholder is undertaking certain obligations and irrevocably directing the proxy holder to vote all securities of Seller directly or beneficially owned by it in favor of the approval of this Agreement and the transactions contemplated hereunder; and
Β
WHEREAS, as of the date hereof, Seller has delivered the offer letters and employment agreements, each substantially in the form set forth in Exhibit B, duly executed by Xxxxxxx X. Xxxxx, Xxxxxxxxx Xxxxxxx, and Xxxxxx Xxxx (collectively, the βEmployment Agreementsβ), the terms of which will be effective as of the Closing Date (as defined below).
Β
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
Β
Β
The following terms have the meanings specified in this ARTICLE I:
Β
β229 Andover Lienβ means that certain Delaware UCC financing statement in favor of Landlord, filed on February 28, 2018 (#20181395868).
Β
βAccounts Receivableβ has the meaning set forth in Section 2.02(b).
Β
Β
Β
Β
βActionβ means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.
Β
βAdverse Recommendation Changeβ means the Seller Board (a) failing to make, withdraw, amend, modify, or materially qualify, in a manner adverse to Buyer, the Seller Board Recommendation, (b) failing to include the Seller Board Recommendation in the Seller Proxy Statement that is mailed to Sellerβs stockholders, (c) recommending a Takeover Proposal, (d) failing to recommend against acceptance of any tender offer or exchange offer for the shares of Sellerβs stock that constitutes a Takeover Proposal within ten (10) Business Days after the commencement of such offer, (e) failing to reaffirm (publicly, if so requested by Buyer) the Seller Board Recommendation within ten (10) Business Days after the date of any Takeover Proposal (or material modification thereto) is first publicly disclosed by Seller or the Person making such Takeover Proposal, or, if the Seller Stockholders Meeting is scheduled to be held within ten (10) Business Days of such request, within one (1) Business DayΒ after such request and in any event, prior to the date of the Seller Stockholders Meeting, (f) making any public statement inconsistent with the Seller Board Recommendation or (g) resolving or agreeing to take any of the foregoing actions.
Β
βAffiliateβ of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term βcontrolβ (including the terms βcontrolled byβ and βunder common control withβ) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
Β
βAgreed Obligationsβ means those specified obligations set forth in Section 1.00 of the Disclosure Schedules.
Β
βAgreementβ has the meaning set forth in the Preamble.
Β
βAllocationβ has the meaning set forth in Section 2.07.
Β
βAlternative Acquisition Agreementβ has the meaning set forth in Section 6.03(a).
Β
βAncillary Documentsβ means the Xxxx of Sale, the Assignment and Assumption Agreement, the Assignment and Assumption of Lease, the Intellectual Property Assignment Agreement, the Patent Assignment Agreement, the Trademark Assignment Agreement, and the other agreements, instruments and documents required to be delivered at the Closing.
Β
βAssigned Contractsβ has the meaning set forth in Section 2.01(b).
Β
βAssignment and Assumption Agreementβ has the meaning set forth in Section 3.02(a)(ii).
Β
βAssignment and Assumption of Leaseβ has the meaning set forth in Section 3.02(a)(viii).
Β
βAssumed Liabilitiesβ has the meaning set forth in Section 2.03.
Β
βAudited Financial Statementsβ has the meaning set forth in Section 4.06(a).
Β
βBalance Sheetβ has the meaning set forth in Section 4.06(a).
Β
2
Β
Β
βBalance Sheet Dateβ has the meaning set forth in Section 4.06(a).
Β
βXxxx of Saleβ has the meaning set forth in Section 3.02(a)(i).
Β
βBusinessβ has the meaning set forth in the Recitals.
Β
βBusiness Dayβ means any day except Saturday, Sunday or any other day on which commercial banks located in Wilmington, Massachusetts, New York, New York or Tokyo, Japan are authorized or required by Law to be closed for business.
Β
βBuyerβ has the meaning set forth in the Preamble.
Β
βBuyer Closing Certificateβ has the meaning set forth in Section 7.03(d).
Β
βCharter Documentsβ has the meaning set forth in Section 4.01.
Β
βClosingβ has the meaning set forth in Section 3.01.
Β
βClosing Consentsβ has the meaning set forth in Section 7.02(c).
Β
βClosing Dateβ has the meaning set forth in Section 3.01.
Β
βCOBRAβ means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and as codified in SectionΒ 4980B of the Code and SectionΒ 601 et seq. of ERISA.
Β
βCodeβ means the United States Internal Revenue Code of 1986, as amended.
Β
βConfidentiality Agreementβ means the Confidentiality Agreement, dated as of August 7, 2017, between Mitsubishi Chemical Corporation and Seller.
Β
βConsentβ has the meaning set forth in Section 4.03(b).
Β
βContinuing Employeesβ shall mean any employee of Seller who accepts an offer of employment with Buyer on or following the Closing Date.
Β
βContractsβ means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.
Β
βCopyrightsβ has the meaning set forth in the definition of βIntellectual Propertyβ.
Β
βDGCLβ has the meaning set forth in the Recitals.
Β
βDisclosure Schedulesβ means the Disclosure Schedules delivered by Seller concurrently with the execution and delivery of this Agreement.
Β
βDollarsβ or β$β means the lawful currency of the United States.
Β
βEmployment Agreementsβ has the meaning set forth in the Recitals.
Β
3
Β
Β
βEncumbranceβ means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment or similar encumbrance.
Β
βEnvironmental Claimβ means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence, Release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with any Environmental Law or term or condition of any Permit.
Β
βEnvironmental Lawβ means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The term βEnvironmental Lawβ includes the following (including their implementing regulations and any state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean Air Act Amendments of 1990, 42 U.S.C. §§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. §§ 651 et seq.
Β
βEnvironmental Permitsβ has the meaning set forth in Section 4.20(a).
Β
βERISAβ means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
Β
βERISA Affiliateβ means all employers (whether or not incorporated) that would be treated together with Seller or any of its Affiliates as a βsingle employerβ within the meaning of SectionΒ 414 of the Code or SectionΒ 4001 of ERISA.
Β
βExchange Actβ means the United States Securities Exchange Act of 1934, as amended.
Β
βExcluded Assetsβ has the meaning set forth in Section 2.02.
Β
βExcluded Liabilitiesβ has the meaning set forth in Section 2.04.
Β
βFinancial Statementsβ has the meaning set forth in Section 4.06(a).
Β
4
Β
Β
βFIRPTA Certificateβ has the meaning set forth in Section 7.02(h).
Β
βGAAPβ means United States generally accepted accounting principles in effect from time to time.
Β
βGovernmental Authorityβ means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.
Β
βGovernmental Orderβ means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.
Β
βHazardous Materialsβ means (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under any Environmental Laws and (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation and polychlorinated biphenyls.
Β
βIntellectual Propertyβ means any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (a) issued patents and patent applications (whether provisional or non-provisional), including utility models and divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, renewals, extensions, or restorations of any of the foregoing, (βPatentsβ); (b) trademarks, service marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill associated with the use of and symbolized by, and all registrations, applications for registration, and renewals and extensions of, any of the foregoing (βTrademarksβ); (c) copyrights and works of authorship, whether or not copyrightable, together with all moral rights associated with, and all registrations, applications for registration, and renewals and extensions of, any of the foregoing (βCopyrightsβ); (d) internet domain names and social media account or user names (including βhandlesβ), whether or not Trademarks, all associated web addresses, URLs, websites and web pages, social media accounts and pages, and all content and data thereon or relating thereto, whether or not Copyrights; (e) mask works, and all registrations, applications for registration, and renewals and extensions thereof; (f) industrial designs, and all Patents, registrations, applications for registration, and renewals and extensions thereof; (g) trade secrets, know-how, inventions (whether or not patentable), invention disclosures, discoveries, improvements, technology, source code, algorithms, prototypes, product roadmaps, business plans, marketing plans, business and technical information, databases, data compilations and collections, data analytics, tools, compositions, formulae, recipes, methods, processes, techniques, and other confidential and proprietary information and all rights therein (βTrade Secretsβ); (h) rights of publicity; and (i) all other intellectual or industrial property and proprietary rights.
Β
βIntellectual Property Agreementsβ means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to xxx, waivers, releases, permissions and other Contracts, whether written or oral, relating to any Intellectual Property (including development, ownership, use, registration or enforcement thereof) that is used or held for use in the conduct of the Business as currently conducted to which Seller is a party, beneficiary or otherwise bound.
Β
5
Β
Β
βIntellectual Property Assetsβ means all Intellectual Property and Software that is owned or purported to be owned by Seller and used or held for use in, or that relates to, the conduct of the Business as currently conducted, together with all claims and causes of action with respect to such Intellectual Property, whether accruing before, on or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal or equitable relief for past, present or future infringement, misappropriation or other violation thereof.
Β
βIntellectual Property Assignment Agreementβ has the meaning set forth in Section 3.02(a)(iii).
Β
βInterim Financial Statementsβ has the meaning set forth in Section 4.06(a).
Β
βInterim Periodβ has the meaning set forth in Section 6.01.
Β
βIntervening Eventβ means, with respect to Seller, any material event, circumstance, change, effect, development or condition occurring or arising after the date hereof that was not known nor reasonably foreseeable to the Seller Board as of the date hereof and did not result from or arise out of the announcement or pendency of, or any actions required to be taken by Seller (or to be refrained from being taken by Seller) pursuant to, this Agreement; provided that in no event shall the following events, circumstances, or changes in circumstances constitute an Intervening Event: (a) the receipt, existence, or terms of a Takeover Proposal or any matter relating thereto or consequence thereof or any inquiry, proposal, offer or transaction from any third party relating to or in connection with a transaction of the nature described in the definition of βTakeover Proposalβ (which, for the purposes of the Intervening Event definition, shall be read without reference to the percentage thresholds set forth in the definition thereof); or (b) any change in the price, or change in trading volume, of Sellerβs stock as listed on the OTCQB; provided further that the exception to this clause (b) shall not apply to the underlying causes giving rise to or contributing to such change or prevent any of such underlying causes from being taken into account in determining whether an Intervening Event has occurred.
Β
βIntervening Event Notice Periodβ has the meaning set forth in Section 6.03(e).
Β
βInventoryβ means inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and similar items.
Β
βIRSβ means the United States Internal Revenue Service.
Β
βKey Employeesβ means Xxxxxxx X. Xxxxx, Xxxxxxxxx X. Xxxxxxx and Xxxxxx Xxxx.
Β
βKnowledge of Sellerβ or βSellerβs Knowledge,β or any other similar knowledge qualification, means the actual knowledge of any of the Key Employees and the knowledge that such individuals would have had after having made reasonable due inquiry; provided, however, that such due inquiry does not include or require conducting any Intellectual Property freedom to operate, invalidity or enforceability investigations or studies.
Β
βLandlordβ means 000 Xxxxxxx Xxxxxx, LLC, a Massachusetts limited liability company.
Β
βLawβ means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.
Β
6
Β
Β
βLeaseβ means all leases, subleases, licenses, concessions, and other agreements (written or oral) under which Seller holds any Leased Real Property, including the right to all security deposits and other amounts and instruments deposited by or on behalf of Seller.
Β
βLease Amendmentβ means that certain First Amendment to Lease, dated as of the Closing Date, by and between Landlord and Seller.
Β
βLeased Real Propertyβ has the meaning set forth in Section 4.18(b)(i).
Β
βLiabilitiesβ means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise.
Β
βMaterial Adverse Effectβ means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, condition (financial or otherwise) or assets of the Business, taken as a whole, or (b) the ability of Seller to consummate the transactions contemplated hereby on a timely basis; provided, however, that for the purposes of clause (a), βMaterial Adverse Effectβ shall not be deemed to include events, occurrences, facts, conditions or changes arising out of, relating to or resulting from (i) general economic or political conditions; (ii) changes in financial, banking or securities markets in general; (iii) the announcement, pendency or completion of the transactions contemplated by this Agreement; (iv) any outbreak or escalation of war or any act of terrorism; (v) general conditions in the industry in which Seller operates; (vi) any changes in applicable Laws or accounting rules (including GAAP) or the enforcement, implementation or interpretation thereof; (vii) any natural or man-made disaster or acts of God; or (viii) any failure by the Business to meet any internal or published projections, forecasts or revenue or earnings predictions (provided that the underlying causes of such failures (subject to the other provisions of this definition) shall not be excluded); provided further that any event, change or effect referred to in clauses (i), (ii) and (iv) through (vii) immediately above shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such event, change or effect has a disproportionate effect on Seller compared to other participants in the industries in which Seller conducts its business.
Β
βMaterial Contractsβ has the meaning set forth in Section 4.21(a).
Β
βOTCQBβ means the OTCQB tier of the OTC Market.
Β
βOutside Dateβ has the meaning set forth in Section 8.01(b)(iii).
Β
βPatent Assignment Agreementβ has the meaning set forth in Section 3.02(a)(iv).
Β
βPatentsβ has the meaning set forth in the definition of βIntellectual Propertyβ.
Β
βPermitsβ means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities, including pursuant to any Environmental Law.
Β
βPermitted Encumbrancesβ has the meaning set forth in Section 4.08.
Β
7
Β
Β
βPersonβ means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.
Β
βPre-Closing Tax Periodβ means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.
Β
βPublicly Available Softwareβ means (a) any Software that contains, or is derived in any manner (in whole or in part) from, any Software that is distributed as free software or open source software (for example, Software distributed under the GNU General Public License, the GNU Lesser General Public License, the Affero General Public License, or the Apache Software License), or pursuant to open source, copyleft or similar licensing and distribution models and (b) any Software that requires as a condition of use, modification and/or distribution of such software that such Software or other Software incorporated into, linked to, derived from or distributed with such Software (i) be disclosed or distributed in source code form, (ii) be licensed for the purpose of making derivative works or (iii) be redistributable at no or minimal charge.
Β
βPurchase Priceβ has the meaning set forth in Section 2.05.
Β
βPurchased Assetsβ has the meaning set forth in Section 2.01.
Β
βReal Propertyβ means real property together with all easements, licenses, interests and all of the rights arising out of the ownership thereof or appurtenant thereto and together with all buildings, structures, facilities, fixtures and other improvements thereon.
Β
βRegistered IPβ has the meaning set forth in Section 4.12(b).
Β
βReleaseβ means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation, ambient air (indoor or outdoor), surface water, groundwater, land surface or subsurface strata or within any building, structure, facility or fixture).
Β
βRepresentativeβ has the meaning set forth in Section 6.03(a).
Β
βRequisite Seller Voteβ means the approval by the holders of a majority of the issued and outstanding stock of Seller entitled to vote at the Seller Stockholder Meeting.
Β
βXxxxxxxx-Xxxxx Actβ means the Xxxxxxxx-Xxxxx Act of 2012, as amended.
Β
βSchedule Supplementβ has the meaning set forth in Section 6.15.
Β
βSECβ means the United States Securities and Exchange Commission
Β
βSectionΒ 409Aβ has the meaning set forth in Section 4.16(j).
Β
βSecurities Actβ means the United States Securities Act of 1933, as amended.
Β
8
Β
Β
βSelf-Help Codeβ means any back door, time bomb, drop dead device, or other Software routine designed to disable a computer program automatically with the passage of time or under the positive control of a Person other than the user of the program.
Β
βSellerβ has the meaning set forth in the Preamble.
Β
βSeller Boardβ has the meaning set forth in the Recitals.
Β
βSeller Board Recommendationβ has the meaning set forth in Section 4.02(b).
Β
βSeller Closing Certificateβ has the meaning set forth in Section 7.02(f).
Β
βSeller Employeeβ has the meaning set forth in Section 4.16(a).
Β
βSeller Employee Plansβ has the meaning set forth in Section 4.16(a).
Β
βSeller Financial Advisorβ has the meaning set forth in Section 4.28.
Β
βSeller IPβ has the meaning set forth in Section 4.12(a).
Β
βSeller IT Systemsβ means all software, computer hardware, servers, networks, platforms, peripherals, data communication lines, and other information technology equipment and related systems that are owned or used or held for use by Seller in the conduct of the Business as currently conducted.
Β
βSeller Proxy Statementβ has the meaning set forth in Section 4.24.
Β
βSeller Required Consentsβ has the meaning set forth in Section 4.03(b).
Β
βSeller SEC Documentsβ has the meaning set forth in Section 4.05.
Β
βSeller Stockholders Meetingβ means the special meeting of the stockholders of Seller to be held to consider the adoption of this Agreement.
Β
βSeller Softwareβ means all Software listed on Section 4.12(d) of the Disclosure Schedules.
Β
βSoftwareβ means computer programs, operating systems, applications, firmware and other code, including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and other documentation thereof.
Β
βSubsidiaryβ of a Person means a corporation, partnership, limited liability company, or other business entity of which a majority of the shares of voting securities is at the time beneficially owned, or the management of which is otherwise controlled, directly or indirectly, through one or more intermediaries, or both, by such Person.
Β
βSuperior Proposalβ means a bona fide written Takeover Proposal (except that, for purposes of this definition, each reference in the definition of βTakeover Proposalβ to β15%β shall be β50%β) that the Seller Board determines in good faith (after consultation with outside legal counsel and the Seller Financial Advisor) is more favorable from a financial point of view to Sellerβs stockholders than the transactions contemplated by this Agreement, taking into account (a) all financial considerations, (b) the identity of the third party making such Takeover Proposal, (c) the anticipated timing, conditions (including any financing condition or the reliability of any debt or equity funding commitments) and prospects for completion of such Takeover Proposal and (d) the other terms and conditions of such Takeover Proposal and the implications thereof on Seller, including relevant legal, regulatory and other aspects of such Takeover Proposal deemed relevant by the Seller Board.
Β
9
Β
Β
βSuperior Proposal Notice Periodβ has the meaning set forth in Section 6.03(d).
Β
βTakeover Proposalβ means an inquiry, proposal, or offer from, or indication of interest in making a proposal or offer by, any Person or group (other than Buyer and its Affiliates), relating to any transaction or series of related transactions (other than the transactions contemplated by this Agreement), involving any (a) direct or indirect acquisition of assets of Seller equal to 15% or more of the fair market value of Sellerβs consolidated assets or that generate 15% or more of Sellerβs net revenues or net income (for the 12-month period ending on the last day of Sellerβs most recently completed fiscal quarter), (b) direct or indirect acquisition of 15% or more of the voting equity interests of Seller, (c) tender offer or exchange offer that if consummated would result in any Person or group (as defined in SectionΒ 13(d) of the Exchange Act) beneficially owning (within the meaning of SectionΒ 13(d) of the Exchange Act) 15% or more of the voting power of Seller, (d) merger, consolidation, other business combination, liquidation, dissolution or other corporate reorganization or similar transaction involving Seller, pursuant to which such Person or group (as defined in SectionΒ 13(d) of the Exchange Act) would own 15% or more of the assets of Seller, or (e) any combination of the foregoing.
Β
βTangible Personal Propertyβ has the meaning set forth in Section 2.01(e).
Β
βTaxesβ means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other Taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.
Β
βTax Returnβ means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
Β
βTrade Secretsβ has the meaning set forth in the definition of βIntellectual Propertyβ.
Β
βTrademark Assignment Agreementβ has the meaning set forth in Section 3.02(a)(v).
Β
βTrademarksβ has the meaning set forth in the definition of βIntellectual Propertyβ.
Β
βTransfer Taxβ means any sales, use, value-added, goods and services, gross receipts, excise, registration, stamp duty, transfer, documentary or other similar Tax or governmental charge or fee.
Β
βUnauthorized Codeβ means any virus, Trojan horse, worm, or other software routines or hardware components designed to permit unauthorized access, to disable, erase, or otherwise harm Software, hardware or data.
Β
10
Β
Β
Β
Section 2.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, at the Closing, Seller shall sell, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, free and clear of any Encumbrances, other than Permitted Encumbrances, all of Sellerβs right, title and interest in, to and under all of the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether now existing or hereafter acquired (other than the Excluded Assets), which relate to, or are used or held for use in connection with, the Business (collectively, the βPurchased Assetsβ), including the following:
Β
(a) all Inventory;
Β
(b) all Contracts set forth in Section 2.01(b) of the Disclosure Schedules, including the Intellectual Property Agreements, and the Leases set forth in Section 4.18(b) of the Disclosure Schedules (the βAssigned Contractsβ);
Β
(c) all Seller IP and Seller IT Systems;
Β
(d) all Software owned or purported to be owned by Seller;
Β
(e) all furniture, fixtures, equipment, machinery, tools, office equipment, supplies, computers, telephones and other tangible personal property (the βTangible Personal Propertyβ);
Β
(f) all Leased Real Property;
Β
(g) all Permits held by Seller in connection with the conduct of the Business as currently conducted or for the ownership and use of the Purchased Assets;
Β
(h) all rights to any Actions of any nature available to or being pursued by Seller to the extent related to the Business, the Purchased Assets or the Assumed Liabilities, whether arising by way of counterclaim or otherwise;
Β
(i) all prepaid expenses, credits, advance payments, claims, security, refunds, rights of recovery, rights of set-off, rights of recoupment, deposits, charges, sums and fees (including any such item relating to the payment of Taxes);
Β
(j) all of Sellerβs rights under warranties, indemnities and all similar rights against third parties to the extent related to any Purchased Assets;
Β
(k) all insurance benefits to the extent covering the Purchased Assets or the Assumed Liabilities;
Β
11
Β
Β
(l) the business records (other than employee records), financial books and records, sales order files, purchase order files, engineering order files, warranty and repair files, supplier lists, customer lists, dealer, representative and distributor lists, studies, surveys, analyses, strategies, plans, forms, designs, diagrams, drawings, specifications, technical data, production and quality control records and formulations of Seller;
Β
(m) to the extent permitted under applicable Law, one copy of Sellerβs personnel records and any other records that Seller is required by Law to retain in its possession; and
Β
(n) all goodwill and the going concern value associated with the Business and any of the assets described in the foregoing clauses.
Β
Section 2.02 Excluded Assets. Notwithstanding the foregoing, the Purchased Assets shall not include the following assets (collectively, the βExcluded Assetsβ):
Β
(a) all cash and cash equivalents and securities of Seller;
Β
(b) all accounts or notes receivable held by Seller, and any security, claim, remedy or other right related to any of the foregoing (collectively, the βAccounts Receivableβ);
Β
(c) the corporate seals, Charter Documents, minute books, stock books or other records having to do with the corporate organization of Seller;
Β
(d) Sellerβs personnel records and any other records that Seller is required by Law to retain in its possession; provided that, to the extent permitted under applicable Law, Buyer shall be entitled to possess one copy of any such records pursuant to Section 2.01(m);
Β
(e) all claims, rights of recovery and causes of action of Seller arising out of any Action to the extent arising from any Excluded Asset or Excluded Liability, and all files, documents, instruments, papers, books and records of Seller related exclusively to the foregoing;
Β
(f) all casualty, liability or other policies of insurance of Seller relating to the ownership of the Purchased Assets or the operation of the Business, and all files, documents, instruments, papers, books and records of Seller related exclusively to the foregoing;
Β
(g) all Seller Employee Plans and all assets owned or held by any Seller Employee Plan, and all files, documents, instruments, papers, books and records of Seller related exclusively to the foregoing;
Β
(h) the Tax Returns and books of account or other records with respect to the Taxes of Seller and all claims and rights of Sellers to any Tax refunds, Tax credits or other Tax attributes of Seller; and
Β
(i) the rights that accrue or will accrue to Seller under this Agreement and the Ancillary Documents.
Β
12
Β
Β
Section 2.03 Assumed Liabilities. Subject to the terms and conditions set forth herein, Buyer shall assume and agree to pay, perform and discharge only the following Liabilities of Seller (collectively, the βAssumed Liabilitiesβ), and no other Liabilities:
Β
(a) all liabilities and obligations of Buyer or its Affiliates relating to employee benefits, compensation or other arrangements with respect to any Continuing Employee arising after the Closing;
Β
(b) all Liabilities in respect of the Assigned Contracts but only to the extent that such Liabilities thereunder are required to be performed after the Closing Date; and
Β
(c) all other liabilities and obligations arising out of or relating to Buyerβs ownership or operation of the Business and the Purchased Assets on or after the Closing.
Β
Section 2.04 Excluded Liabilities. Notwithstanding Section 2.03 or any other provision in this Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform or discharge any Liabilities of Seller or any of its Affiliates of any kind or nature whatsoever other than the Assumed Liabilities (the βExcluded Liabilitiesβ). Seller shall pay and satisfy in due course all Excluded Liabilities. Without limiting the generality of the foregoing, the Excluded Liabilities shall include the following:
Β
(a) all trade accounts payable of Seller to third parties in connection with the Business that remain unpaid as of the Closing Date;
Β
(b) any Liability of Seller arising or incurred in connection with the negotiation, preparation, investigation and performance of this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby, including, without limitation, fees and expenses of counsel, accountants, consultants, advisers and others;
Β
(c) any Liability for (i) Taxes of Seller (or any stockholder or Affiliate of Seller) or the Business, the Purchased Assets or the Assumed Liabilities for any Pre-Closing Tax Period; (ii) Taxes that arise out of the consummation of the transactions contemplated hereby; or (iii) other Taxes of Seller (or any stockholder or Affiliate of Seller) of any kind or description (including any Liability for Taxes of Seller (or any stockholder or Affiliate of Seller) that becomes a Liability of Buyer under any common law doctrine of de facto merger or transferee or successor liability or otherwise by operation of contract or Law);
Β
(d) any Liabilities relating to or arising out of the Excluded Assets;
Β
(e) any Liabilities in respect of any pending or threatened Action arising out of, relating to or otherwise in respect of the operation of the Business or the Purchased Assets to the extent such Action relates to such operation on or prior to the Closing Date;
Β
(f) any product liability or similar claim for injury to a Person or property that arises out of or is based upon any express or implied representation, warranty, agreement or guaranty made by Seller, or by reason of the improper performance or malfunctioning of a product, improper design or manufacture, failure to adequately package, label or warn of hazards or other related product defects of any products at any time manufactured or sold or any service performed by Seller prior to the Closing Date, irrespective of whether such claim or resulting Liability arose prior to, on or after the Closing;
Β
13
Β
Β
(g) any recall, design defect or similar claims of any products manufactured or sold or any service performed by Seller prior to the Closing Date, irrespective of whether such claim or resulting Liability arose prior to, on or after the Closing;
Β
(h) any Liabilities of Seller arising under or in connection with any Seller Employee Plan, irrespective of whether such Liabilities arose prior to, on or after the Closing;
Β
(i) any Liabilities of Seller for any present or former Seller Employee, officers, directors, retirees, independent contractors or consultants of Seller, including any Liabilities associated with any claims for wages or other benefits, bonuses, accrued vacation, workersβ compensation, severance, retention, termination or other payments;
Β
(j) any Liabilities with respect to the Continuing Employees that relate to the period prior to the Closing or that arise on or prior to the Closing;
Β
(k) all Liabilities under Sellerβs 2017 Non-Qualified Equity Incentive Plan, the 2003 CardioTech Stock Incentive Plan and any employee stock ownership plan or program;
Β
(l) any Liabilities and obligations related to the provision of notice or payment in lieu of notice and applicable penalties under the Worker Adjustment and Retraining Notification Act of 1988 (βWARNβ) or any comparable state or local Law or any similar provision in a collective bargaining agreement related to termination for which the initial provision of notice occurs on or prior to the Closing Date;
Β
(m) any Liabilities and obligations related to wages, bonuses, commissions, independent contractor payments, payroll, workersβ compensation, unemployment benefits, stay, change of control, severance, bonus or similar payments due by Seller to any Person under any plan, agreement or arrangement of Seller which obligation, in each case, either arises at or prior to the Closing, is payable or becomes due in whole or in part as a result of the consummation of the transactions contemplated by this Agreement, including all employer Taxes that are payable in connection with or as a result of the payment of such liability or obligation;
Β
(n) any Liabilities and obligations relating to the classification by Seller of any Person who has performed services to, for or on behalf of the Business prior to the Closing as an employee or an independent contractor, or as an exempt or non-exempt employee under the Fair Labor Standards Act of 1938, as amended, and comparable state and local Laws;
Β
(o) any Environmental Claims, or Liabilities under Environmental Laws, to the extent arising out of or relating to facts, circumstances or conditions existing on or prior to the Closing Date, including any post-Closing migration or degradation of Hazardous Materials;
Β
(p) any Liabilities of the Business relating to or arising from unfulfilled commitments, quotations, purchase orders, customer orders or work orders that (i) do not constitute part of the Purchased Assets issued by the Businessβ customers to Seller on or before the Closing; (ii) did not arise in the ordinary course of business; or (iii) are not validly and effectively assigned to Buyer pursuant to this Agreement;
Β
14
Β
Β
(q) any Liabilities to indemnify, reimburse or advance amounts to any present or former officer, director, employee or agent of Seller (including with respect to any breach of fiduciary obligations by same) (other than pursuant to any Assumed Contracts);
Β
(r) any Liabilities under any Contracts (other than Assumed Contracts) (i) that are not validly and effectively assigned to Buyer pursuant to this Agreement, or (ii) to the extent such Liabilities arise out of or relate to a breach by Seller of such Contracts prior to Closing;
Β
(s) any Liabilities associated with debt, loans or credit facilities of Seller or the Business, owing to financial institutions or other third parties; and
Β
(t) any Liabilities arising out of, in respect of or in connection with the failure by Seller or any of its Affiliates to comply with any Law or Governmental Order.
Β
Section 2.05 Purchase Price. In consideration of the sale, transfer, conveyance and delivery of the Purchased Assets to Buyer and the assumption by Buyer of the Assumed Liabilities, Buyer shall pay to Seller a total amount equal to $7,250,000.00 (the βPurchase Priceβ).
Β
Section 2.06 Withholding Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer may be required to deduct and withhold under any provision of Tax Law. All such withheld amounts shall be treated as delivered to Seller hereunder.
Β
Section 2.07 Allocation of Purchase Price. Not later than sixty (60) days prior to the filing due date (without extensions) for Sellerβs U.S. income Tax Return for 2019, Buyer shall provide Seller with an allocation of the Purchase Price (plus any Assumed Liabilities properly taken into account as amount realized for federal income Tax purposes) among the Purchased Assets prepared by Buyer in accordance with SectionΒ 1060 of the Code (the βAllocationβ). Seller will review the Allocation and, to the extent Seller disagrees with the content of the Allocation, Seller will, within twenty (20) days after receipt of the Allocation, provide written notice to Buyer of such disagreement or will be deemed to have indicated its concurrence therewith. Seller and Buyer will attempt in good faith to resolve any such disagreement. Upon any final agreement or determination of the Allocation or any modification thereof, the Allocation shall be conclusive and binding upon Buyer and Seller for all Tax purposes, and Buyer and Seller agree that all Tax Returns (including IRS Form 8594) shall be prepared in a manner consistent with (and Buyer and Seller shall not otherwise file a Tax Return position inconsistent with) the Allocation unless required by the IRS or any other applicable Tax authority. If no final agreement or determination of the Allocation is reached between Buyer and Seller, each party hereto shall be free to make a reasonable allocation under Section 1060 of the Code as it deems appropriate.
Β
Section 2.08 Transfer Taxes. All Transfer Taxes incurred in connection with this Agreement and the Ancillary Documents shall be borne equally by Buyer and Seller. Any Tax Return or other document required to be filed in connection with any such Transfer Taxes shall be prepared by Seller unless the parties agree otherwise. All expenses incurred in connection with such preparation and filing shall be borne equally by Buyer and Seller.
Β
15
Β
Β
Section 2.09 Third Party Consents. To the extent that Sellerβs rights under any Contract or Permit constituting a Purchased Asset, or any other Purchased Asset, may not be assigned to Buyer without the consent of another Person and such consent has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Seller, at its expense, shall use its commercially reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyerβs rights under the Purchased Asset in question so that Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law and the Purchased Asset, shall act after the Closing as Buyerβs agent to obtain for Buyer the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the Purchased Asset, with Buyer in any other reasonable arrangement designed to provide such benefits to Buyer. Notwithstanding any provision in this Section 2.09 to the contrary, Buyer shall not be deemed to have waived its rights under Section 7.02(c) unless and until Buyer either provides written waivers thereof or elects to proceed to consummate the transactions contemplated by this Agreement at Closing.
Β
Section 2.10 Technology Retention. Except as may otherwise be specifically contemplated by this Agreement, following the Closing, Seller shall not retain copies of any Software or other technology included in the Seller IP or Seller IT Systems included in the Purchased Assets, even if such Purchased Assets are such that more than one copy may exist. Seller hereby waives, solely for the benefit of Buyer and its Affiliates, any rights to which Seller is entitled under any employee confidential information and invention assignment agreement or similar Contract or arising under applicable Law with respect to the subject matter thereof.
Β
Β
Section 3.01 Closing. Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the βClosingβ) shall take place at the offices of Winston & Xxxxxx LLP, 000 Xxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx, 00000 on the second (2nd) Business Day after all of the conditions to Closing set forth in ARTICLE VII are either satisfied or waived (other than conditions that, by their nature, are to be satisfied on the Closing Date), or at such other time, date or place as Seller and Buyer may mutually agree upon in writing. The date on which the Closing is to occur is herein referred to as the βClosing Date.β
Β
Section 3.02 Closing Deliverables.
Β
(a) At the Closing, Seller shall deliver to Buyer the following:
Β
(i) a xxxx of sale in the form set forth in ExhibitΒ C (the βXxxx of Saleβ), duly executed by Seller;
Β
(ii) an assignment and assumption agreement in the form set forth in ExhibitΒ D (the βAssignment and Assumption Agreementβ), duly executed by Seller;
Β
16
Β
Β
(iii) an intellectual property assignment agreement in the form set forth in ExhibitΒ E (the βIntellectual Property Assignment Agreementβ), duly executed by Seller;
Β
(iv) a patent assignment agreement in the form set forth in ExhibitΒ F (the βPatent Assignment Agreementβ), duly executed by Seller;
Β
(v) a trademark assignment agreement in the form set forth in ExhibitΒ G (the βTrademark Assignment Agreementβ), duly executed by Seller;
Β
(vi) with respect to the Employment Agreements, written confirmation by Seller that, to the Knowledge of Seller, none of the individuals who is a party to an Employment Agreements has stated orally or in writing that such individual does not intend to perform his or her respective duties and responsibilities under the Employment Agreements;
Β
(vii) evidence that all of the Closing Consents, or waivers in lieu thereof, have been obtained and such Closing Consents (or waivers in lieu thereof) shall (A) not be subject to the satisfaction of any condition that has not been satisfied or waived, (B) be in form and substance reasonably satisfactory to Buyer and (C) be in full force and effect;
Β
(viii) with respect to each Lease, an Assignment and Assumption of Lease substantially in the form of Exhibit H (each, an βAssignment and Assumption of Leaseβ), duly executed by Seller and, if necessary, Sellerβs signature shall be witnessed and/or notarized;
Β
(ix) the Seller Closing Certificate;
Β
(x) the certificates of the Secretary or Assistant Secretary of Seller required by Section 7.02(g).
Β
(xi) the FIRPTA Certificate;
Β
(xii) evidence, in each case in form satisfactory to Buyer in its sole discretion, of termination in full of the 229 Andover Lien and all other Encumbrances relating to the Purchased Assets;
Β
(xiii) copies of executed amendments to the Charter Documents of Seller (in form and substance reasonably satisfactory to Buyer), which shall be filed by Seller in the relevant jurisdictions promptly following the Closing to effectuate the change of Sellerβs name as set forth in Section 6.11;
Β
(xiv) such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Buyer, as may be required to give effect to this Agreement; and
Β
(xv) the Lease Amendment, duly executed by Seller and Landlord.
Β
17
Β
Β
(b) At the Closing, Buyer shall deliver to Seller the following:
Β
(i) an amount equal to the difference between (A) the Purchase Price minus (B) the aggregate Agreed Obligations, by wire transfer of immediately available funds to an account designated in writing by Seller to Buyer;
Β
(ii) the Assignment and Assumption Agreement, duly executed by Buyer;
Β
(iii) the Intellectual Property Assignment Agreement, duly executed by Buyer;
Β
(iv) the Patent Assignment Agreement, duly executed by Buyer;
Β
(v) the Trademark Assignment Agreement, duly executed by Buyer;
Β
(vi) with respect to each Lease, an Assignment and Assumption of Lease duly executed by Buyer and, if necessary, Buyerβs signature shall be witnessed and/or notarized;
Β
(vii) the Buyer Closing Certificate; and
Β
(viii) the certificates of the Secretary or Assistant Secretary of Buyer required by Section 7.03(e).
Β
(c) At the Closing, Buyer shall deliver to the Landlord an amount equal to the aggregate Agreed Obligations, by wire transfer of immediately available funds to an account designated by the Landlord to Buyer.
Β
ARTICLE
IV
Representations and Warranties of Seller
Β
Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Seller represents and warrants to Buyer that the statements contained in this ARTICLE IV are true and correct as of the date hereof.
Β
Section 4.01 Organization; Standing and Power; Charter Documents.
Β
(a) Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power and authority to own, lease and operate its assets and properties and to carry on its business as currently conducted and as currently contemplated to be conducted and to perform its obligations under all Contracts to which it is bound. Seller is duly qualified to do business as a foreign corporation under the laws of all jurisdictions where the nature of its business requires such qualification, except where the failure to be so qualified would not have a Material Adverse Effect.
Β
(b) Seller has provided to Buyer a true and complete copy of its certificate of incorporation, certificates of designation and bylaws, each as amended to date (collectively, the βCharter Documentsβ), and each such document is in full force and effect. There are no approved or proposed amendments to any of such documents not reflected therein.
Β
18
Β
Β
Section 4.02 Authorization; Seller Board Recommendation.
Β
(a) Seller has all requisite corporate power and authority to enter into and to perform its obligations under this Agreement and the Ancillary Documents to which Seller is a party and, subject to, in the case of the consummation of transactions contemplated by this Agreement, adoption of this Agreement by the Requisite Seller Vote, to consummate the transactions contemplated by this Agreement. The execution, delivery and performance of this Agreement by Seller and the consummation by Seller of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Seller and no other corporate proceedings on the part of Seller are necessary to authorize the execution, delivery and performance of this Agreement or to consummate the transactions contemplated hereby, subject only to the receipt of the Requisite Seller Vote. The Requisite Seller Vote is the only vote or consent of the holders of any class or series of Sellerβs capital stock necessary to approve and adopt this Agreement and the Ancillary Documents, and consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by Seller and, assuming due execution and delivery by Buyer, constitutes the legal, valid, and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium and other similar Laws affecting creditorsβ rights generally and by general principles of equity.
Β
(b) The Seller Board, by resolutions duly adopted by a unanimous vote of the directors voting at a meeting of the directors of Seller duly called and held and, not subsequently rescinded or modified in any way, has: (i) resolved to recommend that Sellerβs stockholders adopt this Agreement at the Seller Stockholders Meeting, (ii) declared this Agreement advisable under SectionΒ 271 of the DGCL, (iii) determined that this Agreement is in the best interests of Seller and Sellerβs stockholders, (iv) approved this Agreement and (v) directed that the approval of this Agreement be submitted for consideration by Sellerβs stockholders at the Seller Stockholders Meeting (collectively, the βSeller Board Recommendationβ).
Β
Section 4.03 Non-Contravention.
Β
(a) The execution, delivery and performance by Seller of this Agreement and the Ancillary Documents to which Seller is a party, and the consummation of the transactions contemplated hereby or thereby, do not and will not conflict with or result in any violation of or default under (with or without notice or lapse of time, or both) or give rise to a right of termination, cancellation, modification or acceleration of any obligation or loss of any benefit to which Seller is entitled to under or give rise to the existence of any Encumbrance in connection with (i) any provision of the Charter Documents or other organizational documents of Seller, (ii) any Material Contract to which Seller is party, or (iii) any Law or Governmental Order applicable to Seller or any of its properties or assets (including the Purchased Assets), other than, in the case of clause (ii) above, any such items that would not reasonably be expected to have a Material Adverse Effect.
Β
(b) Except for (i) any consent, approval, order, authorization, registration, declaration, filing or notice (any of the foregoing being a βConsentβ) set forth in Section 4.03(b) of the Disclosure Schedules (the βSeller Required Consentsβ), (ii) the filing of the Seller Proxy Statement in definitive form with the SEC in accordance with the Exchange Act, and such reports under the Exchange Act as may be required in connection with this Agreement and the transactions contemplated hereunder or (iii) such Consent as may be required under applicable state securities or βblue skyβ Laws and the securities Laws of any foreign country or the rules and regulations of the OTCQB, neither the execution and delivery by Seller of this Agreement or any Ancillary Document or any transaction contemplated hereby or thereby to which it is a party, nor the performance of such transactions performed or to be performed by Seller, require any Consent or constitute a material default, or cause any payment obligation to accelerate, under (x) any Law or Governmental Order that is applicable to Seller, (y) any Material Contract, Permit or other document to which Seller is a party or by which the properties or other assets of Seller may be bound or (z) the Charter Documents.
Β
19
Β
Β
Section 4.04 No Subsidiaries. Seller has no Subsidiaries and no assets (whether tangible or intangible) that would otherwise fall within the definition of Purchased Assets that are owned, in whole or in part, by any Affiliate.
Β
Section 4.05 Seller SEC Documents. Since April 1, 2016, Seller has timely filed with or furnished to, as applicable, the SEC all registration statements, prospectuses, reports, schedules, forms, statements, and other documents (including exhibits and all other information incorporated by reference) required to be filed or furnished by it under applicable Law (the βSeller SEC Documentsβ). As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or superseded filing), (a) each Seller SEC Document complied as to form in all material respects with the applicable requirements of the Securities Act, the Exchange Act or the Xxxxxxxx-Xxxxx Act, as the case may be (including, in each case, the rules and regulations promulgated thereunder), each as in effect on the date such Seller SEC Document was filed, and (b) except to the extent amended or superseded by a subsequent filing with the SEC prior to the date hereof, no Seller SEC Document contained any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
Β
Section 4.06 Financial Statements.
Β
(a) Seller has delivered to Buyer complete copies of (i) the audited financial statements consisting of the balance sheet of Seller as at March 31 in each of the years 2018 and 2019 and the related statements of operations, stockholdersβ deficit and cash flow for the fiscal years then ended (the βAudited Financial Statementsβ) and (ii) the unaudited financial statements consisting of the condensed balance sheet of Seller as at June 30, 2019, and the related condensed statements of operations and cash flow for the three (3) month period then ended (the βInterim Financial Statementsβ and, together with the Audited Financial Statements, the βFinancial Statementsβ). The Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the relevant periods involved (except as may be indicated in the notes thereto or, with respect to any unaudited interim financial statements, the absence of footnote disclosures and other presentation items and normal year-end audit adjustments or as permitted by the SECβs rules and forms). The Financial Statements are based on the books and records of Seller, comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto and fairly present in all material respects the financial condition of Seller as of the respective dates they were prepared and the results of the operations of Seller for the periods indicated. The balance sheet of Seller as of March 31, 2019, is referred to herein as the βBalance Sheetβ and the date thereof as the βBalance Sheet Date.β
Β
20
Β
Β
(b) Except as disclosed in the Seller SEC Documents, Seller has no Liabilities with respect to the Business except (i) those that are reflected or reserved against in the Balance Sheet as of the Balance Sheet Date (including notes thereto), (ii) those that have been incurred in the ordinary course of business consistent with past practice since the Balance Sheet Date, (iii) those that are incurred in connection with the transactions contemplated by this Agreement or any agreement to be delivered at Closing, and (iv) those that would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
Β
Section 4.07 Absence of Certain Changes or Events. Except as set forth in the SEC Documents, since the Balance Sheet Date, except in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, the business of Seller has been conducted in the ordinary course of business consistent with past practice and there has not been or occurred:
Β
(a) any event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
Β
(b) any material change in any method of accounting or accounting practice for the Business, except as required by GAAP or as disclosed in the notes to the Financial Statements;
Β
(c) any incurrence, assumption or guarantee of any indebtedness for borrowed money in connection with the Business in an aggregate amount exceeding $50,000, except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice;
Β
(d) any transfer, assignment, sale or other disposition of any of the Purchased Assets shown or reflected in the Balance Sheet, except for the sale of Inventory in the ordinary course of business and except for any Purchased Assets (other than Intellectual Property Assets) having an aggregate value of less than $50,000;
Β
(e) any cancellation of any debts or claims or amendment, termination or waiver of any rights constituting Purchased Assets;
Β
(f) any transfer or assignment of or grant of any license or sublicense under or with respect to any Intellectual Property Assets or Intellectual Property Agreements (except for licenses granted under any existing Intellectual Property Agreements and non-exclusive licenses or sublicenses granted in the ordinary course of business consistent with past practice);
Β
(g) any abandonment or lapse of or failure to maintain in full force and effect any Intellectual Property Registration, or failure to take or maintain commercially reasonable measures to protect the confidentiality of any Trade Secrets included in the Intellectual Property Assets;
Β
(h) any material damage, destruction or loss, or any material interruption in use, of any Purchased Assets, whether or not covered by insurance;
Β
(i) any acceleration, termination, material modification to or cancellation of any Assigned Contract;
Β
21
Β
Β
(j) any capital expenditures in an aggregate amount exceeding $50,000 that would constitute an Assumed Liability;
Β
(k) any imposition of any Encumbrance upon any of the Purchased Assets other than Permitted Encumbrances;
Β
(l) except as may be required by applicable Law or under any Material Contract or Seller Employee Plan in place as of the date hereof: (i) any increase in compensation, incentives, severance or benefits to, or entry into an employment agreement with, any employee of the Business; (ii) any adoption, amendment or termination of any collective bargaining agreement or Seller Employee Plan related to the Business; (iii) any hiring or termination of any employee, independent contractor, or temporary employee whose annual compensation or fees is, or is expected to be, at least $75,000; or (iv) conduct any group reduction in force or mass layoff;
Β
(m) any purchase, lease or other acquisition of the right to own, use or lease any property or assets that would constitute Purchased Assets for an amount in excess of $50,000, except for purchases of equipment, Inventory or supplies in the ordinary course of business consistent with past practice; or
Β
(n) any Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.
Β
Section 4.08 Title to Purchased Assets. Seller has good and valid title to, or a valid leasehold interest in, all of the Purchased Assets. All such Purchased Assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as βPermitted Encumbrancesβ): (a) liens for Taxes not yet due and payable; (b) mechanicsβ, carriersβ, workmenβs, repairmenβs or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to the Business or the Purchased Assets; (c) easements, rights of way, zoning ordinances and other similar encumbrances affecting Real Property; (d) liens arising under original purchase price conditional sales contracts and equipment leases with third parties entered into in the ordinary course of business consistent with past practice which are not, individually or in the aggregate, material to the Business or the Purchased Assets.
Β
Section 4.09 Condition and Sufficiency of Assets. The buildings, plants, structures, furniture, fixtures, machinery, equipment and other items of tangible personal property included in the Purchased Assets are in good operating condition and repair, ordinary wear and tear excepted, and are adequate for the uses to which they are being put by Seller, and none of such machinery, equipment, vehicles and other items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs. The Purchased Assets are sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets necessary to conduct the Business as currently conducted. None of the Excluded Assets are material to the Business. Section 4.09 of the Disclosure Schedules sets forth in all material respects a true and complete list as of the date of this Agreement of each item of tangible personal property included in the Purchased Assets and having a value of at least $10,000.00.
Β
22
Β
Β
Section 4.10 Inventory. All Inventory, whether or not reflected in the Balance Sheet, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All Inventory is owned by Seller free and clear of all Encumbrances, and no Inventory is held on a consignment basis. The quantities of each item of Inventory (whether raw materials, work-in-process or finished goods) are not excessive, but are reasonable in the present circumstances of Seller. All Inventory included in the Balance Sheet and additional items of Inventory arising since the Balance Sheet Date was acquired and has been maintained in accordance with the regular business practices of Seller and is valued at prices equal to the lower of cost or realizable value and in accordance with the internal accounting practices of Seller applied on a basis consistent with the Financial Statements, each consistently applied throughout the periods covered by the Financial Statements.
Β
Β
(a) All Tax Returns required to be filed by Seller for any Pre-Closing Tax Period have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. Seller has made available to Buyer complete and accurate copies of all federal, state, local, and foreign income, franchise, and other material Tax Returns filed by or on behalf of Seller for any Tax period ending after March 31, 2013. All Taxes due and owing by Seller (whether or not shown on any Tax Return) have been, or will be, timely paid.
Β
(b) Seller has withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, stockholder or other party, and complied with all information reporting and backup withholding provisions of applicable Law.
Β
(c) Seller has made available to Buyer complete and accurate copies of all federal, state, local and foreign income, franchise and other material Tax Returns filed by or on behalf of Seller for any Tax period ending after March 31, 2013.
Β
(d) There are no Encumbrances for Taxes upon the assets of Seller other than for current Taxes not yet due and payable for which adequate reserves in accordance with GAAP have been made in Sellerβs most recent financial statements included in the Seller SEC Documents.
Β
(e) No deficiency for any material amount of Taxes that has been proposed, asserted or assessed in writing by any taxing authority against Seller remains unpaid. There are no waivers or extensions of any statute of limitations currently in effect for assessment, collection or other imposition of any Tax of Seller. There are no audits, suits, proceedings, investigations, claims, examinations or other administrative or judicial proceedings in progress, pending or, to Sellerβs Knowledge, threatened with respect to any Taxes or Tax Returns of Seller.
Β
(f) No claim has ever been made by any taxing authority in a jurisdiction where Seller does not file Tax Returns that Seller is or may be subject to Tax in that jurisdiction. Seller has not commenced a voluntary disclosure proceeding in any state or local or non-U.S. jurisdiction that has not been fully resolved or settled.
Β
23
Β
Β
(g) Seller is not a βforeign personβ as that term is used in Treasury Regulations SectionΒ 1.1445-2.
Β
(h) None of the Purchased Assets is (i) required to be treated as being owned by another person pursuant to the so-called βsafe harbor leaseβ provisions of former SectionΒ 168(f)(8) of the Internal Revenue Code of 1954, as amended, (ii) subject to SectionΒ 168(g)(1)(A) of the Code, or (iii) subject to a disqualified leaseback or long-term agreement as defined in SectionΒ 467 of the Code.
Β
(i) Seller has not been a party to, or a material advisor with respect to, a βreportable transactionβ within the meaning of SectionΒ 6707A(c)(1) of the Code and Treasury Regulations SectionΒ 1.6011-4(b).
Β
Section 4.12 Intellectual Property.
Β
(a) Seller is the sole and exclusive owner of all right, title and interest in the Intellectual Property Assets, free and clear of any Encumbrances, other than Permitted Encumbrances, and has a valid and enforceable written license or other right to use all other Intellectual Property used or held for use in, or to Sellerβs Knowledge that is necessary for, the conduct of the Business as currently conducted (collectively, the βSeller IPβ). To Sellerβs Knowledge, the Intellectual Property Assets are valid and enforceable.
Β
(b) Section 4.12(b) of the Disclosure Schedules contains an accurate and complete list of all of the Intellectual Property Assets that are the subject of an application, certificate, filing, registration or other document issued by, filed with or recorded by any Governmental Authority, quasi-governmental authority or registrar (the βRegistered IPβ), including (i) the jurisdictions in which each such item of Registered IP has been issued or registered or in which any such application for issuance or registration has been filed; (ii) the registration or application date, as applicable, for each such item of Registered IP; (iii) the record owner of each such item of Registered IP and (iv) any maintenance fees or actions that fall due within ninety (90) days after the closing with respect thereto. All Registered IP has been maintained by the filing of all necessary filings, maintenance and renewals and timely payment of requisite fees. Section 4.12(b) of the Disclosure Schedules also sets forth all material unregistered Intellectual Property Assets. No loss or expiration of any Intellectual Property Assets is threatened, pending or reasonably foreseeable, except for patents expiring at the end of their statutory terms (and not as a result of any act or omission by Seller, including Sellerβs failure to pay any required maintenance fees).
Β
(c) Seller has taken all commercially reasonable action to maintain and protect all of the Seller IP. Seller has taken commercially reasonable measures to protect the confidentiality of all Trade Secrets and any other material confidential information that constitutes Seller IP owned by Seller or to whom Seller has a written confidentiality obligation. No such Trade Secrets or other confidential information has been disclosed by Seller to any Person other than pursuant to a written agreement restricting the disclosure and use of such Trade Secrets or other confidential information by such Person. No current or to Sellerβs Knowledge former employee, contractor or consultant of Seller (or any of its predecessors in interest) has any right, title or interest, directly or indirectly, in whole or in part, in any Intellectual Property Assets. Seller has obtained from all Persons (including all current Seller Employees, contractors and consultants) who have created any Intellectual Property for Seller valid and enforceable written assignments of any such Intellectual Property to Seller, and Seller has delivered true, correct and complete copies of such assignments to Buyer. To Sellerβs Knowledge, no Person is in violation of any such written confidentiality or assignment agreements.
Β
24
Β
Β
(d) All Software listed on Section 4.12(d) of the Disclosure Schedules (the βSeller Softwareβ) (i) conforms in all material respects with all specifications, representations, warranties and other descriptions established by Seller or conveyed by Seller to its customers or other transferees, (ii) is operative for its intended purpose free of any material defects or deficiencies and does not contain any Self-Help Code, Unauthorized Code or similar programs and (iii) has been maintained by Seller in accordance with its contractual obligations to its customers and industry standards.
Β
(e) To Sellerβs Knowledge, no Person, other than Seller, possesses a copy, in any form (print, electronic or otherwise), of any source code for any of the Seller Software, and all such source code is in Sellerβs sole possession and has been maintained in a strictly confidential manner. Seller has no obligation to afford any Person access to any such source code. Seller is in possession of all other material relating to the Software used in the Business, including installation and user documentation, engineering specifications, flow charts and know-how, reasonably necessary for the use, maintenance, enhancement, development and other exploitation of such Software as used in, or currently under development for, the Business.
Β
(f) No Publicly Available Software has been incorporated in, linked to, distributed with or otherwise used in connection with any Seller Software or any product or service of the Business in any manner that may (i) require or condition the use or distribution of any Seller Software or any such product or service on the disclosure, licensing or distribution of any source code for any portion of such Seller Software, product or service (other than the Publicly Available Software itself) or (ii) otherwise impose any material limitation, restriction or condition on the right or ability of Seller to enforce any Intellectual Property Assets against any Person.
Β
(g) The Seller IT Systems are operational, fulfill the purposes for which they were acquired or developed in all material respects, and have hardware and Software capacity, support, maintenance and trained personnel which are sufficient in all material respects for the current and anticipated future needs of the Business. Seller has disaster recovery and security plans, procedures and facilities and has taken reasonable steps consistent with or exceeding industry standards to safeguard the availability, security and integrity of the Seller IT Systems and all data and information stored thereon, including from unauthorized access and infection by Unauthorized Code. Seller has maintained in the ordinary course of business all required licenses and service contracts, including the purchase of a sufficient number of license seats for all Software, with respect to the Seller IT Systems. The Seller IT Systems have not suffered any material failure within the past five (5) years.
Β
(h) Seller and the former and current products, services and conduct of the Business, including the manufacture, importation, use, offer for sale, sale, licensing, distribution or other commercial exploitation of such products and services, have not infringed, misappropriated or otherwise violated, and do not infringe, misappropriate or otherwise violate, any Intellectual Property of any Person. Seller is not the subject of any pending legal proceeding that (i) alleges a claim of infringement, misappropriation or other violation of any Intellectual Property of any Person, and to Sellerβs Knowledge no such claim has been asserted or threatened against Seller with respect to the Business or (ii) challenges the ownership, use, patentability, registration, validity or enforceability of any Intellectual Property Assets. No Person has notified Seller in writing that any of such Personβs Intellectual Property rights are infringed, misappropriated or otherwise violated by Seller with respect to the Business or that Seller requires a license to any of such Personβs Intellectual Property rights. To Sellerβs Knowledge, there is no actual unauthorized use, interference, disclosure, infringement, misappropriation or other violation by any Person of any of the Seller IP, and no written allegation regarding such infringement, misappropriation or other violation have been made against any Person by Seller (or any of its predecessors in interest).
Β
25
Β
Β
(i) The consummation of the transactions contemplated hereby will not result in the loss or impairment of Sellerβs right to own or use any Seller IP. Immediately subsequent to the Closing, all Seller IP will be owned or available for use by Buyer on terms and conditions identical to those under which Seller owned or used the Seller IP immediately prior to the Closing, without payment of additional fees. Immediately subsequent to the Closing, Seller shall not have any ownership interest in or any right to use, any Seller IP.
Β
Section 4.13 Compliance with Laws. Seller is and, since April 1, 2016, has been in compliance in all material respects with all Laws applicable to the conduct of the Business as currently conducted or the ownership and use of the Purchased Assets, and Seller has not received any written notice of violation with respect to any applicable Laws from any governmental Authority.
Β
Section 4.14 Permits. No material Permits are necessary for the conduct of the Business as currently conducted.
Β
Section 4.15 Litigation. There is no Action pending, or to the Knowledge of Seller, threatened, against Seller or any of its properties or assets (including the Purchased Assets), or with respect to this Agreement, any of the Ancillary Documents or any of the transactions contemplated hereby or thereby. There is no Governmental Order to which Seller is a party or otherwise binding upon Seller that has or may reasonably be expected to have the effect of materially prohibiting or impairing the use of the Purchased Assets.
Β
Section 4.16 Employee Benefits.
Β
(a) Section 4.16(a) of the Disclosure Schedules sets forth a true and complete list, as of the date hereof, of each plan, program, policy, agreement, collective bargaining agreement, or other arrangement providing for compensation, severance, deferred compensation, performance awards, stock or stock-based awards, fringe, retirement, death, disability, medical or wellness benefits, or other employee benefits or remuneration of any kind, including each employment, termination, severance, retention, change in control or consulting or independent contractor plan, program, arrangement or agreement, in each case whether written or unwritten or otherwise, funded or unfunded, insured or self-insured, including each βemployee benefit planβ, within the meaning of SectionΒ 3(3) of ERISA, whether or not subject to ERISA, which is or has been sponsored, maintained, contributed to, or required to be contributed to, by Seller of any Affiliate of Seller for the benefit of any current or former employee of Seller or the Business (each, a βSeller Employeeβ) or of any current or former independent contractor, consultant, or director of Seller or the Business, or with respect to which Seller or any ERISA Affiliate has or may have any Liability (collectively, the βSeller Employee Plansβ).
Β
26
Β
Β
(b) With respect to each Seller Employee Plan, Seller has made available to Buyer a current, true, accurate and complete copy of each such Seller Employee Plan (or if no such copy exists, a written description) and, to the extent applicable, (i) all related trust agreements, funding arrangements, insurance contracts, and service provider agreements; (ii) the most recent determination letter received regarding the tax-qualified status of each Seller Employee Plan; (iii) the most recent financial statements for each Seller Employee Plan; (iv) the Form 5500 Annual Returns/Reports and Schedules for the most recent plan year for each Seller Employee Plan; (v) the current summary plan description for each Seller Employee Plan; and (vi) the three (3) most recent actuarial valuation reports related to any Seller Employee Plan.
Β
(c) All amounts owed by Seller under the terms of any Seller Employee Plan have been timely paid in full when and as required to be paid. Each Seller Employee Plan that provides health or welfare benefits is fully insured, and any incurred but not reported claims under each such Seller Employee Plan that is not fully insured have been accrued in accordance with GAAP.
Β
(d) Each Seller Employee Plan has been established, maintained, administered and operated in accordance with its terms and in material compliance with the applicable terms of ERISA, the Code and all other applicable Laws.
Β
(e) Each Seller Employee Plan that is intended to be qualified under SectionΒ 401(a) of the Code has received, or is based on a form of plan that has received, a favorable determination or opinion letter from the IRS, and to Sellerβs Knowledge, nothing has occurred, whether by action or failure to act, that could be expected to cause such determination letter to be revoked.
Β
(f) Neither the execution and delivery of this Agreement nor the consummation or performance of the transactions contemplated herein shall accelerate the time of vesting for, change the time of payment to, result in severance pay or cause an increase in severance pay upon any termination of employment after the date hereof, or increase the amount of compensation due to, any director, employee or officer of Seller, or result in the loss of deduction pursuant to SectionΒ 280G of the Code (determined without regard to the exceptions provided for in Section 280G(b)(5) of the Code). No individual has a right to receive from Seller any gross-up payment in respect of Taxes that may be imposed under SectionΒ 409A or SectionΒ 4999 of the Code.
Β
(g) Neither Seller nor any ERISA Affiliate contributes to, has any obligation to contribute to or has any liability (contingent or otherwise) with respect to, any plan that is subject to Title IV of ERISA, any βmultiemployer planβ within the meaning of Section 3(37) of ERISA, any βmultiple employer planβ within the meaning of Section 413(c) of the Code, or any βmultiple employer welfare arrangementβ within the meaning of Section 3(40) of ERISA.
Β
(h) There are no Seller Employee Plans that include, nor are there any current or former Seller Employees or current or former officers, directors or consultants of Seller or the Business eligible for, any retiree medical or other post-employment health or welfare benefits, other than those receiving or eligible to receive COBRA continuation coverage under SectionΒ 4980B of the Code.
Β
27
Β
Β
(i) With respect to any Seller Employee Plan, including any assets of any such Seller Employee Plan or any fiduciary to any such Seller Employee Plan, (i) no Actions (other than routine claims for benefits in the ordinary course) are pending or, to Sellerβs Knowledge, threatened, and (ii) no administrative investigation, audit or other administrative proceeding by the United States Department of Labor, the IRS or other Governmental Authority is pending, or, to Sellerβs Knowledge, threatened. There has been no non-exempt βprohibited transactionβ (and there will be none as a result of any of the transactions contemplated hereby) within the meaning of SectionΒ 4975(c) of the Code or SectionΒ 406 of ERISA involving the assets of any Seller Employee Plan.
Β
(j) Each Seller Employee Plan that is subject to SectionΒ 409A of the Code has been operated in material compliance with the applicable provisions of SectionΒ 409A of the Code, the regulations thereunder and other official guidance issued thereunder (collectively, βSectionΒ 409Aβ), and is in material documentary compliance with the applicable provisions of SectionΒ 409A.
Β
Section 4.17 Labor and Employment.
Β
(a) Section 4.17(a) of the Disclosure Schedules sets forth a true and complete list of all Seller Employees, including each employeeβs name, title, employing entity, status (as full-time or part-time, exempt or non-exempt under the Fair Labor Standards Act or other similar Law, or active or a description of leave), and a description of all compensation, including 2018 and 2019 salary or hourly wage rate, 2018 or 2019 bonus and commission, any severance obligations and any deferred compensation paid or payable for each officer, Seller Employee or any consultant and independent contractor of Seller or an Affiliate of Seller related to the Business.
Β
(b) Seller is not a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union or other labor organization representing any Seller Employees, and since April 1, 2017, there has not been any, union organizing effort pending or threatened against Seller with respect to any Seller Employees. Since April 1, 2017, there has not been, nor to Sellerβs Knowledge, has there been any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor activity or dispute affecting Seller.
Β
(c) To Sellerβs Knowledge, Seller is and has been in compliance, in all material respects, with all applicable Laws pertaining to employment and employment practices to the extent they relate to Seller Employees, including hiring, termination, discrimination, workplace safety, leaves of absence, workersβ compensation, payment of taxes, immigration, terms and conditions of employment, discrimination, harassment, the payment and withholding of taxes and social security, retaliation, occupational health and safety, affirmative action, plant closings or layoffs, wages and hours, classification (exempt/nonexempt and independent contractor/employee). There are no Actions against Seller pending, or to Sellerβs Knowledge, threatened to be brought or filed, by or with any Governmental Authority in connection with the employment of any current or former Seller Employee or any current or former consultant or independent contractor of Seller or an Affiliate of Seller with respect to the Business, including, without limitation, any charge, investigation or claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay or any other employment-related matter arising under applicable Laws.
Β
28
Β
Β
(d) Section 4.17(d) of the Disclosure Schedules sets forth a true and complete list of the independent contractors, consultants, and temporary employees of Seller or an Affiliate of Seller with respect to the Business, including the 2018 and 2019 fees paid to each such independent contractor, consultant, and temporary employee. Except as set forth in Section 4.17(d) of the Disclosure Schedules, all independent contractors, consultants, and temporary employees utilized by Seller or any Affiliate of Seller in the operation of the Business are and have been properly characterized as independent contractors, consultants, and temporary employees. Except as set forth in Section 4.17(d) of the Disclosure Schedules, during the past five (5) years neither Seller nor any Affiliate of Seller has treated an independent contractor, consultant, or temporary employee engaged to provide services to the Business as an employee of Seller or an Affiliate of Seller.
Β
(e) Neither Seller nor an Affiliate of Seller has taken any action within the last five (5) years that could reasonably be expected to constitute a βplant closingβ or βmass layoffβ within the meaning of, and subject to, WARN or any applicable similar state or local Law, or otherwise triggered any similar notice requirement or liability under any applicable Law.
Β
(f) Seller has paid in full (i) to all current or former employees of the Business, any wages, salaries, commissions, bonuses, compensation, overtime, cash outs of accrued and unused vacation, paid time off, or other leave and severance, and any other amounts due upon termination of employment that are due and payable; and (ii) to all current and former independent contractors, consultants, and temporary employees related to the Business, any fees for services that are due and payable.
Β
(g) Section 4.17(g) of the Disclosure Schedules lists all employees, independent contractors, consultants, and temporary employees related to the Business who are covered by any written confidentiality, intellectual property assignment, non-competition, or non-solicitation agreement with Seller or an Affiliate of Seller, and Seller has provided or made available to the Buyer the current and complete copies of each such agreement. Neither Seller nor any Affiliate of Seller, as applicable, have sought to enforce any confidentiality, intellectual property assignment, non-competition, or non-solicitation agreement against any current or former Seller Employee in the past five (5) years.
Β
Β
(a) Owned Real Property. Except as set forth in Section 4.18(a) of the Disclosure Schedules, Seller does not own and has never owned any Real Property nor is Seller party to any agreement to purchase or sell any Real Property used in, held for use in or necessary for the operation of the Business.
Β
29
Β
Β
(b) Leased Real Property.
Β
(i) Section 4.18(b)(i) of the Disclosure Schedules sets forth a complete and accurate list and description of all parcels of Real Property leased, subleased, licensed, used or otherwise occupied by Seller and used in, held for use in or necessary for the operation of the Business (together with all fixtures and improvements thereon, the βLeased Real Propertyβ), including the names of the lessor and lessee, the date of the applicable Lease, the dates of any amendments thereto and the address of each parcel of Leased Real Property. Seller is the owner and holder of a valid leasehold interest in each such Leased Real Property and has the right to occupy and use each such Leased Real Property in accordance with the terms of the applicable lease. Seller has made available to Buyer a true, correct and complete copy of each Lease with respect to each such Leased Real Property. With respect to each of the Leases, (i) such Lease is legal, valid, binding, enforceable and in full force and effect, (ii) neither Seller nor to Sellerβs Knowledge any other party to the Lease is in material breach or material default under such Lease (other than with respect to the Agreed Obligations), and no event has occurred or circumstance exists which, with or without notice, lapse of time or both, would constitute a breach or default under such Lease, (iii) Sellerβs possession and quiet enjoyment of the Leased Real Property under such Lease has not been disturbed there are no disputes with respect to such Lease, and (iv) there are no Encumbrances on the estate created by such Lease other than Permitted Encumbrances. Seller has not assigned, pledged, mortgaged, hypothecated or otherwise transferred any Lease or any interest therein nor has Seller subleased, licensed or otherwise granted any Person a right to use or occupy such Leased Real Property or any portion thereof. Section 4.18(b)(i) of the Disclosure Schedules includes a true, correct, and complete description of the Agreed Obligations, in each case as of 11:59 p.m. New York time on the date immediately preceding the date of this Agreement.
Β
(ii) The Leased Real Property is in good operating condition and repair and is suitable for the operation of the Business as presently conducted therein. Neither the operation of Seller on the Leased Real Property nor, to Sellerβs Knowledge, such Leased Real Property, violates any Law relating to such property or operations thereon, except for such violation that, individually or in the aggregate, would not reasonably be expected to materially impair the use and operation of the Leased Real Property as currently operated. All certificates of occupancy and other material Permits or approvals legally required with respect to the occupancy and use of the Leased Real Property have been obtained and are currently in effect. Seller has not received any written notice that there is any condemnation or appropriation or similar proceeding pending and, to Sellerβs Knowledge, none is threatened against any Leased Real Property or any portion thereof or the improvements thereon.
Β
Section 4.19 Product Liability and Warranty; Manufacturing.
Β
(a) To Sellerβs Knowledge since April 1, 2016, all of the products manufactured, sold, leased and delivered by Seller in connection with the Business have conformed in all material respects with all applicable contractual commitments and all express and implied warranties, and Seller does not have any outstanding and unperformed material liability for replacement or repair thereof or other damages in connection therewith, subject only to any reserve for product warranty claims set forth in the Financial Statements, as adjusted for operations and transactions through the Closing Date in accordance with the past practice of the Business.
Β
30
Β
Β
(b) With respect to any product or service manufactured, sold, leased or delivered by Seller since April 1, 2016, Seller has not received any written notice or, to the Knowledge of Seller, any oral notice, of any Action pending or threatened against the Business or Seller with respect to the quality or performance of such products or services (which would include any claims relating to any alleged defects, deficiencies, non-conformance or negligence with respect to any such products or services). Seller has heretofore delivered to Buyer true and correct copies of all written warranties currently in effect covering the respective products of the Business.
Β
(c) To the Knowledge of Seller, since April 1, 2016, all manufacturing, including testing, by Seller has been conducted in all material respects in compliance with industry standard good manufacturing practices and good laboratory practices.
Β
Section 4.20 Environmental Matters.
Β
(a) Seller is, and has been, in material compliance with all Environmental Laws, which compliance includes the possession, maintenance of, compliance with or application for all Permits required under applicable Environmental Laws (βEnvironmental Permitsβ) for the operation of the Business as currently conducted, and Seller has no knowledge that any such Environmental Permit will not be re-issued on substantially the same terms as currently in effect. Any such Environmental Permits that require approval by any Governmental Authority to be transferred to Buyer are listed in Section 4.20 of the Disclosure Schedule;
Β
(b) Except as would not have a Material Adverse Effect, Seller has not disposed of, released, or discharged any Hazardous Materials on, at, under, in or from any Real Property currently or, to the Knowledge of Seller, formerly owned, leased or operated by it or any of its Affiliates or predecessors or at any other location that is (i) currently subject to any investigation, remediation or monitoring or (ii) reasonably likely to result in any Liability to Seller, in either case of (i) or (ii) under any applicable Environmental Laws;
Β
(c) To Sellerβs Knowledge, Seller has not (i) produced, processed, manufactured, generated, transported, treated, handled, used or stored any Hazardous Materials, except in material compliance with Environmental Laws, or (ii) exposed any employee or any third party to any Hazardous Materials under circumstances reasonably expected to give rise to any material Liability under any Environmental Law;
Β
(d) Seller has not received written notice of and there is no Action pending, or to the Knowledge of Seller, threatened against Seller, alleging any Liability or responsibility under or non-compliance with any Environmental Law or seeking to impose any financial responsibility for any investigation, cleanup, removal, containment or any other remediation or compliance under any Environmental Law. Seller is not subject to any Governmental Order, settlement agreement or other written agreement by or with any Governmental Authority or third party imposing any Liability with respect to any of the foregoing;
Β
31
Β
Β
(e) Seller has not assumed or retained any Liabilities under any applicable Environmental Laws of any other Person, including in any acquisition or divestiture of any property or business; and
Β
(f) Seller has provided copies of all environmental audits, assessments, investigation reports prepared by or on behalf of Seller and copies of material correspondences with Governmental Authorities relating to compliance with Environmental Laws or the environmental condition of the property.
Β
Section 4.21 Material Contracts.
Β
(a) Section 4.21(a) of the Disclosure Schedule sets forth a complete and accurate list of each of the following Contracts (x) by which any of the Purchased Assets are bound or affected or (y) to which Seller is a party or by which it is bound in connection with the Business or the Purchased Assets (such Contracts, together with all Leases and Intellectual Property Agreements set forth in Section 2.01(b) of the Disclosure Schedules, being the βMaterial Contractsβ):
Β
(i) all Contracts involving aggregate consideration in excess of $50,000 and which, in each case, cannot be cancelled without penalty or without more than ninety (90) daysβ notice;
Β
(ii) all Contracts involving aggregate payments or receipts in excess of $50,000 that require Seller to purchase or sell a stated portion of the requirements or outputs of the Business or that contain βtake or payβ provisions;
Β
(iii) all Contracts that provide for the indemnification of any Person or the assumption of any Tax, environmental or other Liability of any Person;
Β
(iv) all Contracts that relate to the acquisition or disposition of any business, a material amount of stock or assets of any other Person or any Real Property (whether by merger, sale of stock, sale of assets or otherwise), in each case involving amounts in excess of $50,000;
Β
(v) all broker, distributor, dealer, manufacturerβs representative, franchise, agency, sales promotion, market research, marketing consulting and advertising Contracts;
Β
(vi) all employment agreements and Contracts with independent contractors or consultants (or similar arrangements) and which are not cancellable without material penalty or without more than ninety (90) daysβ notice;
Β
(vii) any staffing, temporary labor or similar Contracts for the provision of temporary employee services;
Β
(viii) except for Contracts relating to trade receivables, all Contracts relating to indebtedness (including, without limitation, guarantees);
Β
(ix) all Contracts with any Governmental Authority;
Β
32
Β
Β
(x) all Contracts that limit or purport to limit the ability of Seller to compete in any line of business or with any Person or in any geographic area or during any period of time;
Β
(xi) all joint venture, partnership or similar Contracts;
Β
(xii) all Contracts for the sale of any of the Purchased Assets or for the grant to any Person of any option, right of first refusal or preferential or similar right to purchase any of the Purchased Assets;
Β
(xiii) all powers of attorney with respect to the Business or any Purchased Asset;
Β
(xiv) all collective bargaining agreements or Contracts with any union or labor organization; and
Β
(xv) all other Contracts that are material to the Purchased Assets or the operation of the Business and not previously disclosed pursuant to this Section 4.21(a).
Β
(b) Each Material Contract is valid and binding on Seller in accordance with its terms and is in full force and effect. None of Seller or, to Sellerβs Knowledge, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Material Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Material Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder) have been made available to Buyer. There are no material disputes pending or threatened under any Contract included in the Purchased Assets.
Β
Section 4.22 Customer and Suppliers.
Β
(a) Section 4.22(a) of the Disclosure Schedules sets forth a true and complete list of (i) the top ten (10) customers and distributors of the Business (based on dollar amount of sales to such customers and distributors) for the twelve (12) month periods ended MarchΒ 31, 2018 and MarchΒ 31, 2019, and (ii) the amount for which each such customer or distributor was invoiced by Seller during such period. Seller has not received any written notice and to Sellerβs Knowledge there is no reason to believe that any of such customers or distributors (A) has, during the last 12 months, ceased or substantially reduced, or will cease or substantially reduce, use of products or services of the Business or (B) has, during the last 12 months, sought or is seeking, to reduce the price it will pay for the services of the Business. To Sellerβs Knowledge, none of such customers or distributors has otherwise threatened in writing to take any action described in the preceding sentence as a result of the consummation of the transactions contemplated by this Agreement and the Ancillary Documents.
Β
(b) Section 4.22(b) of the Disclosure Schedules sets forth a true and complete list of (i) the top ten (10) suppliers of the Business (based on dollar amount of purchases made by Seller) for the twelve (12) month periods ended March 31, 2018 and MarchΒ 31, 2019, and (ii) the amount for which Seller was invoiced by such supplier during such period. Seller has not received any written notice and to Sellerβs Knowledge there is no reason to believe that within the last 12 months there has been any material adverse change in the price of such supplies or services provided by any such supplier, or that any such supplier will not sell supplies or services to Buyer at any time after the Closing Date on terms and conditions substantially the same as those used in its current sales to Seller, subject to general and customary price increases. To Sellerβs Knowledge, no such supplier has otherwise threatened in writing to take any action described in the preceding sentence as a result of the consummation of the transactions contemplated by this Agreement and the Ancillary Documents.
Β
33
Β
Β
Section 4.23 Insurance. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all insurance policies of Seller are in full force and effect and provide insurance in such amounts and against such risks as Seller reasonably has determined to be prudent, taking into account the industries in which Seller operates, and as is sufficient to comply with applicable Law. All premiums due with respect to all such insurance policies have been paid or adequately accrued for. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, Seller is not in breach or default, and Seller has not taken any action or failed to take any action which, with notice or the lapse of time, would constitute such a breach or default, or permit termination or modification of, any of such insurance policies. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect: (i) no insurer of any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation; and (ii) no notice of cancellation or termination, other than pursuant to the expiration of a term in accordance with the terms thereof, has been received with respect to any such policy.
Β
Section 4.24 Proxy Statement. None of the information included or incorporated by reference in the letter to the stockholders, notice of meeting, proxy statement, and forms of proxy (collectively, the βSeller Proxy Statementβ), to be filed with the SEC in connection with this Agreement, will, at the date it is first mailed to Sellerβs stockholders or at the time of the Seller Stockholders Meeting or at the time of any amendment or supplement thereof, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, no representation or warranty is made by Seller with respect to statements made or incorporated by reference therein based on information supplied by Buyer expressly for inclusion or incorporation by reference in the Seller Proxy Statement. The Seller Proxy Statement will comply as to form in all material respects with the requirements of the Exchange Act.
Β
Section 4.25 Anti-Corruption Matters. Since AprilΒ 1, 2016, none of Seller or any director, officer, employee or agent of Seller has (a) used any funds for unlawful contributions, gifts, entertainment or other unlawful payments relating to an act by any Governmental Authority, (b) made any unlawful payment to any foreign or domestic government official or employee or to any foreign or domestic political party or campaign or violated any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or (c) made any other unlawful payment under any applicable Law relating to anti-corruption, bribery or similar matters. Since January 1, 2016, Seller has not disclosed to any Governmental Authority that it violated or may have violated any Law relating to anti-corruption, bribery or similar matters. No Governmental Authority is investigating, examining or reviewing Sellerβs compliance with any applicable provisions of any Law relating to anti-corruption, bribery or similar matters.
Β
34
Β
Β
Section 4.26 No Liquidation, Winding-Up; Creditors.
Β
(a) In the three (3) years immediately prior to the date of this Agreement, no Governmental Order has been made or petition presented, or resolution passed for the winding-up or liquidation of Seller, and there is not outstanding (i) any petition or Governmental Order for the winding-up or administration of Seller, (ii) any appointment of a receiver over the whole or part of the undertaking of assets of Seller, (iii) any assignment by Seller for the benefit of its creditors, (iv) any distress or execution or other process levied in respect of Seller which remains undischarged or (v) any unfulfilled or unsatisfied Order against Seller. Seller has not been deemed unable to pay its debts within the meaning of applicable Law. The operations of Seller have not been terminated. There are no current or past creditors of Seller to whom any applicable Law requires the delivery of notice or from whom any form of consent is required in conjunction with this Agreement, any Ancillary Document to which Seller is a party or any of the transactions contemplated hereby or thereby to which Seller is a party.
Β
(b) Seller is not entering into the Agreement with the actual intent to hinder, delay or defraud either present or future creditors, nor would the consummation of the transactions contemplated by this Agreement be reasonably expected to give rise to a claim of βfraudulent conveyanceβ or similar creditorsβ claims. As of the Closing Date, Seller will pay or make adequate provision for the satisfaction in full of any Excluded Liabilities of Seller under this Agreement. After giving effect to the transactions contemplated by this Agreement, Seller shall not have, as of such time, an unreasonably small amount of capital for the operation of the businesses in which it is proposed to be engaged following such time. and shall be able to pay its Liabilities as they mature.
Β
Section 4.27 Related Person Transactions. Except as set forth in the Seller SEC Documents, there are, and since April 1, 2016, there have been, no Contracts, transactions, arrangements or understandings between Seller, on the one hand, and any Affiliate (including any director, officer or employee) thereof or any holder of 5% or more of the shares of common stock of Seller, on the other hand, that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC in Sellerβs Form 10-K or proxy statement pertaining to an annual meeting of stockholders.
Β
Section 4.28 Brokers. Except for Mirus Capital Advisors (the βSeller Financial Advisorβ), no broker, finder or investment banker is entitled to any brokerage, finderβs or other fee or commission in connection with the transactions contemplated by this Agreement or any Ancillary Document based upon arrangements made by or on behalf of Seller.
Β
Section 4.29 NO OTHER REPRESENTATIONS OR WARRANTIES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS ARTICLE IV (WHICH INCLUDES THE DISCLOSURE SCHEDULES), NEITHER SELLER NOR ANY OTHER PERSON HAS MADE OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, WRITTEN OR ORAL. SELLER HEREBY DISCLAIMS ANY SUCH OTHER REPRESENTATION OR WARRANTY, WHETHER BY SELLER OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OR ANY OTHER PERSON, NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO BUYER OR ANY OTHER PERSON OF ANY DOCUMENTATION OR OTHER WRITTEN OR ORAL INFORMATION BY SELLER OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OR ANY OTHER PERSON, AND EXCEPT IN THE CASE OF FRAUD, NEITHER SELLER NOR ANY OTHER PERSON SHALL HAVE OR BE SUBJECT TO ANY LIABILITY RESULTING FROM SUCH DELIVERY OR DISCLOSURE, OR BUYERβS USE OF ANY SUCH DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY INFORMATION, DOCUMENTS, PROJECTIONS, FORECASTS, BUSINESS PLANS OR OTHER MATERIALS MADE AVAILABLE TO BUYER IN CERTAIN βDATA ROOMS,β OR MANAGEMENT PRESENTATIONS IN CONNECTION WITH THE NEGOTIATION, EXECUTION OR DELIVERY OF THIS AGREEMENT OR THE TRANSACTIONS).
Β
35
Β
Β
ARTICLE
V
Representations and Warranties of Buyer
Β
Buyer hereby represents and warrants to Seller that the statements contained in this ARTICLE V are true and correct as of the date hereof.
Β
Section 5.01 Organization of Buyer. Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.
Β
Section 5.02 Authority of Buyer. Buyer has full corporate power and authority to enter into this Agreement and the Ancillary Documents to which Buyer is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement and any Ancillary Document to which Buyer is a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms. When each Ancillary Document to which Buyer is or will be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto), such Ancillary Document will constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms.
Β
Section 5.03 No Conflicts; Consents. The execution, delivery and performance by Buyer of this Agreement and the Ancillary Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Buyer, (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Buyer or (c) require the consent, notice or other action by any Person under any Contract to which Buyer is a party. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the execution and delivery of this Agreement and the Ancillary Documents, except for such consents, approvals, Permits, Governmental Orders, declarations, filings or notices which, in the aggregate, would not have a material adverse effect on the ability of Buyer to consummate the transactions contemplated hereby on a timely basis.
Β
Section 5.04 Brokers. No broker, finder or investment banker is entitled to any brokerage, finderβs or other fee or commission in connection with the transactions contemplated by this Agreement or any Ancillary Document based upon arrangements made by or on behalf of Buyer.
Β
36
Β
Β
Section 5.05 Sufficiency of Funds. Buyer has sufficient cash on hand or other sources of immediately available funds to enable it to make payment of the Purchase Price and consummate the transactions contemplated by this Agreement.
Β
Section 5.06 Legal Proceedings. There are no Actions pending or, to Buyerβs knowledge, threatened against or by Buyer or any Affiliate of Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action.
Β
Section 5.07 Independent Investigation. Buyer has conducted its own independent investigation, review and analysis of the Business and the Purchased Assets. Buyer acknowledges and agrees that: (a) in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby, Buyer has relied solely upon its own investigation and the express representations and warranties of Seller set forth in ARTICLE IV of this Agreement (including related portions of the Disclosure Schedules); and (b) neither Seller nor any other Person has made any representation or warranty as to Seller, the Business, the Purchased Assets or this Agreement, except as expressly set forth in ARTICLE IV of this Agreement (including the related portions of the Disclosure Schedules.
Β
Β
Section 6.01 Conduct of Business of Seller. During the period from the date of this Agreement until the earlier to occur of the Closing or the termination of this Agreement in accordance with the terms set forth in ARTICLE VIII (the βInterim Periodβ), Seller shall, except as expressly contemplated by this Agreement or as required by applicable Law or with the prior written consent of Buyer, conduct its business in the ordinary course of business consistent with past practice, and, to the extent consistent therewith, Seller shall use its commercially reasonable efforts to preserve substantially intact its business organization, keep available the services of its current officers and employees, and preserve its present relationships with customers, suppliers, distributors, licensors, licensees, and other Persons having business relationships with it. Without limiting the generality of the foregoing, between the date of this Agreement and the Closing Date, Seller shall not, without the prior written consent of Buyer:
Β
(a) amend or propose to amend its Charter Documents;
Β
(b) acquire, by merger, consolidation, acquisition of stock or assets, or otherwise, any business or Person or division thereof or make any loans, advances or capital contributions to or investments in any Person;
Β
(c) transfer, license, sell, lease or otherwise dispose of (whether by way of merger, consolidation, sale of stock or assets, or otherwise) or pledge, encumber or otherwise subject to any Encumbrance (other than a Permitted Encumbrance), any Purchased Assets; provided that the foregoing shall not prohibit Seller from transferring, selling, leasing or disposing of obsolete equipment or assets being replaced, in each case in the ordinary course of business consistent with past practice;
Β
(d) incur any indebtedness for borrowed money or issue any debt securities or assume, guarantee or endorse, or otherwise become responsible for, the obligations of any Person, or make any loans or advances, in each case in excess of $50,000 and affecting the Business or the Purchased Assets, except for any indebtedness that is an Excluded Liability; provided, however, no such indebtedness, guaranty or other obligation shall be secured by any interest of any kind in the Purchased Assets;
Β
37
Β
Β
(e) enter into any Material Contract;
Β
(f) amend, waive, modify in any material respect or in a manner adverse to the Business or the Purchased Assets or consent to the termination of any Assumed Contract, or amend, waive, modify in any material respect or in a manner adverse to the Business or the Purchased Assets or consent to the termination of any of Sellerβs rights;
Β
(g) authorize or make any commitment with respect to any single capital expenditure for the Business that is in excess of $50,000 or capital expenditures which are, in the aggregate, in excess of $150,000 for the Business taken as a whole;
Β
(h) except as may be required by applicable Law or under any Seller Employee Plan or Material Contract: (i) enter into or increase the compensation, severance or benefits under any agreement with any Seller Employee; (ii) accelerate, make or grant, or permit any of their respective Affiliates to accelerate, make or grant, any bonus (other than bonuses payable to employees of Seller which shall not exceed $150,000 in the aggregate), severance or other compensation or modify the rate or terms of compensation, severance or benefits of any Seller Employee or any independent contractor or consultant of the Business; (iii) enter into, amend or terminate any Seller Employee Plan that will have an impact on the Business; or (iv) enter into, amend or terminate any collective bargaining agreement;
Β
(i) enter into any Contract with any Person contemplated by Section 4.27 in connection with or affecting the Business or the Purchased Assets;
Β
(j) make any material change in any method of financial accounting principles or practices, in each case except for any such change required by a change in GAAP or applicable Law;
Β
(k) institute, settle, or compromise any Action involving the payment of monetary damages by Seller of any amount exceeding $50,000 in the aggregate, other than (i) any Action brought against Buyer arising out of a breach or alleged breach of this Agreement by Buyer and (ii) the settlement of claims, liabilities or obligations fully reserved against on the Balance Sheet; provided that Seller shall not settle or agree to settle any Action which settlement involves a conduct remedy or injunctive or similar relief or has a restrictive or reputational impact on the Business or the Purchased Assets;
Β
(l) pay, discharge or satisfy any claim, liability or obligation (absolute, accrued, asserted or unasserted, contingent or otherwise) in excess of $50,000 relating to the Business or the Purchased Assets, other than the payment, discharge or satisfaction, in the ordinary course of business consistent with past practice, of Liabilities reflected or reserved against on the Balance Sheet or subsequently incurred in the ordinary course of business consistent with past practice;
Β
38
Β
Β
(m) (i)Β settle or compromise any material Tax claim, audit or assessment for an amount materially in excess of the amount reserved or accrued on the Balance Sheet (or most recent consolidated balance sheet included in the Seller SEC Documents), (ii)Β make or change any material Tax election, change any annual Tax accounting period, or adopt or change any method of Tax accounting, (iii) amend any material Tax Returns or file claims for material Tax refunds, or (iv) enter into any material closing agreement, surrender in writing any right to claim a material Tax refund, offset or other reduction in Tax liability or consent to any extension or waiver of the limitation period applicable to any material Tax claim or assessment relating to Seller;
Β
(n) enter into any agreement, agreement in principle, letter of intent, memorandum of understanding or similar Contract with respect to any joint venture, strategic partnership or alliance;
Β
(o) except in connection with actions permitted by Section 6.03 hereof, take any action to exempt any Person from, or make any acquisition of securities of Seller by any Person not subject to, any state takeover statute or similar statute or regulation that applies to Seller with respect to a Takeover Proposal or otherwise, except for Buyer or any of its Subsidiaries or Affiliates, or the transactions contemplated by this Agreement;
Β
(p) abandon, allow to lapse, sell, assign, transfer, grant any security interest in, otherwise encumber or dispose of any Seller IP, or grant any right or license to any Seller IP;
Β
(q) accelerate the collection of or discount any Accounts Receivable, delay the payment of Liabilities that would become Assumed Liabilities or defer expenses, reduce Inventories or otherwise increase cash on hand in connection with the Business, except in the ordinary course of business consistent with past practice;
Β
(r) terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy; or
Β
(s) announce an intention, enter into any formal or informal agreement, or otherwise make a commitment to do any of the foregoing.
Β
Section 6.02 Access to Information. During the Interim Period, Seller shall afford to Buyer reasonable access, during normal business hours and upon reasonable advance notice to Seller and in a manner as shall not unreasonably interfere with the business or operations of Seller, to the officers, employees, accountants, agents, properties, offices, and other facilities and to all books, records, contracts, and other assets of Seller, and Seller shall furnish promptly to Buyer such other information concerning the Business and the Purchased Assets as Buyer may reasonably request from time to time. Notwithstanding anything to the contrary in this Agreement, Seller shall not be required to provide access to or disclose any information to Buyer if such access or disclosure would, in Sellerβs sole discretion: (x) jeopardize any attorney-client or other privilege; or (y) contravene any applicable Law, fiduciary duty or binding agreement entered into prior to the date of this Agreement. No investigation byΒ BuyerΒ or other information received byΒ BuyerΒ shall operate as a waiver or otherwise affect any representation, warranty or agreement given or made byΒ SellerΒ in thisΒ Agreement. Buyer shall, and shall cause its Representatives to, abide by the terms of the Confidentiality Agreement with respect to any access or information provided pursuant to this Section 6.02.
Β
39
Β
Β
Β
(a) During the Interim Period, Seller shall not, and shall not authorize or permit its directors, officers, employees, investment bankers, attorneys, accountants, consultants, other agents or advisors (with respect to any Person, the foregoing Persons are referred to herein as such Personβs βRepresentativesβ) to, directly or indirectly, solicit, initiate or knowingly take any action to facilitate or encourage the submission of any Takeover Proposal or the making of any proposal that could reasonably be expected to lead to any Takeover Proposal, or, subject to Section 6.03(b): (i) other than clarifying the terms of the Takeover Proposal in accordance with this Section 6.03(a) or to disclose to such Person the existence of this Section 6.03(a), conduct or engage in any discussions or negotiations with, disclose any non-public information relating to Seller, afford access to the business, properties, assets, books, or records of Seller, or knowingly assist, participate in, facilitate, or encourage any effort by, any third party that is seeking to make, or has made, any Takeover Proposal; (ii) amend or grant any waiver or release under any standstill or similar agreement with respect to any class of equity securities of Seller; or (iii) enter into any agreement in principle, letter of intent, term sheet, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement, or other Contract relating to any Takeover Proposal (each, an βAlternative Acquisition Agreementβ). Except as expressly permitted by this Section 6.03, the Seller Board shall not effect an Adverse Recommendation Change. Seller shall cease immediately and cause to be terminated, and shall not authorize or knowingly permit any of its Representatives to continue, any and all existing activities, discussions, or negotiations, if any, with any third party conducted prior to the date hereof with respect to any Takeover Proposal and shall use its commercially reasonable efforts to cause any such third party (or its agents or advisors) in possession of non-public information in respect of Seller that was furnished by or on behalf of Seller to return or destroy (and confirm destruction of) all such information.
Β
(b) Notwithstanding anything in Section 6.03(a) to the contrary, prior to the receipt of the Requisite Seller Vote, the Seller Board, directly or indirectly through any Representative, may, subject to Section 6.03(c): (i) participate in negotiations or discussions with any third party that has made (and not withdrawn) a bona fide, unsolicited Takeover Proposal in writing that the Seller Board believes in good faith, after consultation with outside legal counsel and the Seller Financial Advisor, constitutes or is reasonably expected to lead to a Superior Proposal; (ii) following receipt of and on account of a Superior Proposal, make an Adverse Recommendation Change; and/or (iii) take any action that any court of competent jurisdiction orders Seller to take (which order remains unstayed), but in each case referred to in the foregoing clauses (i) through (iii), only if the Seller Board determines in good faith, after consultation with outside legal counsel, that the failure to take such action would cause the Seller Board to be inconsistent with its fiduciary duties under applicable Law. Nothing contained herein shall prevent the Seller Board from (x) disclosing to Sellerβs stockholders a position contemplated by Rule 14d-9 and Rule 14e-2(a) promulgated under the Exchange Act or (y) making any βstop, look and listenβ communication to Sellerβs stockholders pursuant to Rule 14d-9(f) under the Exchange Act with regard to a Takeover Proposal, if Seller determines, after consultation with outside legal counsel, that failure to disclose such position would reasonably be expected to constitute a violation of applicable Law.
Β
40
Β
Β
(c)Β The Seller Board shall not take any of the actions referred to in clauses (i) through (iii) of Section 6.03(b) unless Seller shall have delivered to Buyer a prior written notice advising Buyer that it intends to take such action. Seller shall notify Buyer promptly (but in no event later than twenty-four (24) hours) after it obtains Knowledge of the receipt by Seller (or any of its Representatives) of any Takeover Proposal, any inquiry that could reasonably be expected to lead to a Takeover Proposal, any request for non-public information relating to Seller or for access to the business, properties, assets, books or records of Seller by any third party. In such notice, Seller shall identify the third party making, and details of the material terms and conditions of, any such Takeover Proposal, indication or request. Seller shall keep Buyer fully informed, on a current basis, of the status and material terms of any such Takeover Proposal, indication or request, including any material amendments or proposed amendments as to price and other material terms thereof. Seller shall provide Buyer with at least forty-eight (48) hoursβ prior notice of any meeting of the Seller Board (or such lesser notice as is provided to the members of the Seller Board) at which the Seller Board is reasonably expected to consider any Takeover Proposal. Seller shall promptly provide Buyer with a list of any non-public information concerning Sellerβs business, present or future performance, financial condition or results of operations, provided to any third party, and, to the extent such information has not been previously provided to Buyer, copies of such information.
Β
(d)Β Notwithstanding the foregoing, at any time prior to the receipt of the Requisite Seller Vote, the Seller Board may effect an Adverse Recommendation Change or enter into (or permit anyΒ AffiliateΒ to enter into) anΒ Alternative Acquisition Agreement, if: (i) Seller promptly notifies Buyer, in writing, at least five (5) Business Days (the βSuperior Proposal Notice Periodβ) before making an Adverse Recommendation Change or entering into an Alternative Acquisition Agreement, of its intention to take such action with respect to a Superior Proposal, which notice shall state expressly that Seller has received a Takeover Proposal that the Seller Board intends to declare a Superior Proposal and that the Seller Board intends to effect an Adverse Recommendation Change and/or Seller intends to enter into an Alternative Acquisition Agreement; (ii) Seller attaches to such notice the most current version of the proposed agreement (which version shall be updated on a prompt basis) and the identity of the third party making such Superior Proposal; (iii) Seller shall, and shall cause its Representatives to, during the Superior Proposal Notice Period, negotiate with Buyer in good faith to make such adjustments in the terms and conditions of this Agreement so that such Takeover Proposal ceases to constitute a Superior Proposal, if Buyer, in its discretion, proposes to make such adjustments (it being agreed that in the event that, after commencement of the Superior Proposal Notice Period, there is any material revision to the terms of a Superior Proposal, including any revision in price, the Superior Proposal Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Superior Proposal Notice Period subsequent to the xxxx Xxxxxx notifies Buyer of any such material revision (it being understood that there may be multiple extensions)); and (iv) the Seller Board determines in good faith, after consulting with outside legal counsel and its Seller Financial Advisor, that such Takeover Proposal continues to constitute a Superior Proposal after taking into account any adjustments made by Buyer during the Superior Proposal Notice Period in the terms and conditions of this Agreement.
Β
41
Β
Β
(e)Β Notwithstanding anything to the contrary in the foregoing, in response to an Intervening Event that has occurred after the date of this Agreement but prior to the receipt of the Requisite Seller Vote, the Seller Board may effect an Adverse Recommendation Change, if: (i) prior to effecting the Adverse Recommendation Change, Seller promptly notifies Buyer, in writing, at least five (5) Business Days (the βIntervening Event Notice Periodβ) before taking such action of its intent to consider such action (which notice shall not, by itself, constitute an Adverse Recommendation Change), and which notice shall include a reasonably detailed description of the underlying facts giving rise to, and the reasons for taking, such action; (ii) Seller shall, and shall cause its Representatives to, during the Intervening Event Notice Period, negotiate with Buyer in good faith to make such adjustments in the terms and conditions of this Agreement so that the underlying facts giving rise to, and the reasons for taking such action, ceases to constitute an Intervening Event, if Buyer, in its discretion, proposes to make such adjustments (it being agreed that in the event that, after commencement of the Intervening Event Notice Period, there is any material development in an Intervening Event, the Intervening Event Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Intervening Event Notice Period subsequent to the xxxx Xxxxxx notifies Buyer of any such material development (it being understood that there may be multiple extensions)); and (iii) the Seller Board determines in good faith, after consulting with outside legal counsel and its Seller Financial Advisor, that the failure to effect such Adverse Recommendation Change, after taking into account any adjustments made by Buyer during the Intervening Event Notice Period, would continue to be inconsistent with its fiduciary duties under applicable Law. Seller acknowledges and hereby agrees that any Adverse Recommendation Change effected (or proposed to be effected) in response to or in connection with any Takeover Proposal may be made solely and exclusively pursuant to Section 6.03(d) only, and may not be made pursuant to this Section 6.03(e), and any Adverse Recommendation Change may only be made pursuant to this Section 6.03 and no other provisions of this Agreement.
Β
Section 6.04Β Stockholders Meeting; Preparation of Proxy Materials.
Β
(a)Β Seller shall take all action necessary to duly call, give notice of, convene, and hold the Seller Stockholders Meeting as soon as reasonably practicable after the date of this Agreement, and, in connection therewith, Seller shall mail the Seller Proxy Statement to the holders of Sellerβs common stock in advance of such meeting. Except to the extent that the Seller Board shall have effected an Adverse Recommendation Change as permitted by Section 6.03 hereof, the Seller Proxy Statement shall include the Seller Board Recommendation. Subject to Section 6.03 hereof, Seller shall use reasonable best efforts to: (i) solicit the Requisite Seller Vote to effectuate this Agreement; and (ii) take all other actions necessary or advisable to secure the vote or consent of the holders of Sellerβs common stock required by applicable Law to obtain such approval. Seller shall not submit any other proposals for approval at the Seller Stockholders Meeting without the prior written consent of Buyer. Once the Seller Stockholders Meeting has been called and noticed, Seller shall not postpone or adjourn the Seller Stockholders Meeting without the consent of Buyer (other than (x) in order to obtain a quorum of its stockholders or (y) to allow reasonable additional time after the filing and mailing of any supplemental or amended disclosures to the Seller Proxy Statement for compliance with applicable legal requirements). If theΒ Seller BoardΒ makes an Adverse Recommendation Change, such Adverse Recommendation Change shall not alter the obligation ofΒ SellerΒ to submit the adoption of thisΒ AgreementΒ to the holders of Sellerβs common stock at theΒ Seller Stockholders MeetingΒ to consider and vote upon, unless thisΒ AgreementΒ shall have been terminated in accordance with its terms prior to theΒ Seller Stockholders Meeting.
Β
42
Β
Β
(b)Β In connection with the Seller Stockholders Meeting, as soon as reasonably practicable following the date of this Agreement, Seller shall prepare and file the Seller Proxy Statement with the SEC. Buyer and Seller shall cooperate and consult with each other in the preparation of the Seller Proxy Statement. Without limiting the generality of the foregoing, Buyer shall furnish Seller the information relating to it required by the Exchange Act and the rules and regulations promulgated thereunder to be set forth in the Seller Proxy Statement. Seller shall not file the Seller Proxy Statement, or any amendment or supplement thereto, without providing Buyer a reasonable opportunity to review and comment thereon (which comments shall be reasonably considered by Seller). Seller shall use its reasonable best efforts to cause the Seller Proxy Statement at the date that it (and any amendment or supplement thereto) is first published, sent or given to the stockholders of Seller and at the time of the Seller Stockholders Meeting, to comply as to form in all material respects with the requirements of the Exchange Act and the rules and regulations promulgated thereunder. Seller shall use its reasonable best efforts to resolve, and each party hereto agrees to consult and cooperate with the other party in resolving, all SEC comments with respect to the Seller Proxy Statement as promptly as practicable after receipt thereof and to cause the Seller Proxy Statement in definitive form to be cleared by the SEC and mailed to Sellerβs stockholders as promptly as reasonably practicable following filing with the SEC. Seller agrees to consult with Buyer prior to responding to SEC comments with respect to any preliminary Seller Proxy Statement. Each of Buyer and Seller agree to correct any information provided by it for use in the Seller Proxy Statement that shall have become false or misleading and Seller shall promptly prepare and mail to its stockholders an amendment or supplement setting forth such correction. Seller shall as soon as reasonably practicable (i) notify Buyer of the receipt of any comments from the SEC with respect to the Seller Proxy Statement and any request by the SEC for any amendment to the Seller Proxy Statement or for additional information and (ii) provide Buyer with copies of all written correspondence between Seller and its Representatives, on the one hand, and the SEC, on the other hand, with respect to the Seller Proxy Statement.
Β
Section 6.05Β Notices of Certain Events; Stockholder Litigation; No Effect on Disclosure Schedules.
Β
(a)Β During the Interim Period, Seller shall notify Buyer, and Buyer shall notify Seller, promptly of (i) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement, (ii) any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement and (iii) any event, change, or effect between the date of this Agreement and the Closing which causes or is reasonably likely to cause the failure of the conditions set forth in Section 7.02 (in the case of Seller) or Section 7.03 (in the case of Buyer), to be satisfied.
Β
(b)Β Seller shall promptly advise Buyer in writing after becoming aware of any Action commenced, or to Sellerβs Knowledge threatened, after the date hereof against Seller or any of its directors by any stockholder of Seller (on their own behalf or on behalf of Seller) relating to this Agreement or the transactions contemplated hereby and shall keep Buyer reasonably informed regarding any such Action. Seller shall give Buyer the opportunity to consult with Seller regarding the defense or settlement of any such stockholder litigation and shall consider Buyerβs views with respect to such stockholder litigation and shall not settle any such stockholder litigation without the prior written consent of Buyer (which consent shall not be unreasonably withheld, delayed or conditioned).
Β
(c)Β In no event shall (i) the delivery of any notice by a party hereto pursuant to this Section 6.05 limit or otherwise affect the respective rights, obligations, representations, warranties, covenants, or agreements of the parties or the conditions to the obligations of the parties under this Agreement or (ii) disclosure by Seller or Buyer be deemed to amend or supplement the Disclosure Schedules or constitute an exception to any representation or warranty.
Β
43
Β
Β
Section 6.06Β Commercially Reasonable Efforts. On the terms and subject to the conditions set forth in this Agreement, each of Buyer and Seller shall use its respective commercially reasonable efforts to take promptly, or cause to be taken promptly, all actions, and to do promptly, or cause to be done promptly, all things necessary, proper or advisable under applicable Laws to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement and the Ancillary Documents, including using commercially reasonable efforts to cause the conditions to Closing set forth in ARTICLE VII to be satisfied as soon as practicable after the date hereof. Seller shall use its commercially reasonable efforts to obtain in writing as promptly as practicable all Seller Required Consents.
Β
Section 6.07Β Employment Matters.
Β
(a)Β Buyer shall make offers of βat willβ employment to any active Seller Employee on or after the Closing Date. Such offers of employment shall include (i) at least the same base salary or hourly wage rate, as applicable, as such Seller Employees received immediately prior to the Closing Date; and (ii) employee benefits (excluding equity, phantom equity, retention bonuses, change in control bonuses, deferred compensation plans or arrangements, defined benefit pension plans, retiree medical insurance benefits, and/or retiree life insurance benefits) that are substantially similar in the aggregate to those employee benefits (excluding equity, phantom equity, retention bonuses, change in control bonuses, deferred compensation plans or arrangements, defined benefit pension plans, retiree medical insurance benefits, and/or retiree life insurance benefits) that are offered to similarly situated employees of Buyer. Seller shall immediately terminate the employment of any Seller Employee who is offered employment with Buyer, and upon such Seller Employeesβ acceptance of the offer of employment with Buyer, such Seller Employee shall be deemed a Continuing Employee. Seller shall remain responsible for any Liabilities related to any Seller Employee who does not become a Continuing Employee, including any Seller Employee who does not accept Buyerβs offer of employment.
Β
(b)Β Seller shall be responsible for the payment to all current and former Seller Employees, including the Continuing Employees, and any current or former independent contractors, temporary employees, or consultants, all salaries, wages, fees, and benefits due or accrued for periods prior to the Closing Date, irrespective of whether such amounts are payable prior to, on or after the Closing Date. Seller shall be responsible for the payment of any transaction bonus, change in control bonus, retention bonus, severance, or other payments that are payable to current or former Seller Employees, including for the Continuing Employees, or current or former independent contractors in connection with the transactions contemplated by this Agreement. Without limiting the foregoing, Seller shall pay at the Closing or immediately thereafter all bonuses or target bonuses and commissions that are related to the period prior to the Closing, including any target bonuses or commissions related to the period from the beginning of the current performance period through the Closing Date, for all Continuing Employees.
Β
44
Β
Β
(c)Β Seller shall remain solely responsible for all Liabilities under the Seller Employee Plans, including all claims for medical, dental, life, health, accident, or disability benefits that are brought by any current or former Seller Employee, or the beneficiaries thereof, including any of the Continuing Employees, which claims relate to events occurring prior to, on, or in the case of Seller Employees other than the Continuing Employees after the Closing Date. Seller shall pay, or cause to be paid, all such amounts to the appropriate persons as and when due. Seller also shall remain solely responsible for all workersβ compensation claims of any current or former Seller Employees, including for the Continuing Employees as it relates to events that occur prior to the Closing Date. Seller shall remain responsible for any Liabilities under COBRA with respect to any Seller Employee who was a participant in a Seller Employee Plan, irrespective of when such Liabilities arise under COBRA.
Β
(d)Β If Seller or an Affiliate of Seller must make a payment to a Continuing Employee with respect to his or her unused vacation, personal days, or sick days related to the pre-Closing period, then Seller shall be responsible for any such payment and Buyer shall not be required to honor such unused vacation, personal days, or sick days.
Β
(e)Β Seller shall provide the Buyer with a schedule which shall, as of the Closing Date, set forth a list of each former employee of the Business whose employment was involuntarily terminated within the ninety (90) day period immediately preceding the Closing Date. Seller shall be responsible for, and shall assume all Liabilities in connection with, compliance with WARN and any similar state or local Law in connection with any Seller Employee for terminations that occur prior to or on the Closing. Buyer shall assume responsibility for compliance with WARN and any similar state of local law in connection with the termination of any Continuing Employee that takes place after the Closing Date.
Β
(f)Β Seller shall assign to Buyer all confidentiality, intellectual property assignment, non-competition, non-solicitation, and non-disparagement agreements with Seller and any Continuing Employee on the Closing Date.
Β
Section 6.08Β Public Announcements. The initial press release with respect to this Agreement and the transactions contemplated hereby shall be a release mutually agreed to by Seller and Buyer. Thereafter, Buyer and Seller agree that no public release or announcement concerning the transactions contemplated hereby shall be issued by any party without the prior written consent of Seller and Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable Law or the rules or regulations of any applicable United States securities exchange or other Governmental Authority to which the relevant party is subject or submits, in which case the party required to make the release or announcement shall use its reasonable best efforts to allow the other party reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, the restrictions set forth in this Section 6.08 shall not apply to any release or announcement made or proposed to be made in connection with and related to an Adverse Recommendation Change or in compliance with Section 6.03.
Β
45
Β
Β
Section 6.09Β Anti-Takeover Statutes. If any βcontrol share acquisition,β βfair price,β βmoratorium,β or other anti-takeover Law becomes or is deemed to be applicable to Seller or Buyer or any other transaction contemplated by this Agreement, then each of Seller and the Seller Board shall grant such approvals and take such actions as are necessary so that the transactions contemplated hereby may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to render such anti-takeover Law inapplicable to the foregoing.
Β
Section 6.10Β Confidentiality.
Β
(a)Β Buyer acknowledges and agrees that the Confidentiality Agreement remains in full force and effect and, in addition, covenants and agrees to keep confidential, in accordance with the provisions of the Confidentiality Agreement, information provided to Buyer pursuant to this Agreement. If this Agreement is, for any reason, terminated prior to the Closing, the Confidentiality Agreement and the provisions of this Section 6.10 shall nonetheless continue in full force and effect.
Β
(b)Β From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Business, except to the extent that Seller can show that such information (a) is generally available to and known by the public through no fault of Seller, any of its Affiliates or their respective Representatives, or (b) is lawfully acquired by Seller, any of its Affiliates or their respective Representatives from and after the Closing from sources that are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, then Seller shall promptly notify Buyer in writing and shall disclose only that portion of such information that Seller is advised by its counsel in writing it is legally required to be disclosed; provided that Seller shall use commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.
Β
Section 6.11Β Change of Name. Promptly following the Closing, Seller shall file the necessary documentation in its jurisdiction of incorporation and any jurisdiction where it is registered to do business to amend its Charter Documents to change its name to βEKIMAS Corporationβ. From and after the Closing Date, except (a) as permitted by this Section 6.11, (b) in connection with Sellerβs performance of the transactions contemplated by this Agreement and the Ancillary Documents and (c) in connection with its ordinary course corporate filings and the preparation of its Tax Returns, Seller shall not conduct business under the name βAdvanSource Biomaterials Corporation,β βASBβ or any name similar thereto in any jurisdiction, and Seller shall execute any documentation necessary for Buyer or any of its Affiliates to use any such names or any name similar thereto.
Β
Section 6.12Β Release of Encumbrances. Prior to the Closing, Seller shall take any and all actions necessary to release any and all Encumbrances on the Purchased Assets. Without in any way limiting the foregoing, Seller shall have delivered to Buyer evidence of the execution of UCC-3 termination statements, releases of any security interests in any intellectual property rights and other agreements, filings and notices as necessary or reasonably requested to release all Encumbrances of record on the Purchased Assets, in form and substance reasonably satisfactory to Buyer.
Β
46
Β
Β
Section 6.13Β Bulk Sales. Buyer and Seller each hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.
Β
Section 6.14Β Further Assurances; Wrong Pockets.
Β
(a)Β Seller shall, and shall cause its Affiliates to, execute and deliver such further instruments of conveyance and transfer and take such additional action as Buyer may reasonably request to effect, consummate, confirm or evidence the sale and transfer to Buyer of the Purchased Assets and the other transactions contemplated by this Agreement. Buyer shall, and shall cause its Affiliates to, execute and deliver such further instruments of assumption and take such additional action as Seller may reasonably request to effect, consummate, confirm or evidence the transactions contemplated hereby, including the assumption by Buyer of the Assumed Liabilities.
Β
(b)Β Without limiting the generality of the foregoing, if at any time following the Closing it becomes apparent that any Purchased Asset (including any Contract) that should have been transferred to Buyer pursuant to this Agreement was not so transferred, or any Excluded Asset was inadvertently transferred to Buyer, then Seller shall, or Buyer shall, and shall cause its Affiliates to, as applicable, in each case as promptly as practicable, (i) transfer all rights, title and interest in (A) such Purchased Asset to Buyer or as Buyer may direct, or (B) such Excluded Asset to Seller or as Seller may direct, as applicable, in each case for no additional consideration, and (ii) hold its right, title and interest in and to such Purchased Asset or Excluded Asset, as applicable, in trust for the applicable transferee until such time as such transfer is completed.
Β
Section 6.15Β Supplement to Disclosure Schedules. From time to time prior to the Closing, Seller shall promptly supplement or amend the Disclosure Schedules hereto with respect to any matter hereafter arising or of which it becomes aware after the date hereof, which, if existing or occurring at the date of thisΒ Agreement, would constitute a material breach of any representation and warranty of Seller in this Agreement (each a βSchedule Supplementβ). Any disclosure in any such Schedule Supplement shall not be deemed to have cured any inaccuracy in or breach of any representation or warranty contained in this Agreement, including for purposes of termination rights contained in this Agreement or of determining whether or not the conditions set forth in Section 7.02(a) have been satisfied.
Β
Section 6.16Β Accounts Receivable. From and after the Closing, if Seller or any of its Affiliates receives or collects any funds relating to the Business and any post-Closing period or business activity, then Seller or its Affiliate shall remit such funds to Buyer within ten (10) Business Days after its receipt thereof. From and after the Closing, if Buyer or any of its Affiliates receives or collects any funds relating to any Excluded Asset, then Buyer or its Affiliate, as the case may be, shall remit any such funds to Seller within ten (10) Business Days after its receipt thereof.
Β
Section 6.17Β Agreed Obligations. Seller shall deliver to Buyer no later than two (2) Business Days prior to the Closing Date a true and correct payoff letter from the Landlord containing the calculation of the Agreed Obligations.
Β
47
Β
Β
Conditions to Closing
Β
Section 7.01Β Conditions to Obligations of Both Parties. The obligations of each party hereto to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions any of which may, to the extent permitted by applicable Law, be waived in writing by either party in its sole discretion (provided that such waiver shall only be effective as to the obligations of such party):
Β
(a)Β No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order which is in effect and has the effect of (i) preventing the performance of this Agreement or the consummation of any of the transactions contemplated hereby or declaring unlawful any of the transactions contemplated hereby, (ii) causing any of the transactions contemplated hereby to be rescinded following consummation or (iii) affecting adversely the right of Buyer to own the Purchased Assets following consummation of the transactions contemplated hereby.
Β
(b)Β No Action shall be pending before any Governmental Authority pursuant to which an unfavorable Governmental Order in respect thereof would (i) prevent the performance of this Agreement or the consummation of any of the transactions contemplated hereby or declare unlawful any of the transactions contemplated hereby, (ii) cause any of the transactions contemplated hereby to be rescinded following consummation or (iii) affect adversely the right of Buyer to own the Purchased Assets.
Β
(c)Β The Requisite Seller Vote shall have been obtained.
Β
Section 7.02Β Conditions to Obligations of Buyer. The obligations of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Buyerβs waiver, at or prior to the Closing, of each of the following conditions:
Β
(a)Β Other than the representations and warranties of Seller contained in Section 4.01, Section 4.02, Section 4.03, Section 4.05 and Section 4.28, the representations and warranties of Seller contained in this Agreement, the Ancillary Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (without giving effect to any limitation indicated by the words βMaterial Adverse Effect,β βin all material respects,β βin any material respect,β βmaterial,β or βmateriallyβ) when made and as of immediately prior to the Closing, as if made at and as of such time (except those representations and warranties that address matters only as of a particular date, which shall be true and correct in all respects as of that date), except where the failure of such representations and warranties to be so true and correct would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The representations and warranties of Seller contained Section 4.01, Section 4.02, Section 4.03, Section 4.05 and Section 4.28 shall be true and correct in all respects when made and as of immediately prior to the Closing, as if made at and as of such time (except those representations and warranties that address matters only as of a particular date, which shall be true and correct in all respects as of that date).
Β
48
Β
Β
(b)Β Seller shall have performed and complied in all material respects with all covenants and obligations required by this Agreement and each of the Ancillary Documents to be performed or complied with by it prior to or on the Closing Date.
Β
(c)Β Buyer shall have received the Seller Required Consents set forth in Section 7.02(c) of the Disclosure Schedules (the βClosing Consentsβ), each of which shall not be subject to the satisfaction of any condition that has not been satisfied or waived, shall be in full force and effect and shall be evidenced by documentation in form and substance reasonably satisfactory to Buyer.
Β
(d)Β From the date of this Agreement, there shall not have occurred any Material Adverse Effect, nor shall any event or events have occurred that, individually or in the aggregate, with or without the lapse of time, could reasonably be expected to result in a Material Adverse Effect.
Β
(e)Β Seller shall have delivered to Buyer duly executed counterparts to the Ancillary Documents and such other documents and deliveries set forth in Section 3.02(a).
Β
(f)Β Buyer shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Seller, that each of the conditions set forth in Section 7.02(a) and Section 7.02(b) have been satisfied (the βSeller Closing Certificateβ).
Β
(g)Β Buyer shall have received a certificate of the Secretary (or equivalent officer) of Seller certifying (i) that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Seller authorizing the execution, delivery and performance of this Agreement and the Ancillary Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby and (ii) the names and signatures of the officers of Seller authorized to sign this Agreement, the Ancillary Documents and the other documents to be delivered hereunder and thereunder.
Β
(h)Β Buyer shall have received a certificate pursuant to Treasury Regulations Section 1.1445-2(b) (the βFIRPTA Certificateβ) that Seller is not a foreign person within the meaning of Section 1445 and 897 of the Code duly executed by Seller.
Β
(i)Β Seller shall have delivered to Buyer such other documents or instruments as Buyer reasonably requests and are reasonably necessary to consummate the transactions contemplated by this Agreement.
Β
Section 7.03Β Conditions to Obligations of Seller. The obligations of Seller to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Sellerβs waiver, at or prior to the Closing, of each of the following conditions:
Β
(a)Β The representations and warranties of Buyer contained in this Agreement, the Ancillary Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (without giving effect to any limitation indicated by the words βMaterial Adverse Effect,β βin all material respects,β βin any material respect,β βmaterial,β or βmateriallyβ) when made and as of immediately prior to the Closing, as if made at and as of such time (except those representations and warranties that address matters only as of a particular date, which shall be true and correct in all respects as of that date), except where the failure of such representations and warranties to be so true and correct would not reasonably be expected to be, individually or in the aggregate materially adverse to the ability of Buyer to consummate the transactions contemplated hereby on a timely basis.
Β
49
Β
Β
(b)Β Buyer shall have performed and complied in all material respects with all covenants and obligations required by this Agreement and each of the Ancillary Documents to be performed or complied with by it prior to or on the Closing Date.
Β
(c)Β Buyer shall have delivered to Seller duly executed counterparts to the Ancillary Documents and such other documents and deliveries set forth in Section 3.02(b).
Β
(d)Β Seller shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Buyer, that each of the conditions set forth in Section 7.03(a) and Section 7.03(b) have been satisfied (the βBuyer Closing Certificateβ).
Β
(e)Β Seller shall have received a certificate of the Secretary (or equivalent officer) of Buyer certifying (i) that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Buyer authorizing the execution, delivery and performance of this Agreement and the Ancillary Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby and (ii) the names and signatures of the officers of Buyer authorized to sign this Agreement, the Ancillary Documents and the other documents to be delivered hereunder and thereunder.
Β
(f)Β Buyer shall have delivered to Seller such other documents or instruments as Seller reasonably requests and are reasonably necessary to consummate the transactions contemplated by this Agreement.
Β
Termination
Β
Section 8.01Β Termination. This Agreement may be terminated at any time prior to the Closing:
Β
(a)Β by the mutual written consent of Seller and Buyer;
Β
(b)Β by Buyer or Seller by written notice to the other party in the event that:
Β
(i)Β there shall be any Law that makes consummation of this Agreement illegal or otherwise prohibited,
Β
(ii)Β any Governmental Authority shall have issued a Governmental Order restraining or enjoining this Agreement, and such Governmental Order shall have become final and non-appealable,
Β
50
Β
Β
(iii)Β the Closing shall not have occurred by March 31, 2020 (the βOutside Dateβ); provided that the right to terminate this Agreement pursuant to this Section 8.01(b)(iii) shall not be available to any party whose failure to perform or comply with any of the covenants, agreements or conditions herein has been the primary cause of, or the primary factor that resulted in, the failure of the Closing to be consummated by the Outside Date, or
Β
(iv)Β if the Requisite Seller Vote shall not have been obtained at the Seller Stockholders Meeting duly convened therefor or at any adjournment or postponement thereof at which a vote to approve the transactions contemplated by this Agreement was taken; provided that Seller shall not be permitted to terminate this Agreement pursuant to this Section 8.01(b)(iv) if the failure to obtain such Requisite Seller Vote is proximately caused by any action or failure to act of Seller that constitutes a breach of this Agreement;
Β
(c)Β by Buyer by written notice to Seller if Buyer is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Seller pursuant to this Agreement that would give rise to the failure of any of the conditions specified in ARTICLE VII and such breach, inaccuracy or failure has not been cured by Seller within fifteen (15) Business Days of Sellerβs receipt of written notice of such breach from Buyer;
Β
(d)Β by Seller by written notice to Buyer if Seller is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Buyer pursuant to this Agreement that would give rise to the failure of any of the conditions specified in ARTICLE VII and such breach, inaccuracy or failure has not been cured by Buyer within fifteen (15) Business Days of Buyerβs receipt of written notice of such breach from Seller;
Β
(e)Β by Buyer by written notice to Seller, if at any time the Seller Board (or a committee thereof) has effected an Adverse Recommendation Change; or
Β
(f)Β by Seller by written notice to Buyer, at any time prior to receiving the Requisite Seller Vote, if (i) (x) Seller has received a Superior Proposal and the Seller Board authorized Seller to enter into an Alternative Acquisition Agreement to consummate a transaction contemplated by that Superior Proposal or (y) the Seller Board made an Adverse Recommendation Change as a result of an Intervening Event; and (ii) Seller has complied in all material respects with Section 6.03 with respect to such Superior Proposal.
Β
Section 8.02Β Effect of Termination. In the event of the termination of this Agreement in accordance with this ARTICLE VIII, this Agreement shall forthwith become void and there shall be no liability on the part of any party hereto except:
Β
(a)Β as set forth in Section 6.09, Section 6.10, this ARTICLE VIII and ARTICLE IX; and
Β
(b)Β that nothing herein shall relieve any party hereto from liability for any willful breach of any provision hereof.
Β
51
Β
Β
Miscellaneous
Β
Section 9.01Β Expenses. Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.
Β
Section 9.02Β Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt), (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested), (c) on the date sent by e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient (provided, that if given by e-mail, such notice, request, consent, claim, demand, waiver or other communication shall be followed up within one (1) Business Day of dispatch pursuant to one of the other methods described herein and provided further that such confirmatory dispatch shall not be deemed the date of transmission) or (d) on the third (3rd) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 9.02):
Β
(a)Β If to Buyer, to:
Mitsubishi Chemical Performance Polymers, Inc.
2000 Xxxx Xxxx
Xxxxx, XX 00000
Attention: President
Β
with a copy (which shall not constitute notice) to:
Β
Mitsubishi Chemical Holdings America, Inc.
650 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
Attention: General Counsel
Β
and
Β
Winston & Xxxxxx LLP
200 Xxxx Xxxxxx
Xxx Xxxx, XX 00000
Attention: Xxxxx Xxxxx
Email: Xxxxxx@xxxxxxx.xxx
Telephone No.: (000) 000-0000
Β
52
Β
Β
(b)Β If to Seller, to:
Β
AdvanSource Biomaterials Corporation
220 Xxxxxxx Xxxxxx
Xxxxxxxxxx, XX 00000
Attention: Xxxxxxx X. Xxxxx
Email: Xxxxxx@xxxxxxxxxxxxxxx.xxx
Telephone No.: (000) 000-0000
Β
with a copy (which shall not constitute notice) to:
Β
Ellenoff Xxxxxxxx & Schole LLP
1345 Avenue of the Amxxxxxx, 00xx Xxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxx Xxxxxxxx, Esq.
Email: Xxxxxxxxxx@xxxxxx.xxx
Telephone No.: (000) 000-0000
Β
Section 9.03Β Interpretation. For purposes of this Agreement, (a) the words βinclude,β βincludesβ and βincludingβ shall be deemed to be followed by the words βwithout limitationβ; (b) the word βorβ is not exclusive; and (c) the words βherein,β βhereof,β βhereby,β βheretoβ and βhereunderβ refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document mean such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute mean such statute as amended from time to time and include any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.
Β
53
Β
Β
Section 9.04Β Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
Β
Section 9.05Β Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that this Agreement be consummated as originally contemplated to the greatest extent possible.
Β
Section 9.06Β Entire Agreement. This Agreement and the Ancillary Documents constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the Ancillary Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.
Β
Section 9.07Β Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed; provided that prior to the Closing Date, Buyer may, without the prior written consent of Seller, assign all or any portion of its rights under this Agreement to one or more of its Affiliates. No assignment shall relieve the assigning party of any of its obligations hereunder.
Β
Section 9.08Β No Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Β
Section 9.09Β Amendment and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Β
54
Β
Β
Section 9.10Β Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.
Β
(a)Β This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
Β
(b)Β Each of the parties hereto irrevocably agrees that any Action with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by any party hereto or its successors or assigns, shall be brought and determined exclusively in the Court of Chancery of the State of Delaware, or in the event (but only in the event) that such court does not have subject matter jurisdiction over such Action, in the Superior Court of the State of Delaware. Each of the parties hereto agrees that mailing of process or other papers in connection with any such Action in the manner provided in Section 9.02 or in such other manner as may be permitted by applicable Laws, shall be valid and sufficient service thereof. Each of the parties hereto hereby irrevocably submits with regard to any such Action for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it shall not bring any Action relating to this Agreement or any of the transactions contemplated by this Agreement in any court or tribunal other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any Action with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder: (i) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to serve process in accordance with this Section 9.10(b); (ii) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise); and (iii) to the fullest extent permitted by the applicable Law, any claim that (A) the suit, action or proceeding in such court is brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper, or (C) this Agreement or the subject matter hereof may not be enforced in or by such courts.
Β
(c)Β EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE ANCILLARY DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE ANCILLARY DOCUMENTS. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF AN ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.10(C).
Β
55
Β
Β
Section 9.11Β Specific Performance. The parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Β
Section 9.12Β Non-Survival of Representations and Warranties. The representations and warranties contained herein and in any certificate or other writing delivered pursuant hereto shall not survive the Closing. This Section 9.12 shall not limit any covenant or agreement of the parties which by its terms contemplates performance after the Closing.
Β
Section 9.13Β Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by means of facsimile or portable document format (β.PDFβ) signature and such signature shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
Β
[Signature page follows.]
Β
56
Β
Β
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION Β | |
Β | Β | Β |
Β | By: | /s/ Xxxxxxx Xxxxx |
Β | Name: | Xxxxxxx Xxxxx |
Β | Title: | President and CEO |
Β | Β | Β |
Β | MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. Β | |
Β | Β | Β |
Β | By: | /s/ Xxxxx Xxxxxxx |
Β | Name: | Xxxxx Xxxxxxx |
Β | Title: | President |
Β
Β
Β
[Signature page to Asset Purchase Agreement]
Β
Β
Β
Β
Exhibit A
Β
VOTING AND SUPPORT AGREEMENT
Β
This Voting and Support Agreement (this βAgreementβ) is made and entered into as of November 25, 2019 by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βBuyerβ) and the undersigned stockholder (the βStockholderβ) of AdvanSource Biomaterials Corporation, a Delaware corporation (βSellerβ). Capitalized terms that are used but not defined herein shall have the respective meanings ascribed thereto in the Purchase Agreement (defined below).
Β
RECITALS
Β
WHEREAS, as an inducement for Buyer to enter into that certain Asset Purchase Agreement of even date herewith, by and between Buyer and Seller (as it may be amended from time to time by the parties thereto, the βPurchase Agreementβ), which provides for the transfer to Buyer or its designee all of the Purchased Assets in exchange for the consideration set forth in the Purchase Agreement in accordance with its terms (the βPurchaseβ), Buyer has requested that Stockholder execute and deliver this Agreement;
Β
WHEREAS, as of the date hereof, Stockholder is the beneficial owner (as defined in Rule 13d-3 promulgated under the Exchange Act) of the number of shares of Sellerβs common stock and other securities convertible into, or exercisable or exchangeable for, shares of Sellerβs common stock, all as set forth on the signature page of this Agreement (collectively, the βSharesβ); and
Β
WHEREAS, as a condition and inducement for Buyer to enter into the Purchase Agreement, Stockholder and Buyer are entering into this Agreement.
Β
NOW, THEREFORE, the parties hereto hereby agree as follows:
Β
1. Agreement to Vote Shares.
Β
(a) Until the Expiration Date (defined below), at the Seller Stockholders Meeting and at every other stockholder meeting of Seller called to consider the adoption of the Purchase Agreement, and at every postponement or adjournment thereof, and on every action or approval by written consent of Sellerβs stockholders with respect to any of the following, Stockholder shall vote all outstanding Shares and any outstanding New Shares (defined below):
Β
(i) in favor of the adoption of the Purchase Agreement and approval of the Purchase and any action reasonably required in furtherance of the foregoing, including any proposal to adjourn or postpone any meeting of the stockholders of Seller at which the adoption of the Purchase Agreement and approval of the Purchase is submitted for the consideration and vote of the stockholders of Seller to a later date if there are not proxies representing a sufficient number of shares of Seller common stock to approve such matters on the date on which the meeting is held;
Β
A-1
Β
Β
(ii) against any action or agreement that would reasonably be expected to result in a breach of any covenant, representation or warranty or any other obligation or agreement of Seller contained in the Purchase Agreement such that a condition to Closing would not be satisfied, or of any Stockholder contained in this Agreement;
Β
(iii) against any Takeover Proposal made by any Person (other than Buyer) and any Alternative Acquisition Agreement proposed by any Person;
Β
(iv) against any change in the Seller Board, including the individuals who serve as members of the Seller Board or the number of seats that make up the Seller Board;
Β
(v) against any action with respect to the conversion of any of Sellerβs common stock that may adversely affect or otherwise impair such Stockholderβs ability to perform its obligation under this Agreement; and
Β
(vi) against any other action, agreement or transaction involving Seller that is intended, or would reasonably be expected, to impede, materially interfere with, materially delay, materially postpone, materially and adversely affect or prevent the consummation of the Purchase or the other material transactions contemplated by the Purchase Agreement or this Agreement or the performance by Seller of its obligations under the Purchase Agreement or by any Stockholder of its obligations under this Agreement, including (x) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving Seller (other than the Buyerβs acquisition of the Purchased Assets), (y) a sale, lease or transfer of a material amount of assets of Seller or any reorganization, recapitalization or liquidation of Seller or (z) any change in the present capitalization of Seller or any amendment or other change to its certificate of incorporation or bylaws.
Β
(b) Prior to the Expiration Date, Stockholder shall not enter into any agreement or legally binding understanding with any person to vote or give instructions in any manner inconsistent with this Section 1.
Β
2. New Shares. Stockholder agrees that any shares of Sellerβs common stock that Stockholder purchases or with respect to which Stockholder otherwise acquires beneficial ownership after the date of this Agreement and prior to the Expiration Date, including, without limitation, shares issued or issuable upon the conversion, exercise or exchange, as the case may be, of all securities held by Stockholder that are convertible into, or exercisable or exchangeable for, shares of Seller common stock (βNew Sharesβ), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted Shares.
Β
3. Transfer and Encumbrance; No Inconsistent Action.
Β
(a) Other than pursuant to this Agreement, Stockholder agrees, during the period beginning on the date hereof and ending on the Expiration Date, not to sell, transfer, exchange, pledge or otherwise dispose of or encumber (collectively, βTransferβ), any Shares or any New Shares, or to discuss, negotiate, or make any offer or agreement relating thereto, other than to or with Buyer, in each case without the prior written consent of Buyer. Stockholder acknowledges that the intent of the foregoing sentence is to ensure that the Shares and any New Shares are voted in accordance with the terms hereof.
Β
A-2
Β
Β
(b) Section 3(a) shall not prohibit a Transfer of Shares by Stockholder (i) to any family member or trust for the benefit of any family member, (ii) to any Affiliate of Stockholder, or (iii) to any person or entity if and to the extent required by any non-consensual Governmental Order, by divorce decree or by will, intestacy or other similar applicable Law, so long as in the case of the foregoing clauses (i), (ii) and (iii), the assignee or transferee agrees to be bound by the terms of this Agreement and executes and delivers to the parties hereto a written consent and joinder memorializing such agreement.
Β
(c) Stockholder shall not:
Β
(i) grant or permit the grant of any proxy, power-of-attorney or other authorization or consent with respect to any of the Shares or New Shares;
Β
(ii) seek to influence any Person with respect to the voting of any of the Companyβs common stock in connection with the Buyerβs acquisition of the Purchased Assets or any other transaction, other than to recommend that the stockholders of Seller vote in favor of approval of the Purchase Agreement; or
Β
(iii) take or permit any other action that would be expected to adversely affect such Stockholderβs ability to perform its obligations hereunder.
Β
4. No Class Claims. Stockholder hereby agrees not to commence or participate in, and use reasonable best efforts to, if requested by Buyer, take all actions necessary to opt out of any class in any class action with respect to any claim, derivative or otherwise, against Buyer, Seller or any of their respective successors relating to the negotiation, execution or delivery of this Agreement or the Purchase Agreement or the consummation of the Purchase, including any claim (a) challenging the validity, or seeking to enjoin the operation, of any provision of this Agreement or the Purchase Agreement or (b) alleging a breach of any fiduciary duty of the Seller Board in connection with the Purchase Agreement or the transactions contemplated thereby.
Β
5. Share Legends. If so requested by Buyer, and to the extent the Shares or New Shares are represented by certificates, Stockholder agrees that the Shares and any New Shares shall bear a legend stating that they are subject to this Agreement. Subject to the terms of Section 1 hereof, Stockholder agrees that Stockholder will not Transfer certificated Shares or any certificated New Shares without first having the aforementioned legend affixed to the certificates representing the Shares or any New Shares. Stockholder shall instruct Seller to affix a legend to any certificates representing the Shares (upon a request for the Transfer of such Shares) and any New Shares (upon issuance) stating that such Shares or New Shares are subject to this Agreement. Stockholder shall cause Seller to further agree to make a notation on its records and give instructions to its transfer agent(s) for the Shares and any New Shares in order to implement the restrictions set forth in this Agreement.
Β
A-3
Β
Β
6. Representations and Warranties of Stockholder. Stockholder hereby represents, warrants and covenants to Buyer as follows:
Β
(a) If such Stockholder is not an individual, the execution, delivery and performance by such Stockholder of this Agreement and the consummation by such Stockholder of the transactions contemplated hereby are within the powers of such Stockholder and have been duly authorized by all necessary action. If such Stockholder is an individual, he or she has full legal capacity, right and authority to execute and deliver this Agreement and to perform his or her obligations hereunder. Such Stockholder has duly executed and delivered this Agreement and, assuming the due authorization, execution and delivery by Buyer, this Agreement constitutes such Stockholderβs legal, valid and binding obligation, enforceable against it in accordance with its terms except, in each case, as enforcement may be limited by bankruptcy, insolvency, reorganization or similar legal requirements affecting creditorsβ rights generally and by general principles of equity. If such Stockholder is married and any of the Shares or New Shares constitute community property or spousal approval is otherwise necessary for this Agreement to be legal, valid, binding and enforceable, this Agreement has been duly executed and delivered by, and, assuming the due authorization, execution and delivery by Buyer, constitutes the legal, valid and binding obligation of, such Stockholderβs spouse, enforceable in accordance with its terms except, in each case, as enforcement may be limited by bankruptcy, insolvency, reorganization or similar legal requirements affecting creditorsβ rights generally and by general principles of equity.
Β
(b) The Shares are and the New Shares will be beneficially owned (as defined in Rule 13d-3 promulgated under the Exchange Act) or owned of record by such Stockholder and/or one or more of such stockholderβs Affiliates. Such Stockholder has and will have good and valid title to such Shares and New Shares, free and clear of any Encumbrances other than pursuant to this Agreement. As of the date hereof, such Stockholderβs Shares (and the applicable portion of the New Shares) constitute all of the shares of Seller common stock beneficially owned or owned of record by such Stockholder and such Affiliates. Except as provided for herein, such Stockholder and certain Affiliates of such Stockholder collectively have sole voting power (including the right to control such vote as contemplated herein), sole power of disposition (except with respect to Shares underlying restricted stock awards issued to directors of Seller), sole power to issue instructions with respect to the matters set forth in herein, and sole power to agree to all of the matters set forth in this Agreement, in each case with respect to all of such Stockholderβs Shares and New Shares.
Β
(c) The execution and delivery of this Agreement by such Stockholder do not, and the performance by such Stockholder of its obligations under this Agreement will not, (i) if such Stockholder is not an individual, violate the certificate of formation, agreement of limited partnership, certificate of incorporation or similar organizational documents of such Stockholder, (ii) conflict with or violate any law, ordinance or regulation of any Governmental Authority applicable to such Stockholder or by which any of its assets or properties is bound, or (iii) conflict with, result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any encumbrance on the properties or assets of such Stockholder pursuant to, any Contract, permit, franchise or other instrument or obligation to which such Stockholder is a party or by which such Stockholder and/or any of its assets or properties is bound, except for any of the foregoing as would not reasonably be expected, either individually or in the aggregate, to impair the ability of such Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby on a timely basis.
Β
A-4
Β
Β
(d) The execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder of its obligations under this Agreement and the consummation by it of the transactions contemplated hereby will not, require such Stockholder to obtain any consent, approval, authorization or permit of, or to make any filing with or notification to, any Governmental Authority, other than the filings of any reports with the SEC.
Β
(e) As of the date hereof, there is no Action pending or, to the knowledge of such Stockholder, threatened against or affecting such Stockholder and/or any of its Affiliates before or by any Governmental Authority that would reasonably be expected to impair the ability of such Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby on a timely basis.
Β
(f) With respect to its equity ownership in Seller, Stockholder has full voting power, full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement. None of Stockholderβs Shares are subject to any Stockholdersβ agreement, proxy, voting trust or other agreement or arrangement with respect to voting.
Β
(g) No investment banker, broker, finder or other intermediary is entitled to a fee or commission from Buyer or Seller in respect of this Agreement based upon any arrangement or agreement made by or on behalf of such Stockholder (other than as an officer or director of Seller).
Β
(h) Such Stockholder understands and acknowledges that Buyer is entering into the Purchase Agreement in reliance upon the execution and delivery of this Agreement by Stockholder and the representations, warranties and covenants of Stockholder contained herein. Such Stockholder understands and acknowledges that the Purchase Agreement governs the terms of the Purchase and the other transactions contemplated thereby.
Β
7. Representations and Warranties of Buyer. Buyer hereby represents, warrants and covenants to Stockholder as follows:
Β
(a) Buyer is a duly organized and validly existing corporation in good standing under the Laws of the jurisdiction of its organization.
Β
A-5
Β
Β
(b) Buyer has full power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated thereby. This Agreement has been duly executed and delivered by Buyer and, assuming due authorization, execution and delivery by Stockholder, constitutes a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditorsβ rights and by general principles of equity (whether applied in a proceeding at law or in equity).
Β
8. Stockholder Capacity. Stockholder is signing and entering into this Agreement solely in his, her or its capacity as a beneficial owner of the Shares and New Shares, if any. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall (a) limit or affect in any way any actions that may hereafter be taken by Stockholder in his, her or its capacity as an officer or director of Seller, including in exercising rights under the Purchase Agreement (including by voting to withdraw, amend or modify, or publicly propose or resolve to withdraw, amend or modify, in a manner adverse to Buyer, the recommendation of the Seller Board that Sellerβs stockholders vote in favor of the adoption of the Purchase Agreement in accordance with the terms of the Purchase Agreement), and no such actions or omissions shall be deemed a breach of this Agreement, or (b) be construed to prohibit, limit or restrict Stockholder from exercising his, her or its fiduciary duties as an officer or director to Seller.
Β
9. Consents and Waivers. Stockholder hereby gives any consents or waivers that are reasonably required for the consummation of the Purchase under the terms of any agreement to which Stockholder is a party or pursuant to any rights Stockholder may have.
Β
10. Documentation and Information.
Β
(a) Except as required by applicable Law, Stockholder shall not make any public announcement regarding this Agreement, the Purchase Agreement or the transactions contemplated hereby or thereby without the prior written consent of Buyer (which consent may be withheld in Buyerβs sole discretion); provided that Stockholder may disclose the terms of this Agreement and file a copy hereof in a Schedule 13D filed with the SEC. Stockholder hereby consents to the disclosure in the Seller Proxy Statement and, if required by applicable Law or the SEC or any other securities authorities, any other documents or communications provided by Buyer or Stockholder to any Governmental Entity or to the Stockholders of the Company, of such Stockholderβs identity and beneficial ownership of the Sellerβs common stock and the nature of such Stockholderβs commitments under this Agreement and a copy of this Agreement.
Β
(b) Stockholder agrees to promptly give Buyer any information that is in its possession that Buyer may reasonably request for the preparation of any such disclosure documents and promptly notify Buyer of any required corrections with respect to any written information supplied by it, if Stockholder shall become aware that any such information shall have become false or misleading in any material respect.
Β
11. Cessation of Ongoing Discussion and Negotiations. Stockholder shall, and shall cause each of its Representatives to, (a) immediately cease and cause to be terminated all existing discussions and negotiations with any Person or such Personβs Representatives (other than Buyer and any of its Affiliates or any of Buyer or its Affiliatesβ respective Representatives) regarding any Takeover Proposal and (b) not terminate, amend, release or modify any provision of any standstill agreement (including any standstill provisions contained in any confidentiality or other agreement) to which it or any of its Affiliates or Representatives is a party.
Β
A-6
Β
Β
12. Termination. This Agreement shall automatically terminate and shall have no further force or effect as of the earliest to occur of (a) the Closing, (b) the date the Seller Board makes an Adverse Recommendation Change in accordance with Section 6.03 of the Purchase Agreement, (c) the date the Purchase Agreement shall have been validly terminated pursuant to Article IX thereof, and (d) the mutual consent of Buyer and Stockholder (the earliest to occur of clauses (a), (b), (c) and (cd) of this Section 12, the βExpiration Dateβ); provided, however, that notwithstanding the foregoing, the provisions in Section 14 hereof shall survive in full force and effect following the termination of this Agreement.
Β
13. No Partnership, Agency or Joint Venture. This Agreement is intended to create a contractual relationship between Stockholder and Buyer, and is not intended to create, and does not create, any agency, partnership, joint venture or any like relationship between the parties hereto or among any other stockholders of Seller entering into voting agreements with Buyer. Nothing contained in this Agreement shall be deemed to vest in Buyer any direct or indirect ownership or incidence of ownership of or with respect to any Shares.
Β
14. Miscellaneous.
Β
(a) Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (1) when delivered by hand (with written confirmation of receipt), (2) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested), (3) on the date sent by e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient (provided, that if given by e-mail, such notice, request, consent, claim, demand, waiver or other communication shall be followed up within one (1) Business Day of dispatch pursuant to one of the other methods described herein and provided further that such confirmatory dispatch shall not be deemed the date of transmission) or (4) on the third (3rd) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 14(a):
Β
(i) if to Buyer, to:
Β
Mitsubishi Chemical Performance Polymers, Inc.
2000 Xxxx Xxxx
Xxxxx, XX 00000
Attention: President
Β
A-7
Β
Β
with a copy (which shall not constitute notice) to:
Β
Mitsubishi Chemical Holdings America, Inc.
650 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
Attention: General Counsel
Β
and
Β
Winston & Xxxxxx LLP
200 Xxxx Xxxxxx
Xxx Xxxx, XX 00000
Attention: Xxxxx Xxxxx
Email: XXxxxx@xxxxxxx.xxx
Telephone No.: (000) 000-0000
Β
(ii) If to Stockholder, to the address set forth on the signature page hereto.
Β
(b) Certain Interpretations.
Β
(i) The words βinclude,β βincludesβ and βincludingβ when used herein shall be deemed in each case to be followed by the words βwithout limitation.β
Β
(ii) The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.
Β
(c) Entire Agreement. This Agreement and the documents and instruments and other agreements among the parties hereto referenced herein: (i) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and supersede all prior agreements, understandings, representations and conditions, both written and oral, among the parties hereto with respect to the subject matter hereof, and (ii) are not intended to confer upon any other person any rights or remedies hereunder.
Β
(d) Assignment. This Agreement shall not be assigned by operation of law or otherwise, except that Buyer may assign the rights and delegate its obligations hereunder to any wholly owned direct or indirect Subsidiary of Buyer so long as Buyer remains obligated to perform those obligations required to be performed by Buyer hereunder.
Β
(e) Amendments and Modification. This Agreement may not be modified, amended, altered or supplemented except by the execution and delivery of a written agreement executed by all of the parties hereto.
Β
(f) Waiver. No waiver by any party hereto of any condition or of any breach of any provision of this Agreement shall be effective unless in writing.
Β
(g) Further Assurances. Each party hereto shall perform such further acts and execute such further documents as may reasonably be required to carry out the provisions of this Agreement. Stockholder agrees to notify Buyer promptly in writing of the number and description of Shares or New Shares acquired after the date hereof that is not listed on the signature page below.
Β
A-8
Β
Β
(h) Severability. In the event that any provision of this Agreement or the application thereof becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto. The parties hereto further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.
Β
(i) Specific Performance. The parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Β
(j) Fees and Expenses. Except as otherwise provided in the Purchase Agreement, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by the party incurring such costs and expenses. If any action or other proceeding relating to the enforcement of any provision of this Agreement is brought by any party hereto, the prevailing party shall be entitled to recover reasonable attorneysβ fees, costs and disbursements from the opposing party or parties in such action or other preceding (in addition to any other relief to which the prevailing party may be entitled).
Β
(k) GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). EACH PARTY HERETO hereby irrevocably and unconditionally agrees to be subject to, and hereby consents and submits to, the jurisdiction of the courts of the State of Delaware and agrees that any action involving any equitable or other claim shall be brought exclusively in the Delaware Court of Chancery. In the event that the Delaware Court of Chancery does not accept OR DOES NOT HAVE jurisdiction over any such action, EACH PARTY HERETO hereby irrevocably and unconditionally agrees that any such action then shall be brought exclusively in the United States District Court for the District of Delaware.
Β
(l) WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.
Β
(m) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by means of facsimile or portable document format (β.PDFβ) signature and such signature shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
Β
(n) Purchase Agreement. Buyer acknowledges that Stockholder has been induced to enter into this Agreement based on the terms and conditions of the Purchase Agreement.
Β
[Signature page follows.]Β
Β
A-9
Β
Β
IN WITNESS WHEREOF, the undersigned have executed this Agreement on the date first above written.
Β
Β | Buyer: | |
Β | Β | Β |
Β | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β |
Β | Name: | Β |
Β | Title: | Β |
Β
[Signature Page to Voting and Support Agreement]Β
Β
A-10
Β
Β
IN WITNESS WHEREOF, the undersigned have executed this Agreement on the date first above written.
Β
Β | Stockholder: | |
Β | Β | Β |
Β | By: | Β |
Β | Β | (Signature) |
Β | Β | Β |
Β | Name: | Β |
Β | Β | (Print Name) |
Β | Β | Β |
Β | Title: | Β |
Β | Β | (If Applicable) |
Β | Address: | Β |
Β | Β | |
Β | Β | |
Β | Β | Β |
Β | Company Stock Beneficially Owned: | |
Β | Β | Β |
Β | Shares: | Β |
Β | Β | Β |
Β | Common Stock issuable upon the exercise of outstanding options, warrants | |
Β | Β | |
Β | or other rights: | Β |
Β
[Signature Page to Voting and Support Agreement]
Β
A-11
Β
Β
Exhibit B
Β
Β
Β
[Date]
Β
EMPLOYEE OFFER LETTER
Β
[Name]
[Address]
[Address]
Β
Dear [Name],
Β
We are pleased to offer you the position of [Title] for Mitsubishi Chemical Performance Polymers (herein referred to βMCPPβ or the βCompanyβ). This position will be located in [City, State] reporting to [Name, Managerβs Title]. Your annual base salary will be $XXXXX.XX per year payable $XXXX.XX biweekly [change appropriately], less applicable withholdings for taxes. You will be considered an exempt [or nonexempt] employee; therefore, any hours worked above 40 hours in a week βwill not [or will] be paid overtime. Your anticipated start date will be [Date] or sooner (based on completion of the background process).
Β
Bonus: (remove if not applicable) You will be eligible to participate in the bonus plan. Your target award is XX% of your base salary. The bonus award will be prorated for the first year and is paid out the following year. Bonus payments are contingent on your individual performance and the performance of the Company and your continued employment through the bonus payment date. Any bonus payments shall be less applicable withholdings for taxes.
Β
Company Vehicle (remove if not applicable): The Company will provide you with a company paid vehicle including maintenance and fuel used for business purposes.
Β
Benefits: You will be eligible to participate in the benefit plans listed below on your first day of employment and following enrollment. A copy of the benefit enrollment guide will be provided with this offer to give you an understanding of our benefit programs. Please thoroughly read the enrollment guide and contact us with any questions. Employees contribute bi-weekly through payroll deduction a portion of the monthly cost of certain benefits. Employee contribution amounts are based on enrollment and benefit selections and can be found on the premium contribution sheet enclosed with this offer.
Β
Β· | Health Coverage: This benefit is offered through Aetna and employees may select between two plans that are offered. Employees pay a portion of the monthly premium for this coverage. |
Β· | Dental Coverage: This benefit is offered through Aetna and employees may select between two plans that are offered. Employees pay 100% of the monthly premium for this coverage. |
Β· | Vision Coverage: This benefit is offered through EyeMed. Employees pay 100% of the monthly premium for this coverage. |
Β· | Life Insurance/AD&D: This benefit is offered through Mutual of Omaha and a description of coverage may be found in the enclosed benefit enrollment guide. At present, employees do not contribute to the cost of this benefit. |
Β· | Short-Term Disability: This benefit is offered through Mutual of Omaha and a description of coverage may be found in the enclosed benefit enrollment guide. At present, employees do not contribute to the cost of this benefit. |
Β· | Long Term Disability: This benefit is offered through Mutual of Omaha and a description of coverage may be found in the enclosed benefit enrollment guide. At present, employees do not contribute to the cost of this benefit. |
Β· | Employee Voluntary Plans: You are eligible and may enroll, through payroll deduction additional life insurance for you and your eligible dependents, legal and identification shield and a flexible spending plan. |
Β
![]() |
Β | Β |
Β | Β | Β |
xxx.xxxx-xxxxxx.xxx Β Bellevue Plant - 350 Xxxxx Xxxxxxx Xxxxxx, Xxxxxxxx, Xxxx 00000, Tel (000) 000-0000 Greer Plant - 2000 Xxxx Xxxx, X.X.Xxx 0000, Xxxxx, Xxxxx Xxxxxxxx 00000, Tel (000) 000-0000 Warren Plant - 24000 Xxxxxx Xxxx, Xxxxxx, Xxxxxxxx 00000, Tel (000) 000-0000 |
Β |
HRF 0002 REVISION: 1 rEVISION DATE: 9/19/18 Β |
Β
B-1
Β
Β
Β
Β
Β· | 401(k) Plan β You are eligible to participate in the 401(k) plan immediately. The Company will match 50% of the first 6% of your base pay that you contribute. The matched portion will fully vest after 3 years of employment with the company. Prudential is the record-keeper. |
Β· | Vacation: The vacation year is January 1 through December 31 and you are eligible for [XX]weeks of vacation effective January 1, 20XX. Vacation time for 20XX will be pro-rated based on your actual start date and you are eligible for XX days/weeks in 20XX. All remaining vacation time offered will be in accordance with the Company Vacation Policy. |
Β· | Personal Days: You are eligible for 40 hours of personal time each calendar year. Personal time will be pro-rated based on your actual start date and you are eligible for XX hours in 20XX. |
Β
The benefits outlined above are subject to change at Company discretion.
Β
This offer is contingent upon your successful completion of the following:
Β
Β· | Completion of the Companyβs employment application; |
Β· | Execution of the employment agreement enclosed herein; |
Β· | Completion of the I-9 form along with documentation that will show you are legally authorized to work in the United States as required by the US Department of Homeland Security; |
Β· | Post-offer/Pre-employment drug screen and physical; and |
Β· | Successful completion of the Companyβs background process including, employment verification and criminal background check. |
Β
At-will: We are an at-will employer and your employment is on an at-will basis for an indefinite term. No provision of this offer of employment shall be deemed to create any expressed or implied contract of employment between the company and you for any particular or definite period of time. Either you or the company may discontinue your employment at any time, for any reason, with or without cause, and with or without notice. Your at-will employment status may only be modified with a written, signed agreement from the President of MCPP.
Β
If the details listed in this offer meet with your expectations, please accept our offer of employment and sign one copy of this Letter of Offer and return it to the attention of [HR Name, Title] no later than [Date].
Β
[Name], perhaps the most important consideration in making your career decision is the opportunity for personal development in a challenging and stimulating business environment. Based upon your qualifications and past accomplishments, we are convinced that you have the potential to make substantial contributions to the Company. We also believe the Company can furnish a rewarding opportunity for you.
Β
We look forward to a positive response to this Letter of Offer and if you have any questions, please do not hesitate to contact me.
Β
Sincerely, | Β |
Β | Β |
HR Name | Β |
Title | Β |
Β
I understand and accept this offer extended to me. I also understand that shall I not respond to this offer by [Date] the offer shall be considered null & void.
Β
Β | Β | Β | Β |
Name | Β | Date | Β |
Β
![]() |
Β | Β |
Β | Β | Β |
xxx.xxxx-xxxxxx.xxx Β Bellevue Plant - 350 Xxxxx Xxxxxxx Xxxxxx, Xxxxxxxx, Xxxx 00000, Tel (000) 000-0000 Greer Plant - 0000 Xxxx Xxxx, X.X.Xxx 0000, Xxxxx, Xxxxx Xxxxxxxx 00000, Tel (000) 000-0000 Warren Plant - 00000 Xxxxxx Xxxx, Xxxxxx, Xxxxxxxx 00000, Tel (000) 000-0000 |
Β |
HRF 0002 REVISION: 1 rEVISION DATE: 9/19/18 Β |
Β
B-2
Β
Β
NEW EMPLOYEES
Β
EMPLOYMENT AGREEMENT
Β
I understand that Mitsubishi Chemical Performance Polymers (βMCPPβ) and its affiliates (collectively, the βCompanyβ) have developed and use valuable confidential information and trade secrets in their businesses that are vital to the success of the Company. I also understand that, during my employment, I will have access to certain of this confidential information in the performance of my duties. If this information were obtained by a competitor, became public or otherwise did not remain confidential, the Companyβs interests and competitive position would be harmed. In consideration of the Companyβs agreement to provide me with access to this confidential information, and in consideration of my employment with MCPP, I agree to the following terms and conditions of this Employment Agreement (βAgreementβ) as set forth below:
Β
1. Confidentiality of Information. I will not use or disclose any Company Confidential Information (as defined below), either during or after my employment with MCPP, that I had access to, learned or generated during my employment, except as required to perform my work for the Company. Nothing in this Agreement will prevent me from (i) disclosing information that is readily available to the public (as shown by written records and other than as a result of a breach or misconduct or violation of company policy or law, keeping in mind that the linkage between Company and certain information readily available to the public, and the combination of publicly known elements, may still be confidential unless expressly disclosed in information readily available to the public) or (ii) responding to lawful subpoenas or court orders, so long as I provide written notice of any such subpoena to MCPP promptly following my receipt thereof and fully cooperate with the Companyβs efforts to protect the Confidential Information. I also understand that by law, anyone is permitted to disclose a trade secret in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney if it is solely for the purpose of reporting or investigating a suspected violation of law, or is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal (confidentially). In addition, by law, anyone who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to their attorney and can use the trade secret information in the court proceeding, if they file any document containing the trade secret under seal (confidentially) and do not otherwise disclose the trade secret, except as ordered by a court.
Β
βProprietaryβ or βConfidentialβ information includes, but is not limited to, trade secrets, technical information, such as know-how, secret processes or machines, improvements, combinations, selections, formulas, inventions, and research products, as well as product and material samples; and also business information, such as information about costs, profits, markets, sales, lists of customers, customer identities, preferences, and purchase histories, information regarding the skills and compensation of employees and others working with the Company and any other information that reasonably could be expected to aid a competitor or potential competitor of the Company.
Β
B-3
Β
Β
For the avoidance of doubt, this section does not prohibit or restrict me (or my attorney) from responding to any inquiry about this Agreement or its underlying facts and circumstances by the Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), any other self-regulatory organization or governmental entity, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation or from disclosing details or from retaining substantive or procedural rights with respect to any claim of discrimination, retaliation, or harassment. I understand and acknowledge that I do not need the prior authorization of the Company to make any such reports or disclosures and that I am not required to notify the Company that I have made such reports or disclosures.
Β
2. Third Party Information. I understand that the Company has received and, in the future will receive confidential information of third parties (βThird Party Informationβ) that the Company is required to protect as confidential and use only for certain limited purposes. During the term of my employment and thereafter, I will (a) hold Third Party Information in confidence; and (b) not disclose it to anyone (other than Company personnel who need to know such information in connection with their work for the Company); and (c) not use it, except as required by my work for the Company, unless expressly authorized in writing by an officer of the Company.
Β
3. No Improper Use of Information of Prior Employers and Others. During my employment by MCPP, I will not use or disclose any confidential information of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any confidential documents or property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.
Β
4. Developments
Β
a. Disclosure. I agree to disclose promptly to the Company all intellectual property, including all discoveries, concepts, ideas, inventions, improvements, systems, writings, programs or software (βIntellectual Propertyβ) made, conceived, or created by me or those I supervise, in connection with my employment.
Β
b. Assignment. I assign to the Company all rights, title, and interest in all Intellectual Property made, conceived, or created by me during my period of employment, alone or with others, and whether on Company property or otherwise, that relate to the business or activities of the Company or that are made using the Companyβs resources. I understand that I have no right to any royalties or other compensation for the use of any patents, copyrights, or other Intellectual Property covered by this Agreement, unless agreed to in writing by the Company. At the Companyβs request, I will cooperate with the Company in doing whatever is appropriate to apply for, obtain, and enforce U.S. and foreign patents on any inventions or other Intellectual Property rights. My obligations to cooperate will continue after my employment ends, provided that I am reasonably compensated for my time.
Β
c. Works Made for Hire. Any writings, graphics, artwork, computer programs, computer software, or other written, printed, or electronic materials I prepare, either alone or with others, in connection with my employment or using Company resources will be owned exclusively by the Company and will be considered βworks made for hireβ to the extent possible under the copyright laws. I assign all copyrights and other rights, title, and interest in these materials, including the right to modify and adapt the materials, to the Company and will assist the Company in obtaining and maintaining copyright protection of such materials. I will not publish or cause to be published any of these materials without the Companyβs prior written approval. This obligation will continue after my employment ends.
Β
B-4
Β
Β
5. Return of Company Property. I agree that, immediately upon the end of my employment, or earlier if requested by MCPP, I will deliver to MCPP all Company property that is in my possession, under my control or otherwise provided to me, including but not limited to electronic devices, computers, cell phones, storage media, key card, identification, access badges, books, papers, electronic files, and any other property belonging to the Company or relating to the employees, business, suppliers, and/or customers of the Company without making or retaining any copies.
Β
6. Inspection. I agree that any property situated on the Companyβs premises or owned by the Company, including computers, electronic devices, cell phones, disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.
Β
7. Restrictive Covenants.
Β
a. Non-Solicitation of Personnel. During my employment with MCPP and for a period of twenty-four (24) months thereafter, I agree that I will not directly or indirectly, without the prior written consent of an officer of MCPP, on behalf of myself or any other third party, solicit for hire, or hire any employee, consultant or contractor of the Company.
Β
b. Non-Solicitation of Customers. During my employment with MCPP and for a period of twelve (12) months thereafter, I agree that I will not directly or indirectly, solicit or attempt to solicit any business similar to the business of the Company from anyone who is or was a customer or prospective customer of the Company at any time during the twelve (12) months prior to my discharge with whom I had meaningful professional contact and/or about whom I obtained Confidential information as an employee or contractor of MCPP.
Β
c. Non-Competition. During my employment with MCPP and for a period of twelve (12) months thereafter, I agree that I will not be employed or engaged in any capacity (including as a director) in any business or activity that is similar to the business or activity of the Company that I was engaged in at any time during the two (2) year period preceding the termination of my employment with the Company in those geographic jurisdictions in which I performed service or had a material presence at any time during the two (2) year period preceding the termination of my employment with the Company. During the twelve (12) month period following the termination of my employment with the Company that this non-competition restriction is applicable, MCPP shall pay a monthly fee to me that is equal to fifty percent (50%) of the highest monthly salary that I earned in the two (2) year period preceding the termination of my employment with the Company, less applicable withholdings. I agree that this consideration is adequate for this non-competition restriction.
Β
B-5
Β
Β
d. Interference. During my employment with MCPP and for a period of twenty-four (24) months thereafter, I will not directly or indirectly disrupt, impair, damage or interfere with the Companyβs relationships with its employees, consultants, contractors, customers, vendors, suppliers or anyone else with whom the Company does business.
Β
8. Enforcement. I agree that the Company will be irreparably harmed if I breach my obligations of confidentiality under this Agreement and that the Company would not have an adequate remedy at law in the event of an actual or threatened violation by me of any material obligation of this Agreement. In the event that I breach this Agreement, or in the event that breach appears to be an imminent possibility, the Company will be entitled to all legal and equitable remedies it may have as a result of that breach or anticipated breach. I agree that in addition to any other remedies, the Company is entitled to an injunction preventing further disclosure or use of Confidential or Proprietary Information without bond or proof of damage.
Β
9. Conflict of Interest. I confirm that neither I nor any member of my immediate family is employed by or has, or plans to have, any substantial economic interest in any of Companyβs suppliers or customers, and will notify MCPP promptly if this changes. While employed by MCPP, I will not plan, organize, or engage in any business that competes with any current or planned product or service owned, licensed, manufactured or marketed by the Company, or conspire with others to do so. During my employment with MCPP, I will disclose to MCPP any competitive plans I have under consideration or that I intend to act on after I leave MCPP.
Β
10. Employee At-Will. I understand and agree that I am an βemployee at-willβ and just as I am free to leave my employment with MCPP at any time for any reason, MCPP may terminate my employment at any time, with or without cause or notice, subject to applicable law. I also understand that nothing contained in any policies, rules or handbook, or any representation to the contrary, will in any manner alter this relationship, except by a written employment contract signed by an officer of MCPP
Β
11. Mediation and Arbitration Program. In recognition that differences between the Company and its employees may arise during the employment relationship and as a result of the termination of that relationship, the Company has adopted a mandatory Arbitration and Mediation Program (the βProgramβ), attached hereto as Exhibit 1, to provide a streamlined and efficient process for resolving such differences as an alternative to litigation in court. I understand that the Program provides for mutual binding mediation and/or arbitration as the exclusive forum for resolving employment claims and that I and the Company enter into the Program as a condition of my employment; provided that, any claim that arises from or relates to the enforceability of the non-competition provision set forth in Section 7(c) will not be subject to mediation or arbitration, but instead can be brought in the state courts of Massachusetts in the county in which I reside at the time the claim arises.
Β
12. Assignment. MCPP is free to assign this Agreement to its successors in interest or affiliates.
Β
B-6
Β
Β
13. Controlling Law; Severability. I agree that any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of Massachusetts, without regard to the conflict of law provisions thereof (and, as applicable, applied by the arbitrator selected as per the Program, as described in Exhibit 1). I further agree that if one or more of the provisions of this Agreement are held to be illegal or unenforceable under applicable state law, such illegal or unenforceable portion(s) shall be limited or excluded from the Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms.
Β
14. Other Employee Obligations. I agree that this Agreement does not purport to set forth all the terms and conditions of my employment, and that as an employee of MCPP, I have obligations to MCPP, which are not set forth in this Agreement.
Β
15. Consultation with an Attorney. I acknowledge and agree that I have the right to consult with an attorney regarding Section 7(c) of this Agreement, and that I have been provided at least ten (10) business days to consider the terms of this Agreement, including Section 7(c) herein.
Β
I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND AND ACCEPT THE OBLIGATIONS IT IMPOSES UPON ME WITHOUT RESERVATION. HAVING DONE SO, I AGREE THAT THE RESTRICTIONS ARE FAIR AND REASONABLE AND ARE REASONABLY REQUIRED FOR THE PROTECTION OF THE LEGITIMATE INTERESTS OF THE COMPANY. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY.
Β
EMPLOYEE | Β | MITSUBISHI CHEMICAL PERFORMANCE POLYMER |
Β | Β | Β |
Β | Β | |
Legal Signature | Β | Legal Signature |
Β | Β | Β |
Β | Β | Β |
Name | Β | Name |
Β | Β | Β |
Β | Β | Β |
Date | Β | Title |
Β | Β | Β |
Β | Β | Β |
Β | Β | Date |
Β
B-7
Β
Β
EXHIBIT 1
Β
MEDIATION & ARBITRATION PROGRAM
Β
In recognition that differences between Mitsubishi Chemical Performance Polymers and its employees may arise during the employment relationship and as a result of the termination of that relationship, the Company has adopted this mandatory Mediation & Arbitration Program (βProgramβ) to provide a streamlined and efficient arbitration process for resolving such differences as an alternative to litigation in court. This Program provides for mutual binding arbitration as the exclusive forum for resolving employment claims and you and the Company enter into this Program as a condition of your employment. This Program is entered into under the Federal Arbitration Act and shall be interpreted and construed in accordance with the law and procedures developed under that statute.
Β
1. Parties: The Parties to this Program are the undersigned Employee, _____________________________ (βEmployeeβ) and Mitsubishi Chemical Performance Polymenrs, its officers, directors, agents, parents, subsidiaries, and affiliated entities (collectively, βMCPPβ). MCPP and Employee are collectively referred to herein as the Parties.
Β
2. Claims Covered by this Program: To the extent permitted by law and subject to the exclusions in Section 3, the Parties mutually agree to the resolution, exclusively by final and binding arbitration, of all claims or controversies that Employee may have against MCPP or MCPP may have against Employee relating to, resulting from, or in any way arising out of Employeeβs employment relationship with MCPP and/or the termination of such employment relationship which could be brought in a court of a law (collectively βClaimsβ). The Claims covered by this Program include, without limitation, claims for breach of any contract or covenant (written or oral, express or implied); tort claims; claims for unlawful discrimination, retaliation and/or harassment; claims for wrongful or constructive termination; claims arising under Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act of 1967, the Older Workersβ Benefit Protection Act of 1990, the Americans with Disabilities Act, the Family & Medical Leave Act, the Consolidated Omnibus Budget Reconciliation Act of 1985, the Fair Labor Standards Act; and any other claims for violation of any federal, state or local law, statute, regulation, ordinance, constitution, or common law.
Β
3. Claims Not Covered Under this Program: This Program does not cover claims Employee may have for workersβ compensation benefits (excluding retaliation claims under workersβ compensation statutes, which are covered), unemployment compensation benefits or any other claims found not subject to mandatory binding arbitration by governing law. Additionally, nothing in this Program precludes Employee from filing a charge or from participating in an administrative investigation of a charge before a state or federal government agency such as the Equal Employment Opportunity Commission, the National Labor Relations Board or similar state agency. However, Employee may seek monetary relief with respect to Claims only through the terms of the Program
Β
B-8
Β
Β
4. Phase I - Mediation: If a Claim arises, the Parties will try to resolve the Claim through good faith discussion and negotiation, if possible. If this is not possible, the Parties will try to settle the Claim through mediation in accordance with the employment mediation procedures of the Judicial Arbitration and Mediation Services (βJAMSβ) in effect at the time of the mediation. The Parties will cooperate with JAMS and with one another in selecting a mediator from JAMSβ panel of neutrals and in scheduling the mediation proceedings and covenant that they will participate in the mediation in good faith. The mediation shall take place at the closest JAMSβ office to the location where Employee performs or performed work for MCPP or an alternative location mutually agreed to by the Parties.
Β
(a) Initiation. A party may start Phase I by giving the other party notice in writing.
Β
(b) Fees and Expenses. Employee acknowledges that MCPP shall bear the costs for mediation, including the mediatorβs fees; provided, however, that the parties shall each bear their own individual attorneysβ fees and costs for mediation.
Β
(c) Attorney Representation. Employee may, but is not required to, be represented by counsel in the mediation.
Β
(d) Mediation Rules. JAMSβ current mediation procedures are available at JAMSβ website at xxx.xxxxxxx.xxx.Β
Β
(e) Termination of Phase I. Phase I shall end after sixty (60) days, whether or not the Claim has been resolved, unless the Parties have agreed otherwise in writing.
Β
5. Phase II - Arbitration: If a Claim is not resolved in Phase I, either party may choose to proceed to binding arbitration, as provided below.
Β
(a) Phase I default. If a party files a lawsuit relating to a Claim in court in violation of the terms of this Program, the other party may choose to proceed directly to Phase II or to seek an order requiring the party who filed the lawsuit to satisfy the requirements of this Program.
Β
(b) Provider. The provider for Phase II Arbitration shall also be JAMS. The Parties may, however, mutually agree to use an alternative but comparable provider (such as the American Arbitration Association (βAAAβ)).
Β
(c) Initiation. A party may start Phase II by filing a Demand for Arbitration (βDemandβ) with the office of JAMS located closest to the location where Employee performs or performed work for MCPP or an alternative location mutually agreed to by the Parties and serving the other party with a copy of the Demand.
Β
(d) Applicable Rules. A single arbitrator shall be selected from the JAMS panel and all rules governing the arbitration process, including the method of selecting an arbitrator, shall be conducted pursuant to JAMSβ Employment Arbitration Rules & Procedures (βJAMSβ Rulesβ). The JAMSβ Rules are available for review on the JAMS website at xxx.xxxxxxx.xxx. Employee may request a copy of the JAMSβ Rules by calling MCPPβs Human Resources Department at (___) ___-____. If there is any discrepancy between JAMSβ Rules (or rules of an alternative provider) and this Program, this Program shall prevail.
Β
B-9
Β
Β
(e) Location of Arbitration Hearing. The arbitration shall take place at a mutually convenient location in the county in which Employee performs or performed work for MCPP. If the Parties cannot agree upon a location, then the arbitration will be held at the closest JAMSβ (or alternative providerβs) office to Employeeβs work location.
Β
(f) Scope of Authority/Applicable Law. The Arbitrator shall have exclusive authority to resolve any claims covered by this Program. The Arbitrator shall apply the governing state or federal substantive law, as applicable, of the state of New York to all Claims, without reference to conflict of law provisions of any other jurisdiction. The Arbitrator shall have the authority to award the same damages and other relief that a court could award pursuant to applicable law, including the discretion to award monetary and other damages, or no damages, and to fashion such other relief as the Arbitrator deems appropriate. Statutes of limitations shall be applied in accordance with applicable law. The Parties further agree that they shall have the right to bring a dispositive motion in arbitration (e.g. Motion to Dismiss, Motion for Judgment on the Pleadings, Motion for Summary Judgment, etc.) and that any such motion will be decided under the appropriate standards set forth in the Federal Rules of Civil Procedure. The Arbitrator shall not have the authority to add to, amend, or modify this Program, existing law or the at-will employment relationship of the Parties.
Β
(g) Reasonable Discovery. The Parties agree that reasonable discovery is essential to the just resolution of any claims that may be covered by this Program. Accordingly, nothing in this Program or in the Provider Rules shall be interpreted to limit the Partiesβ rights to reasonable discovery. Generally, the Parties agree that reasonable discovery means up to three non-expert depositions per side for no more than seven (7) hours each, the deposition of any expert witness designated by the other party, one set of requests for production of documents not to exceed 35 requests, and one set of interrogatories not to exceed 25 requests. In the event the Parties believe this scope of discovery is inadequate, the Parties shall meet and confer and try to reach Program on the scope of discovery. The Arbitrator shall have discretion to resolve any disagreement concerning the scope of discovery and to allow discovery the Arbitrator determines to be reasonably necessary to the just resolution of the dispute considering the streamlined nature and purpose of arbitration. The Arbitrator will issue subpoenas to third parties for such documentary evidence on the reasonable request of a party, if permitted by law.
Β
(h) Written Opinion and Award. The Arbitrator shall issue a written opinion and award within thirty (30) days of the close of the arbitration hearing, which shall be signed and dated, and which shall set forth the reasons for the Arbitratorβs decision, including essential factual findings and conclusions of law. The Arbitrator shall be permitted to award those remedies and damages that are available under federal and New York law, as applicable to the Claims asserted, and that would otherwise be available in a court of law. The Arbitratorβs decision regarding the claims shall be final and binding upon the Parties. The Arbitratorβs award shall be enforceable in any court having proper jurisdiction. The Partiesβ appeal rights are governed by the Federal Arbitration Act.
Β
B-10
Β
Β
(i) Arbitration Fees and Costs. The party filing a Demand shall pay the initial Provider Case Management Fee. MCPP shall pay all other fees and costs that are unique to the arbitration process, including the Arbitrator's fees. Employee is not required to, but may contribute a greater portion of filing and administrative fees if Employee so chooses, not to exceed (50%) of such fees.
Β
Each party may, but is not required to, be represented by an attorney or other representative. Except as set forth above, each party shall pay its own costs, expenses and attorneysβ fees. If, however, any party prevails on a statutory claim that affords the prevailing party attorneysβ fees and costs, or if there is a written agreement between the Parties providing for attorneysβ fees and costs, the Arbitrator may award reasonable fees and costs to the prevailing party in accordance with applicable law or such agreement. The arbitration hearing is not required to be stenographically recorded, but may be at the option of a party. The party requesting the arbitration hearing to be stenographically recorded is responsible for paying the costs of the court reporter.
Β
(j) Final and Binding. Employee and MCPP agree that arbitration as provided for in this Program will be the exclusive and binding remedy for any Claim and will be used instead of any court action, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Program. The decision and award of the Arbitrator shall be final and binding on both parties and enforceable by a court as set forth in subsection (h).
Β
6. Waiver of Class Action. Because this Program is intended to resolve the particular dispute as quickly as possible, Employee and MCPP agree that all Claims covered by this Program may be brought and resolved on an individual basis only. As such, the Parties hereby agree to waive any right to bring Claims, or join or participate as a party or member, in any class, collective, or representative actions in any forum, including any court or arbitration proceeding. The Arbitrator may not consolidate more than one individualβs claims, and may not otherwise preside over any form of a class, collective, or representative proceeding. Any consolidation of the Claims of two or more employees or allowing of class or collective action arbitration would be contrary to the intent of this Program.
Β
7. Application for Emergency Injunctive and/or Other Equitable Relief. Claims by MCPP or Employee for emergency injunctive and/or other equitable relief shall be submitted to JAMS (or an alternative provider) for emergency treatment. The Parties agree that the JAMS administrator may select a neutral hearing officer (subject to conflicts) to hear the emergency request only. The hearing officer should be experienced in considering requests for emergency injunctive and/or other equitable relief. The hearing officer shall conform his or her consideration and ruling with the applicable legal standards as if this matter were heard in a court of law in the applicable jurisdiction for such a dispute.
Β
8. Arbitrability. Any dispute concerning the validity or enforceability of this Program or the arbitrability of any particular claim shall be resolved by a court of law. The interpretation and enforceability of this Program shall be governed by the Federal Arbitration Act. In the event it is determined that a dispute between the Parties involves both arbitrable claims and non-arbitrable claims (any claim required to be resolved in court as opposed to arbitration), the Parties agree that arbitrable claims shall be resolved first and that all non-arbitrable claims shall be stayed pending resolution of the arbitrable claim(s)).
Β
B-11
Β
Β
9. Term of Program and Modification. This Program shall remain in effect after the termination of Employeeβs employment with MCPP. However, the Parties may mutually agree, in writing, not to arbitrate any Claim that otherwise may be covered by this Program. Additionally, MCPP may unilaterally modify or terminate this Program at any time by providing 30 daysβ written notice. Any modification or termination shall be prospective only and shall not apply to any Claim pending in arbitration or Demand filed by Employee or MCPP prior to the expiration of the 30-day notice period.
Β
10. Entire Agreement. This is the complete agreement of the Parties on the subject of arbitration of disputes (except for any arbitration agreement that may exist in connection with any pension or benefit plan). This Program supersedes any prior or contemporaneous oral or written understanding on the subject. No party is relying on any promises, oral or written, on the subject of the effect, enforceability, or meaning of this Program, except as specifically set forth in this Program. Once executed, this Program constitutes a binding contract between the Parties.
Β
11. Construction of Program. This Program shall be enforceable to the fullest extent allowed by law in accordance with the Federal Arbitration Act. If any provision of this Program is adjudged by a court or arbitrator to be invalid or otherwise unenforceable, in whole or in part, such provision shall be severable such that the invalid provision shall not affect the validity of the remainder of this Program. In such a case, this Program shall be reformed to the extent necessary to carry out its provisions to the greatest extent possible under the Federal Arbitration Act, and to ensure that the resolution of any and all conflicts between the Parties be resolved by neutral, binding arbitration.
Β
12. Waiver of Trial by Jury. THE PARTIES UNDERSTAND AND FULLY AGREE THAT BY ENTERING INTO THIS PROGRAM PROVIDING FOR BINDING MEDIATION AND ARBITRATION OF THEIR CLAIMS, THEY ARE EXPRESSLY WAIVING THEIR RIGHT TO BRING A CLAIM AGAINST THE OTHER IN A COURT OF LAW, EITHER STATE OR FEDERAL, AND ARE WAIVING THE RIGHT TO HAVE A TRIAL BY JURY. THE PARTIES ANTICIPATE THAT BY ENTERING INTO THIS PROGRAM THEY WILL GAIN THE BENEFITS OF A SPEEDY, IMPARTIAL DISPUTE RESOLUTION PROCEDURE.
Β
13. At-Will Employment. Nothing in this Program shall constitute a contract or guarantee of employment for any specific period of time and this Program shall not be construed in any way to change the relationship between MCPP and Employee from that of an at-will employment relationship which may be terminated by either Party, at any time, for any or no reason.
Β
14. Confidentiality. All aspects of Phase I and Phase II, including any award or resolution made, shall be confidential, except to the extent disclosure is required by law or applicable professional standards, or is necessary in a later proceeding between the Parties.
Β
B-12
Β
Β
15. Notice. Any notice required to be given to Employee shall be directed to Employeeβs last known address as reflected in the records of MCPP. Any notice required to be given to MCPP shall be directed to:
Β
General Counsel
Mitsubishi Chemical Holdings America, Inc.
000 Xxxxx Xxxxxx β 00xx Xxxxx
Xxx Xxxx, XX 00000
Β
16. Understanding of Program. Because this Program changes the forum in which Employee may pursue Claims against MCPP and affects Employeeβs legal rights, MCPP encourages Employee to review this Program with an attorney or other advisor of Employeeβs choosing.
Β
B-13
Β
Β
ACKNOWLEDGEMENT OF RECEIPT AND AGREEMENT TO MEDIATION & ARBITRATION PROGRAM
Β
I, the undersigned employee, acknowledge that I have received a copy of Mitsubishi Chemical Performance Polymers Mediation & Arbitration Program, that I have been given an opportunity to read the Program, and that I agree to its terms.
Β
Date: | Β | Β |
Β
Employee Printed Name: | Β | Β |
Β
Employee Signature: | Β | Β |
Β
Date: | Β | Β |
Β
Mitsubishi Chemical America, Inc.
Β
By: | Β | Β |
Β
Title: | Β | Β |
Β
X-00
Β
Β
Xxxxxxx X
Β
XXXX XX XXXX
Β
THIS XXXX OF SALE (this βXxxx of Saleβ), dated as of [ ], 2020, is made by and between AdvanSource Biomaterials Corporation, a Delaware corporation (βSellerβ), and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βBuyerβ).
Β
WHEREAS, Seller and Buyer have entered into to that certain Asset Purchase Agreement, dated as of November 25, 2019, (the βAgreementβ; capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Agreement) pursuant to which, among other things, Seller has agreed to sell, transfer, convey and deliver to Buyer, and Buyer has agreed to purchase from Seller, all of Sellerβs right, title and interest in and to the Purchased Assets, subject to the terms and conditions set forth in the Agreement;
Β
WHEREAS, pursuant to the Agreement, on the date hereof, Seller is transferring the Purchased Assets to Buyer; and
Β
WHEREAS, the execution and delivery of this Xxxx of Sale by Buyer and Seller is done pursuant to the Agreement.
Β
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth herein and in the Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Buyer and Seller agree as follows:
Β
Section 1. Transfer of Purchased Assets. Effective as of the date of this Xxxx of Sale, Seller does hereby irrevocably and unconditionally sell, transfer, convey and deliver to Buyer all of Sellerβs right, title and interest in, to and under the Purchased Assets, free and clear of all Encumbrances other than Permitted Encumbrances. Buyer hereby accepts title to the Purchased Assets.
Β
Section 2. Excluded Assets. Notwithstanding anything in this Xxxx of Sale or the Agreement to the contrary, in no event shall Seller sell, transfer, convey or deliver to Buyer any Excluded Assets.
Β
Section 3. Further Assurances. Seller shall, and shall cause its Affiliates to, execute and deliver such further instruments of conveyance and transfer and take such additional action as Buyer may reasonably request to effect, consummate, confirm or evidence the sale and transfer to Buyer of the Purchased Assets and the other transactions contemplated by this Agreement.
Β
Section 4. Amendment and Modification; Waiver. This Xxxx of Sale may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Xxxx of Sale shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Β
C-1
Β
Β
Section 5. No Third Party Beneficiaries. This Xxxx of Sale is for the sole benefit of Buyer and Seller and each of their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Xxxx of Sale.
Β
Section 6. GOVERNING LAW. THIS XXXX OF SALE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF DELAWARE WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICTS OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION).
Β
Section 7. Headings. The headings of this Xxxx of Sale are for reference only and shall not affect the interpretation of this Xxxx of Sale.
Β
Section 8. Agreement. This Xxxx of Sale is subject in all respects to the terms and conditions of the Agreement. To the extent of any conflict between the terms of the Agreement and this Xxxx of Sale, the Agreement shall control. Nothing contained in this Xxxx of Sale shall be deemed to supersede any of the covenants, agreements, representations or warranties of Buyer and Seller contained in the Agreement.
Β
Section 9. Severability. If any term or provision of this Xxxx of Sale is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Xxxx of Sale or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, Buyer and Seller shall negotiate in good faith to modify this Xxxx of Sale so as to effect the original intent of Buyer and Seller as closely as possible in a mutually acceptable manner in order that this Xxxx of Sale be consummated as originally contemplated to the greatest extent possible.
Β
Section 10. Counterparts. This Xxxx of Sale may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Xxxx of Sale delivered by means of facsimile or portable document format (β.PDFβ) signature and such signature shall be deemed to have the same legal effect as delivery of an original signed copy of this Xxxx of Sale.
Β
[SIGNATURE PAGE FOLLOWS]Β
Β
C-2
Β
Β
IN WITNESS WHEREOF, the parties hereto have executed this Xxxx of Sale as of the date first above written.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION | |
Β | Β | Β |
Β | By: | Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β |
Β | Name: | Β |
Β | Title: | Β |
Β | Β | Β |
Β | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β |
Β | Name: | Β Β |
Β | Title: | Β |
Β
[Signature Page to Xxxx of Sale]
Β
C-3
Β
Β
Exhibit D
Β
ASSIGNMENT AND ASSUMPTION AGREEMENT
Β
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this βAssignment and Assumption Agreementβ), dated as of [ ], 2020, is made by and between AdvanSource Biomaterials Corporation, a Delaware corporation (βSellerβ), and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βBuyerβ).
Β
WHEREAS, Seller and Buyer have entered into to that certain Asset Purchase Agreement, dated as of November 25, 2019, (the βAgreementβ; capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Agreement) pursuant to which, among other things, Seller has agreed to sell, transfer, convey and deliver to Buyer, and Buyer has agreed to purchase from Seller, all of Sellerβs right, title and interest in and to the Purchased Assets, including without limitation the Assigned Contracts, and to assume and pay, perform and discharge the Assumed Liabilities, subject to the terms and conditions set forth in the Agreement;
Β
WHEREAS, pursuant to the Agreement, on the date hereof, Seller is transferring the Purchased Assets to Buyer; and
Β
WHEREAS, the execution and delivery of this Assignment and Assumption Agreement by Buyer and Seller is done pursuant to the Agreement.
Β
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth herein and in the Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Buyer and Seller agree as follows:
Β
Section 1. Assignment of Assigned Contracts. Effective as of the date of this Assignment and Assumption Agreement, Seller does hereby irrevocably and unconditionally sell, transfer, convey and deliver to Buyer all of Sellerβs right, title and interest in, to and under the Assigned Contracts.
Β
Section 2. Assumption of Liabilities. Effective as of the date of this Assignment and Assumption Agreement, Buyer shall assume and agrees to pay, perform and discharge only the Assumed Liabilities. Notwithstanding anything in this Assignment and Assumption Agreement or the Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform or discharge any Liabilities of Seller or any of its Affiliates of any kind of nature whatsoever other than the Assumed Liabilities.
Β
Section 3. Further Assurances. Seller shall, and shall cause its Affiliates to, execute and deliver such further instruments of conveyance and transfer and take such additional action as Buyer may reasonably request to effect, consummate, confirm or evidence the sale and transfer to Buyer of the Purchased Assets and the other transactions contemplated by this Agreement. Buyer shall, and shall cause its Affiliates to, execute and deliver such further instruments of assumption and take such additional action as Seller may reasonably request to effect, consummate, confirm or evidence the transactions contemplated hereby, including the assumption by Buyer of the Assumed Liabilities.
Β
D-1
Β
Β
Section 4. Amendment and Modification; Waiver. This Assignment and Assumption Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Assignment and Assumption Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Β
Section 5. No Third Party Beneficiaries. This Assignment and Assumption Agreement is for the sole benefit of Buyer and Seller and each of their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Assignment and Assumption Agreement.
Β
Section 6. GOVERNING LAW. THIS ASSIGNMENT AND ASSUMPTION AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF DELAWARE WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICTS OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION).
Β
Section 7. Headings. The headings of this Assignment and Assumption Agreement are for reference only and shall not affect the interpretation of this Assignment and Assumption Agreement.
Β
Section 8. Agreement. This Assignment and Assumption Agreement is subject in all respects to the terms and conditions of the Agreement. To the extent of any conflict between the terms of the Agreement and this Assignment and Assumption Agreement, the Agreement shall control. Nothing contained in this Assignment and Assumption Agreement shall be deemed to supersede any of the covenants, agreements, representations or warranties of Buyer and Seller contained in the Agreement.
Β
Section 9. Severability. If any term or provision of this Assignment and Assumption Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Assignment and Assumption Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, Buyer and Seller shall negotiate in good faith to modify this Assignment and Assumption Agreement so as to effect the original intent of Buyer and Seller as closely as possible in a mutually acceptable manner in order that this Assignment and Assumption Agreement be consummated as originally contemplated to the greatest extent possible.
Β
Section 10. Counterparts. This Assignment and Assumption Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment and Assumption Agreement delivered by means of facsimile or portable document format (β.PDFβ) signature and such signature shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment and Assumption Agreement.
Β
[SIGNATURE PAGE FOLLOWS]Β
Β
D-2
Β
Β
IN WITNESS WHEREOF, the parties hereto have executed this Assignment and Assumption Agreement as of the date first above written.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION | |
Β | Β | Β |
Β | By: | Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β |
Β | Name: | Β |
Β | Title: | Β |
Β | Β | Β |
Β | MITSUBISHI CHEMICAL PERFORMANCE POLYMERS, INC. | |
Β | Β | Β |
Β | By: | Β |
Β | Name:Β Β | Β |
Β | Title: | Β |
Β
[Signature Page to Assignment and Assumption Agreement]
Β
D-3
Β
Β
Exhibit E
Β
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
Β
This Intellectual Property Assignment Agreement (βAssignment Agreementβ), dated as of [Β Β Β ], 2020 (βEffective Dateβ), is by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βBuyerβ), and AdvanSource Biomaterials Corporation, a Delaware corporation (βAssignorβ or βSellerβ).
Β
A. Pursuant to that certain Asset Purchase Agreement, dated as of November 25, 2019 (as it may be amended, restated or otherwise modified from time to time, the βPurchase Agreementβ), by and between Company and Seller, the parties thereto have agreed to effect the acquisition of certain assets of Seller, upon the terms and subject to the conditions set forth in the Purchase Agreement;
Β
B. Pursuant to the Purchase Agreement, the execution and delivery of this Assignment Agreement is a condition precedent to the closing of the transactions contemplated by the Purchase Agreement; and
Β
C. Assignor is willing to assign all rights it may have in and to all Assigned Contracts, Seller IP, Seller IT Systems and all Software owned or purported to be owned by Seller on the terms and subject to the conditions set forth in this Assignment Agreement.
Β
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Assignor and Company, Assignor and Company agree as follows:
Β
1. Definitions. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Purchase Agreement.
Β
2. Assignment. Effective as of the Effective Date, Assignor hereby irrevocably sells, transfers, assigns, sets over and conveys to Buyer, its successors and assigns, all of Assignorβs worldwide right, title and interest in and to all Assigned Contracts, Seller IP, Seller IT Systems and all Software owned or purported to be owned by Seller, including all worldwide right, title and interest in and to all of the following that constitute Intellectual Property Assets:
Β
(a) issued patents and patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, renewals, extensions, or restorations of any of the foregoing, all applications for and inventions disclosed in any of the foregoing, and all rights to claim priority of any of the foregoing, including the patents and patent applications identified in Exhibit A attached hereto (the βAssigned Patentsβ), any related or corresponding United States provisional or non-provisional application embodying the inventions described in the Patents or any other United States application claiming priority to a provisional application under 35 U.S.C. Β§ 119(e) or converted therefrom, or any application claiming the benefit of a non-provisional application under 35 U.S.C. Β§120, including all divisions, continuations, reexaminations, and reissues thereof and all patents that may be granted thereon, including any other counterparts thereto worldwide, patents of addition, utility models, inventorsβ certificates, industrial property protection, patent rights and right to claim priority thereto in any country, and all extensions and renewals thereof existing now or in the future, including all applications for patents, utility models and designs that may hereafter be filed for in any country or countries other than the United States, together with the right to file such applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, and all forms of industrial property protection, including patents, utility models, inventorsβ certificates and designs, which may be granted in any country or countries foreign to the United States and all extensions, renewals and reissues therefor;
Β
E-1
Β
Β
(b) trademarks, service marks, brands, certification marks, logos, trade dress, trade names and other similar indicia of source or origin, including the trademarks, trademark registrations, trademark applications and domain names identified in Exhibit A (the βAssigned Trademarksβ), together with the goodwill associated with the use of an symbolized by, and all registrations and applications for registration and renewals and extensions of any of the foregoing, and any other trademark, service xxxx or trade dress confusingly similar to any of the foregoing;
Β
(c) copyrights and works of authorship, whether or not copyrightable, together with all moral rights associated with, and all registrations, applications for registration, and renewals and extensions of, any of the foregoing, including the copyrights, mask works and registrations and applications therefor identified in Exhibit A, and all moral rights associated with any of the foregoing;
Β
(d) internet domain names and social media account or user names (including βhandlesβ), whether or not Trademarks, all associated web addresses, URLs, websites and web pages, social media accounts and pages, and all content and data thereon or relating thereto, whether or not Copyrights;
Β
(e) mask works, and all registrations, applications for registration, and renewals and extensions thereof;
Β
(f) industrial designs, and all Patents, registrations, applications for registration, and renewals and extensions thereof;
Β
(g) trade secrets, know-how, inventions (whether or not patentable), invention disclosures, discoveries, improvements, technology, source code, algorithms, prototypes, product roadmaps, business plans, marketing plans, business and technical information, databases, data compilations and collections, data analytics, tools, compositions, formulae, recipes, methods, processes, techniques, and other confidential and proprietary information and all rights therein, including the trade secrets identified in Exhibit A;
Β
(h) rights of publicity;
Β
(i) all other intellectual or industrial property and proprietary rights, including such rights in, arising out of, in connection with or in relation to any of the foregoing (collectively, the βAssigned IPβ), the same to be held and enjoyed by Company, its successors and assigns;
Β
(j) all of Assignorβs right to file patent, trademark and copyright applications in the United States and throughout the world for the Assigned IP in the name of Buyer, its successors and assigns; and
Β
(k) all claims, demands, income, damages, royalties, payments, accounts and accounts receivable now or hereafter due and/or payable, and rights to causes of action and remedies, related to any of the Intellectual Property, including all proceeds to infringement suits, the right to xxx and prosecute for past, present and future infringement, misappropriation or other violation of rights related to the Assigned IP, and all rights corresponding thereto throughout the world for the Intellectual Property rights assigned herein.
Β
E-2
Β
Β
3. Authorization. Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States, and the corresponding entities or agencies in any applicable foreign jurisdictions, whose duty is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Company and to record Company as owner of the Patents and Trademarks, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Company, its successors, assigns or other legal representatives.
Β
4. Further Assurances. Assignor shall provide Buyer, its successors and assigns with all such assistance as it may reasonably request for the full utilization of the rights granted in Section 1, above, including upon request by Buyer to execute and cause its current or former employees or contractors to execute, as applicable, all applications and any further assignments or other documents or instruments, sign all lawful papers, and make all rightful oaths necessary or desirable to carry out the purposes or intent of this Assignment Agreement and to aid Buyer or its successors, assigns or other legal representatives to obtain and enforce proper protection for the Assigned IP in all jurisdictions and to record Buyer as owner of the Assigned IP, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Buyer, its successors, assigns or other legal representatives. Without limiting the foregoing, Assignor will do all things necessary, proper or advisable to reasonably assist Assignee in transferring all domain names that are Assigned IP, including as applicable, placing each of the domain names in βunlockedβ status and provide to Company the Internet domain name registrarsβ transfer authorization codes for each of the domain names and any other information required to effectuate the transfer of Assignorβs right, title and interest in the domain names to Company. Assignor shall not assert any right, title or interest in or to any of the Intellectual Property and shall not use any of the Assigned IP except as may be expressly authorized by Buyer in writing.
Β
5. General.
Β
(a) Interpretation. For purposes of this Assignment Agreement, (a) the words βinclude,β βincludesβ and βincludingβ shall be deemed to be followed by the words βwithout limitationβ; (b) the word βorβ is not exclusive; and (c) the words βherein,β βhereof,β βhereby,β βheretoβ and βhereunderβ refer to this Assignment Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Assignment Agreement; (y) to an agreement, instrument or other document mean such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute mean such statute as amended from time to time and include any successor legislation thereto and any regulations promulgated thereunder. This Assignment Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Assignment Agreement to the same extent as if they were set forth verbatim herein.
Β
(b) Headings. The headings in this Assignment Agreement are for reference only and shall not affect the interpretation of this Assignment Agreement.
Β
E-3
Β
Β
(c) Severability. If any term or provision of this Assignment Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Assignment Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Assignment Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that this Assignment Agreement be consummated as originally contemplated to the greatest extent possible.
Β
(d) Entire Agreement. This Assignment Agreement and the Purchase Agreement and the Ancillary Documents constitute the sole and entire agreement of the parties to this Assignment Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Assignment Agreement and those in the Purchase Agreement, the Ancillary Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of the Purchase Agreement will control.
Β
(e) Successors and Assigns. This Assignment Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed; provided that prior to the Effective Date, Company may, without the prior written consent of Seller, assign all or any portion of its rights under this Assignment Agreement to one or more of its Affiliates. No assignment shall relieve the assigning party of any of its obligations hereunder.
Β
(f) No Third-party Beneficiaries. This Assignment Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Assignment Agreement.
Β
(g) Amendment and Modification; Waiver. This Assignment Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Assignment Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Β
(h) Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.
Β
(i) This Assignment Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
Β
E-4
Β
Β
(ii) Each of the parties hereto irrevocably agrees that any Action with respect to this Assignment Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Assignment Agreement and the rights and obligations arising hereunder brought by any party hereto or its successors or assigns, shall be brought and determined exclusively in the Court of Chancery of the State of Delaware, or in the event (but only in the event) that such court does not have subject matter jurisdiction over such Action, in the Superior Court of the State of Delaware. Each of the parties hereto agrees that mailing of process or other papers in connection with any such Action in the manner provided in Section 5(h) or in such other manner as may be permitted by applicable Laws, shall be valid and sufficient service thereof. Each of the parties hereto hereby irrevocably submits with regard to any such Action for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it shall not bring any Action relating to this Assignment Agreement or any of the transactions contemplated by this Assignment Agreement in any court or tribunal other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any Action with respect to this Assignment Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Assignment Agreement and the rights and obligations arising hereunder: (i) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to serve process in accordance with this Section 5(h); (ii) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise); and (iii) to the fullest extent permitted by the applicable Law, any claim that (A) the suit, action or proceeding in such court is brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper, or (C) this Assignment Agreement or the subject matter hereof may not be enforced in or by such courts.
Β
(iii) EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS ASSIGNMENT AGREEMENT OR THE ANCILLARY DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION ARISING OUT OF OR RELATING TO THIS ASSIGNMENT AGREEMENT AND THE ANCILLARY DOCUMENTS. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF AN ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS ASSIGNMENT AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION(5H)
Β
(i) Specific Performance. The parties hereto agree that irreparable damage would occur if any provision of this Assignment Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Β
(j) Counterparts. This Assignment Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment Agreement delivered by means of facsimile or portable document format (β.PDFβ) signature and such signature shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment Agreement.
Β
[SIGNATURE PAGE FOLLOWS]
Β
E-5
Β
Β
IN WITNESS WHEREOF, the parties hereto have caused this Assignment Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION | |
Β | Β | Β |
Β | By: | Β |
Β | Β | Name: |
Β | Β | Title: |
Β
Β | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β |
Β | Β | Name: |
Β | Β | Title: |
Β
[Signature Page to Intellectual Property Assignment Agreement]
Β
E-6
Β
Β
EXHIBIT A
Intellectual Property
Β
Β ***
Β
Β
E-7
Β
Β
Exhibit F
Β
Patent Assignment
Β
THIS PATENT ASSIGNMENT (the βAssignmentβ), dated as of [ ], 2020 (βEffective Dateβ), is by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βAssigneeβ), and AdvanSource Biomaterials Corporation, a Delaware corporation (βAssignorβ).
Β
WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of November 25, 2019 (as it may be amended, restated or otherwise modified from time to time, the βPurchase Agreementβ), pursuant to which Assignor agreed to sell, and Assignee agreed to acquire, certain issued patents and patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, renewals, extensions, or restorations of any of the foregoing, all applications for and inventions disclosed in any of the foregoing, and all rights to claim priority of any of the foregoing, including the patents and patent applications identified in Exhibit A attached hereto (the βAssigned Patentsβ), in accordance with the terms of the Purchase Agreement;
Β
WHEREAS, Assignor is the record owner of the Assigned Patents listed in Exhibit A and Assignor desires to transfer, on a worldwide basis, any and all of its right, title and interest in, to and under the Assigned Patents listed in Exhibit A; and
Β
WHEREAS, Assignee desires to acquire and Assignor is willing to assign to Assignee all of Assignorβs right, title and interest in and to the Assigned Patents and inventions listed in Exhibit A.
Β
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement and subject to the terms and conditions therein, Assignor and Assignee intending to be legally bound, agree as follows:
Β
Assignor hereby irrevocably assigns, transfers, grants, conveys, and relinquishes exclusively to Assignee, its successors and assigns, any and all of Assignorβs worldwide right, title and interest worldwide in and to the Assigned Patents set forth in Exhibit A, any related or corresponding United States provisional or non-provisional application embodying the inventions described in the Patents or any other United States application claiming priority to a provisional application under 35 U.S.C. Β§ 119(e) or converted therefrom, or any application claiming the benefit of a non-provisional application under 35 U.S.C. Β§120, including all divisions, continuations, reexaminations, and reissues thereof and all patents that may be granted thereon, including any other counterparts thereto worldwide, patents of addition, utility models, inventorsβ certificates, industrial property protection, patent rights and right to claim priority thereto in any country, and all extensions and renewals thereof existing now or in the future, including all applications for patents, utility models and designs that may hereafter be filed for in any country or countries other than the United States, together with the right to file such applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, and all forms of industrial property protection, including patents, utility models, inventorsβ certificates and designs, which may be granted in any country or countries foreign to the United States and all extensions, renewals and reissues therefor; including (a) the right to file patent applications in the United States and throughout the world for the any of the foregoing in the name of Assignee, its successors and assigns; and (b) all claims, demands, income, damages, royalties, payments, accounts and accounts receivable now or hereafter due and/or payable, and rights to causes of action and remedies, related to any of the foregoing, including all proceeds to infringement suits, the right to xxx and prosecute for past, present and future infringement, misappropriation or other violation of rights related to the Assigned Patents, and all rights corresponding thereto throughout the world for the Assigned Patents assigned herein.
Β
F-1
Β
Β
Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States, and the corresponding entities or agencies in any applicable foreign jurisdictions, whose duty is to issue patents, trademarks or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee and to record Assignee as owner of the Assigned Patents, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.
Β
Assignor shall provide Assignee, its successors and assigns with all such assistance as it may reasonably request for the full utilization of the rights granted above, including upon request by Assignee to execute and cause its current or former employees or contractors to execute, as applicable, all applications and any further assignments or other documents or instruments, sign all lawful papers, and make all rightful oaths necessary or desirable to carry out the purposes or intent of this Assignment and to aid Assignee or its successors, assigns or other legal representatives to obtain and enforce proper protection for the Assigned Patents in all jurisdictions and to record Assignee as owner of the Assigned Patents, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.
Β
This Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
Β
[SIGNATURE PAGE FOLLOWS]
Β
F-2
Β
Β
IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed as of the date first written above by their respective officers thereunto duly authorized.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION | |
Β | Β | Β |
Β | By: | Β |
Β | Β | Name: |
Β | Β | Title: |
Β | Β | Β |
Β | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β |
Β | Β | Name: |
Β | Β | Title: |
Β
[Signature Page to Patent Assignment]
Β
F-3
Β
Β
EXHIBIT A
Β
Assigned Patents
Β
Β ***
Β
F-4
Β
Β
Exhibit G
Β
TRADEMARK ASSIGNMENT
Β
THIS TRADEMARK ASSIGNMENT (the βAssignmentβ), dated as of [ ], 2020 (βEffective Dateβ), is by and between Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (βAssigneeβ), and AdvanSource Biomaterials Corporation, a Delaware corporation (βAssignorβ).
Β
WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of November 25, 2019 (as it may be amended, restated or otherwise modified from time to time, the βPurchase Agreementβ) pursuant to which Assignor agreed to sell, and Assignee agreed to acquire, certain trademarks, service marks, brands, certification marks, logos, trade dress, trade names and other similar indicia of source or origin, including the trademarks, trademark registrations, trademark applications and domain names identified in Exhibit A (collectively, the βAssigned Trademarksβ), together with the goodwill associated with the use of and symbolized by, and all registrations and applications for registration and renewals and extensions of any of the foregoing, and any other trademark, service xxxx or trade dress confusingly similar to any of the foregoing, in accordance with the terms of the Purchase Agreement;
Β
WHEREAS, Assignor owns rights in such Assigned Trademarks and the goodwill associated with and symbolized by the Assigned Trademarks; and
Β
WHEREAS, Assignor wishes to assign to Assignee any and all of its right, title, and interest in and to the Assigned Trademarks and the goodwill associated with any symbolized by the Assigned Trademarks.
Β
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement and subject to the terms and conditions therein, Assignor hereby irrevocably assign, transfers and conveys to Assignee, its successors and assigns, any and all worldwide right, title, and interest in and to the Trademarks, including, without limitation, any registrations, applications, renewals and extensions therefor and all rights of priority, together with the ongoing and existing business of Assignor to which the Trademarks pertain and any and all goodwill of the business associated with and symbolized by said Trademarks and all other rights accruing thereunder or pertaining thereto in any jurisdiction throughout the world for Assigneeβs own use and enjoyment, and for the use and enjoyment of Assigneeβs successors and assigns, as full and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, including: (a) all of Assignorβs right to file patent, trademark and copyright applications in the United States and throughout the world for the Assigned Trademarks in the name of Assignee, its successors and assigns; and (b) all claims, demands, income, damages, royalties, payments, accounts and accounts receivable now or hereafter due and/or payable, and rights to causes of action and remedies, related to any of the Assigned Trademarks, including all proceeds to infringement suits, the right to xxx and prosecute for past, present and future infringement, misappropriation or other violation of rights related to the Assigned Trademarks, and all rights corresponding thereto throughout the world for the Assigned Trademarks rights assigned herein.
Β
G-1
Β
Β
Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States, and the corresponding entities or agencies in any applicable foreign jurisdictions, whose duty is to issue patents, trademarks or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee and to record Assignee as owner of the Assigned Trademarks, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.
Β
Assignor shall provide Assignee, its successors and assigns with all such assistance as it may reasonably request for the full utilization of the rights granted above, including upon request by Assignee to execute and cause its current or former employees or contractors to execute, as applicable, all applications and any further assignments or other documents or instruments, sign all lawful papers, and make all rightful oaths necessary or desirable to carry out the purposes or intent of this Assignment and to aid Assignee or its successors, assigns or other legal representatives to obtain and enforce proper protection for the Assigned Trademarks in all jurisdictions and to record Assignee as owner of the Assigned Trademarks, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.
Β
This Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
Β
[SIGNATURE PAGE FOLLOWS]
Β
G-2
Β
Β
IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed as of the date first written above by their respective officers thereunto duly authorized.
Β
Β | ADVANSOURCE BIOMATERIALS CORPORATION | |
Β | Β | Β |
Β | By: | Β Β Β Β |
Β | Β | Name: |
Β | Β | Title: |
Β | Β | Β |
Β | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β |
Β | Β | Name: |
Β | Β | Title: |
Β
[Signature Page to Trademark Assignment]
Β
G-3
Β
Β
EXHIBIT A
Β
Assigned Trademarks
Β
Β ***
Β
G-4
Β
Β Β
Exhibit H
ASSIGNMENT AND
ASSUMPTION OF LEASE
Β
THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this βAssignmentβ) is made as of the [ ] day of [ ], 2020 (the βAssumption Dateβ), by and between ADVANSOURCE BIOMATERIALS CORPORATION, a Delaware corporation, as assignor (βAssignorβ), and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation, as assignee (βAssigneeβ).
Β
RECITALS:
Β
WHEREAS, this Assignment is being executed and delivered pursuant to that certain Asset Purchase Agreement dated as of November 25, 2019 (as amended, modified and/or supplemented from time to time, the βPurchase Agreementβ) between Assignor, as Seller and Assignee, as Buyer.
Β
WHEREAS, Assignor is the holder of the tenantβs interest in that certain lease dated as of December 22, 2011 between 000 Xxxxxxx Xxxxxx, LLC, as landlord, and Assignor, as tenant (the βLeaseβ), for those certain premises (the βDemised Premisesβ) more particularly described in the Lease; and
Β
WHEREAS, Assignor desires to assign unto Assignee all of Assignorβs right, title and interest as tenant under the Lease and Assignee desires to succeed to the interest of Assignor under the Lease and to assume all of the obligations of Assignor under the Lease from and after the Assumption Date.
Β
AGREEMENT:
Β
In consideration of ten dollars ($10.00) in hand paid by Assignee, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
Β
1. Assignment. Effective as of the Assumption Date, Assignor hereby assigns, grants, transfers and quitclaims to Assignee all of Assignorβs right, title and interest as tenant under the Lease, subject to the terms, covenants and conditions of the Lease and to the terms and conditions set forth herein.
Β
2. Assumption. Assignee hereby accepts the aforementioned assignment from and after the Assumption Date, assumes the performance of all of the obligations of tenant under the Lease and agrees to be bound by and to perform and observe, all of the agreements, terms, covenants and conditions contained in the Lease on the part of the tenant to be performed or observed arising from and after the Assumption Date.
Β
H-1
Β
Β
3. Miscellaneous.
Β
a. This Assignment shall be construed in accordance with the laws of the Commonwealth of Massachusetts and may not be amended, except by written agreement executed by Assignor and Assignee. This Assignment shall inure to the benefit of Assignor and Assignee and their respective successors and assigns.
Β
b. This Assignment is made without warranty or representation, express or implied, by or recourse against, Assignor of any kind or nature whatsoever, except as and to the extent expressly provided in the Purchase Agreement.
Β
c. This Assignment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same Assignment.
Β
[SIGNATURES APPEAR ON THE FOLLOWING PAGE]
Β
H-2
Β
Β
IN WITNESS WHEREOF, the parties have executed this Assignment as of the date first above written.
Β
ASSIGNOR: | ADVANSOURCE BIOMATERIALSΒ CORPORATION | |
Β | Β | Β |
Β | By: | Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β |
Β | Name: | Β |
Β | Title: | Β |
Β | Β | Β |
ASSIGNEE: | Mitsubishi Chemical Performance Polymers, Inc. | |
Β | Β | Β |
Β | By: | Β Β Β Β Β |
Β | Name: | Β |
Β | Title: | Β |
Β
Β
H-3
Β